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Abstract
In 2007 genome wide sequencing led to the identification of common genetic vari-
ations within intronic regions of the human FTO gene that are associated with
obesity related traits. To date, neither the consequence of these variations for FTO
expression, nor the exact molecular function of the FTO protein are known.
This study shows that inactivation of the murine Fto gene alters the function
of the midbrain dopaminergic circuitry. Loss of FTO impairs the dopamine neu-
ron autoreceptor feedback inhibition that depends on dopamine receptors type 2
(DRD2), type 3 (DRD3) and G protein coupled inwardly rectifying potassium chan-
nels (GIRKs). This attenuation of the autoinhibitory feedback loop was observed
for both whole body Fto-deficient and dopamine neuron restricted Fto knock out
(Fto∆DAT) mice. While Fto-deficient mice exhibited deficits in their responses to
stimulation with cocaine, Fto∆DAT mice displayed a hypersensitivity to the locomo-
tor and reward stimulating effects of cocaine and resembled DRD2 autoreceptor-
deficient mice.
On the molecular level, FTO encodes a nucleic acid demethylase that is able
to remove N6-methyladenosine (m6A) from messenger RNA. Analysis of m6A in
mRNA of Fto-deficient midbrain and striatum showed that FTO acts as a m6A
demethylase in vivo. Increased methylation, however, was only demonstrated for
a subset of all m6A methylated transcripts. This subset included many transcripts
important for cell-cell and neuronal signaling. Furthermore, many of these hy-
permethylated transcripts are components of dopaminergic signaling and some of
these displayed a deregulation on the protein level in Fto-deficient mice, such as
DRD3, GIRK2 and NMDAR1.
Taken together, FTO, via acting as a m6A demethylase, plays an important role
xiv
in regulating the dopamine autoinhibitory feedback loop and hence impinges on
dopamine circuit function. Malfunction of dopamine signaling has been implicated
in a variety of diseases such as depression, schizophrenia or ADHD and therefore
poses the question whether FTO genomic variation is associated with diseases other
than obesity and whether association with obesity related traits is partly due to
alterations in dopamine circuit function.
Zusammenfassung
Genomweite Sequenzierung führte in 2007 zur Entdeckung weit verbreiteter genetis-
cher Variationen in nicht-kodierenden Regionen des humanen FTO Gens, welche
mit verschiedenen Merkmalen krankhaften Übergewichts assoziiert sind. Bis heute
sind sowohl die Auswirkungen dieser Variationen auf die Expression von FTO, als
auch die exakte molekulare Funktion des FTO Proteins unbekannt.
In dieser Studie konnte gezeigt werden, dass die Inaktivierung von murinem
Fto die Funktion des dopaminergen Systems des Mittelhirns beeinflusst. Ver-
lust von FTO führte zu einer Beeinträchtigung der autoinhibitorischen Rückkop-
plungsschleife dopaminerger Neurone, welche von Dopaminrezeptoren des Typs
2 (DRD2), Typs 3 (DRD3) und G Protein gekoppelten einwärts gleichrichtenden
Kalium Kanälen (GIRKs) abhängig ist. Diese Fehlfunktion der autoinhibitorischen
Rückkopplung konnte sowohl bei ganzkörper-Fto-defizienten, als auch bei spezifis-
chem Verlust der Fto Expression in dopaminergen Neuronen (Fto∆DAT) beobachtet
werden. Während dies in ganzkörper-Fto-defizienten Mäusen zu verminderten
Antworten auf Kokain Stimulation führte, erfuhren Fto∆DAT Mäuse eine erhöhte
Sensitivität für die bewegungs- und belohnungsstimulierende Wirkung von Kokain.
Auf molekularer Ebene kodiert das FTO Protein für eine Nukleinsäure Demethy-
lase, die N6-Methyladenosin (m6A) von Boten-RNA (mRNA) entfernen kann. Die
Analyse von m6A Modifizierungen in mRNA Fto defizienter Mäuse zeigte, dass
FTO in vivo als m6A Demethylase agiert. Erhöhte Methylierungsmuster konnten
allerdings nur in einem Teil aller prinzipiell m6A modifizierten Transkripte nach-
gewiesen werden. Diese Teilmenge hypermethylierter Transkripte beinhaltete zum
großen Teil wichtige Komponenten der Zell-Zell und neuronalen Kommunikation.
Darüber hinaus befanden sich unter den hypermethylierten Transkripten wichtige
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Bestandteile der dopaminergen Signalweiterleitung. Für einige dieser Komponen-
ten (z.B. DRD3, GIRK2 und NMDAR1) wurde eine verminderte Proteinexpression
nachgewiesen.
Zusammengefasst erfüllt FTO als m6A Demethylase eine wichtige Rolle in der
Kontrolle der autoinhibitorischen Rückkopplungsschleife in dopaminergen Neuro-
nen und beeinflusst die Funktion des dopaminergen Systems sowohl auf Netzwerk-
, als auch auf Einzelzellebene. Fehlfunktionen des dopaminergen Systems treten
bei verschiedensten Krankheitsbildern auf, wie z.B. Depression, Schizophrenie oder
Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung. Daher stellt sich die Frage, ob
genomische Variabilität im FTO Locus auch mit anderen Erkrankungen als Über-
gewicht assoziiert ist, beziehungsweise ob den Assoziationen mit verschiedenen
Merkmalen krankhaften Übergewichts zum Teil eine Veränderung des dopaminer-
gen Systems zu Grunde liegt.
1 Introduction
1.1 Obesity and obesity associated diseases
Over the last decades the prevalence of obesity has dramatically increased, prompt-
ing the World Health Organisation (WHO) to classify obesity as an epidemic of
global proportion. Recent estimations suggest that about 1.4 billion people are
overweight of which one third is considered obese (source: WHO). This increase
in obesity is not only observed in western society, but is also identified as a threat
to developing countries [Malik et al., 2013]. Overweight (body mass index (BMI)
≥ 25 kg/m2) and obesity (BMI ≥ 30 kg/m2) are known risk factors for type
2 diabetes mellitus (T2DM), cardiovascular disease and certain forms of cancer,
all of which contribute to the increased mortality that is observed for obese pa-
tients [Katzmarzyk et al., 2003]. Moreover, even neurodegenerative diseases such
as Alzheimer’s disease have been associated with obesity [Hildreth et al., 2012].
These comorbidities render obesity one of the biggest challenges to modern soci-
ety. Obesity not only decreases the individual quality of life, but is also becoming
a far reaching socio-economic problem, placing a massive burden on our health
systems [Cawley & Meyerhoefer, 2012; Finkelstein et al., 2009]. Thus, a necessity
emerged to understand the genetics and molecular mechanisms of body weight
regulation and to develop strategies to tackle the progressing obesity epidemic.
1.1.1 Monogenic obesity
Since obesity has moved into focus, the study of severely obese patients has led to
the identification of several loss-of-function mutations within the human genome
[Farooqi & O’Rahilly, 2006]. These rare cases of monogenic obesity include e.g.
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mutations of leptin [Montague et al., 1997], the leptin receptor [Clément et al.,
1998], proopiomelanocortin (POMC)[Krude et al., 1998] and melanocortin 4 recep-
tor (MC4R) [Yeo et al., 1998; Farooqi et al., 2003]. Individuals suffering from one of
these mutations inevitably face obesity, regardless of environmental factors. Many
of these studies have helped to identify critical components of the mechanisms
governing energy homeostasis. Some of these patients have even benefited from
treatment made available through their diagnosis. Leptin deficient patients, for
example, are treated with recombinant leptin, leading to body weight loss and
enabling them to lead a normal life [Farooqi et al., 1999].
Monogenic forms of obesity are rare within the population and the frequency of
these genomic variations has not changed since the prevalence of obesity is rising
[Caballero, 2007]. Hence, rare loss-of-function mutations are not the underlying
reason for the steady increase in overweight people observed since the middle of
the 20th century.
1.1.2 Polygenic obesity
Current research on the increasing prevalence of obesity in the general population,
hence termed common obesity, investigates the influence of environmental fac-
tors on energy homeostasis. Our sedentary lifestyle, lack of physical activity and
unlimited access to energy rich, highly palatable nutrition promote a misbalance
between energy intake and energy expenditure, ultimately leading to weight gain
[Swinburn et al., 2011]. Still, considerable variation of BMI is observed in a given
population that in general faces the same environmental changes and temptations.
Common variations in the human genome are believed to shape the individual
susceptibility to environmental factors, thus leading to the apparent divergence of
BMI within a population [Maes et al., 1997]. The sum of the variations carried by
an individual may therefore define how environmental factors impact on certain
features, such as body weight regulation.
In former years, identification of obesity related traits in the human genome
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was a laborious task that had to rely on the candidate approach. Genes that were
functionally related to body weight regulation were investigated for variations and
subsequently tested for associations with body weight [Loos, 2012]. Due to the
hypothesis driven approach, however, this method lacked the power to identify yet
unknown players in body weight regulation.
Since whole genome sequencing has become affordable, genome wide associa-
tion studies (GWAS) represent the means to perform hypothesis generating studies.
Increasing sample sizes over the years has increased the discovery rate tremen-
dously. In recent years, GWAS helped to identify several common genetic vari-
ations that are associated with obesity related traits, regardless of any known or
unknown function for these genes [Loos, 2012; Willer et al., 2009; Speliotes et al.,
2010]. To date, 52 loci have been associated with BMI, body fat percentage, waist
circumference, waist-to-hip ratio and early onset obesity. Some of those were al-
ready known to take part in the regulation of energy homeostasis, such as variants
near the insulin receptor substrate (IRS) 1 [Kilpeläinen et al., 2011], near MC4R
[Loos et al., 2008] or within the brain-derived neurotrophic factor (BDNF) locus
[Thorleifsson et al., 2009]. Many of the identified loci, however, have not been
known for any association with obesity related traits before [Loos, 2012].
The effect size of each individual genomic variant is relatively small, increasing
the body weight per allele by as little as 200 grams [Loos, 2012]. Rather the effect
of all variants present in the genome will define each individual’s susceptibility to
obesity. Thus, not only identifying predisposing loci and their respective molecular
function, but also understanding the network of the entirety of genomic variation
is important.
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1.2 Regulation of body weight
1.2.1 Energy homeostasis
In order to ensure a steady body weight, a process called energy homeostasis en-
sures that both energy intake and energy expenditure are balanced. Usually, times
of excessive binge eating or undernutrition are compensated over the following
course of days or weeks to maintain body weight [Schwartz et al., 2000; Schwartz
& Porte, 2005]. Malfunction of these regulatory mechanisms favoring increased
energy intake and reduced energy expenditure lead to increased body weight and
obesity [Schwartz et al., 2000; Schwartz & Porte, 2005].
Over the past decades, several peripheral hormones have been identified that
convey the current energy status of the human organism. The anorectic hormone
leptin, produced by white adipocytes relative to their lipid content and released
into the blood stream, is a measure for the current energy storage of the body
[Friedman, 2011, 2010]. While initially administration of recombinant leptin was
thought to be a potential treatment for obesity, studies showed that obese patients
have high levels of circulating leptin and the body lost its ability to process the
signal [Könner & Brüning, 2012; Myers et al., 2008]. The second hormone insulin
is released by pancreatic β-cells in response to increasing blood glucose levels af-
ter food intake and ensures the uptake of glucose in peripheral organs such as
the liver, muscle and adipose tissue [Kahn, 1994; Könner et al., 2009]. Moreover,
insulin, like leptin, was found to signal to specific neuronal populations and regu-
late food intake [Könner et al., 2009; Könner & Brüning, 2012; Belgardt & Brüning,
2010]. A third hormone, the orexigenic ghrelin, is secreted by the stomach and
intestine, with levels decreasing after food intake and increasing with food depri-
vation [Cummings & Overduin, 2007]. Leptin, insulin and ghrelin, are only three
examples of hormones involved in energy homeostasis. Jointly, these hormones
are the signal infrastructure conveying information about the peripheral energy
status to the central nervous system, the master regulator of energy homeostasis
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[Schwartz et al., 2000; Könner et al., 2009]. The evaluation of these hormonal sig-
nals within the brain then leads to the behavioral outcome. Further investigations
showed, that failure of brain circuits to interpret the circulating signals, e.g. in-
sulin and/or leptin resistance, has major impacts on energy homeostasis [Könner
& Brüning, 2012].
1.2.2 CNS in regulation of energy homeostasis
Already more than 70 years ago, lesion experiments in rats demonstrated that the
hypothalamic area of the brain plays a critical role in the regulation of body weight
[Hetherington & Ranson, 1940]. Since then, further refinement of methodology
led to the dissection of different nuclei within the hypothalamus in the control of
energy homeostasis [Könner et al., 2009; Belgardt & Brüning, 2010; Kleinridders
et al., 2009].
The first order neurons of the homeostatic system reside within the mediobasal
hypothalamus [Könner et al., 2009; Belgardt & Brüning, 2010]. The close prox-
imity to the blood-brain barrier render the anorexigenic POMC/CART (pro-opio-
melanocortin/cocaine and amphetamine regulated transcript) and the orexigenic
AgRP/NPY (agouti-related peptide/neuropeptide Y) neurons of the arcuate nu-
cleus (ARC) sensitive to the hormones circulating in the blood stream. Consistently,
activity of these neurons is regulated by insulin, leptin, ghrelin and even circulat-
ing levels of glucose [Könner et al., 2009; Belgardt & Brüning, 2010]. POMC/CART
neurons release α-MSH (α-melanocyte stimulating hormone), a cleavage product
of pro-opiomelanocortin, which in turn activates MC4 receptors on the second or-
der neurons that reside e.g. within the paraventricular nucleus of the hypotha-
lamus (PVN) [Könner et al., 2009]. Activation of those second order neurons in
the PVN leads to a decrease in food intake [Balthasar et al., 2005]. Activation of
AgRP/NPY neurons on the other hand silences the POMC/CART neurons through
γ-aminobutyric acid (GABA) released from AgRP/NPY neuron synapses [Atasoy
et al., 2012; Könner et al., 2009; Belgardt & Brüning, 2010]. Moreover, these neurons
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release AgRP, which is an inverse agonist of MC4 receptors, blocking those recep-
tors and thereby preventing α-MSH mediated activation of second order neurons
[Könner et al., 2009; Belgardt & Brüning, 2010]. As a result, food intake is increased,
while energy expenditure is reduced [Könner et al., 2009; Belgardt & Brüning, 2010].
Additionally, other hypothalamic nuclei feed into the homeostatic control of
body weight, such as the ventromedial (VMH), dorsomedial (DMH) and lateral hy-
pothalamic (LH) areas [Belgardt & Brüning, 2010; Könner et al., 2009]. The LH is of
special notion, as it represents one possible link of the homeostatic system to other
brain areas, such as the dopaminergic midbrain neurons which control the hedo-
nic and reward related behaviours [Sternson, 2013; Berthoud, 2011; Simerly, 2006;
Saper et al., 2002]. Orexin, secreted from orexinergic neurons within the LH, has
been demonstrated to be a potent mediator of wakefulness in control of sleep/wake
cycles in mammals [Sakurai et al., 1998; Harris & Aston-Jones, 2006; Adamantidis
et al., 2007; Tsunematsu et al., 2011]. Consistently, leptin inhibits orexinergic neu-
rons, thus allowing periods of rest and sleep in the satiated state [Yamanaka et al.,
2003]. Neurons of the LH project onto midbrain dopaminergic neurons and release
orexin, which subsequently alters dopaminergic neuron function via orexin recep-
tors [Sharf et al., 2010; Borgland et al., 2006]. Hence, the LH represents one possible
interface of homeostatic and hedonic regulation of food intake. Further evidence
points towards projections from the hypothalamus (AgRP/NPY neurons) directly
to DA neurons [Palmiter, 2012]. Conceptually, the ventral striatum (nucleus ac-
cumbens, NAc), may represent the integrative center, processing information from
the energy sensing hypothalamic nuclei, from the midbrain that conveys reward-
ing aspects of food intake and from higher brain centers that feed experience and
decision making into the equation. Consolidation of all inputs will then lead to a
subsequent behavioural outcome that may lead to food intake [Simerly, 2006].
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1.3 The dopaminergic system
1.3.1 Dopamine and dopaminergic neurons
Dopamine (DA) belongs to the family of catecholamine neurotransmitters and as
such is a precursor of norepinephrine and epinephrine [Björklund, 2007]. Initially
not regarded as such, dopamine is an independent neurotransmitter involved in
important physiological processes [Carlsson et al., 1958]. The total number of do-
paminergic neurons (DA neurons) increases in mammals according to the growth
of cortical and striatal regions, with mice having approximately 20,000 to 30,000
DA neurons, monkeys 160,000 to 320,000 and humans 400,000 to 600,000 [Björk-
lund, 2007]. About 70 to 75 % of these neurons reside within the midbrain in the
ventral tegmental area (VTA), substantia nigra (SN) and retrorubral field, while
the remaining dopamine neurons are found, for example, within the hypothala-
mus and olfactory bulbs [Björklund, 2007; Bentivoglio & Morelli, 2005]. Opposing
the relatively low number of dopamine neurons is the fact that each dopaminergic
neuron may have synaptic contact to 300-400 neurons, placing the dopaminergic
pathways among the most prominent innervating circuits in the brain [Schultz,
1998].
Classically, midbrain dopaminergic neurons have been categorized into three
different pathways. First, the nigrostriatal pathway of SN dopamine neurons pro-
jecting to the dorsal striatum (caudate putamen, CPu). Second, the mesolimbic
pathway of VTA dopamine neurons projecting to the ventral striatum (nucleus ac-
cumbens, NAc), the amygdala and olfactory tubercle. Third and finally, the meso-
cortical pathway of dopamine neurons projecting to cortical areas [Björklund, 2007].
Novel tracing methods, however, question this view of dopaminergic projections
and suggest a more complex projection pattern and cross-projections along these
classical pathways [Björklund, 2007].
Dopamine has been implicated in a variety of processes including voluntary
movement, reward, attention, motivation, sleep, memory and learning [Iversen &
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Iversen, 2007; Beaulieu & Gainetdinov, 2011; Björklund, 2007; Di Chiara, 2005; Dun-
nett, 2005]. Loss of striatal dopamine neuron inervation represents the hallmark of
Parkinson’s disease, moving dopaminergic function into the focus of Parkinson’s
treatment [Iversen & Iversen, 2007; Sulzer, 2007].
1.3.2 Dopamine receptors and dopamine signaling
Five different dopamine receptors belonging to two different classes are known.
The D1-like dopamine receptors, including dopamine receptors D1 (DRD1) and
D5 (DRD5), and the D2-like receptors, including dopamine receptors D2 (DRD2),
D3 (DRD3) and D4 (DRD4) [Beaulieu & Gainetdinov, 2011]. Dopamine receptors
are widely expressed within the brain, but also in peripheral tissues, such as the
adrenal glands and sympathetic ganglia. DRD1 is mainly expressed within the
ventral and dorsal striatum, the substantia nigra, amygdala and olfactory bulb
and represents the major receptor of the direct basal ganglia pathway [Beaulieu &
Gainetdinov, 2011]. DRD2s are the main receptors involved in the indirect basal
ganglia pathway and are highly expressed in dorsal and ventral striatum, as well
as the olfactory tubercle [Beaulieu & Gainetdinov, 2011]. DRD3s are mainly found
within the ventral striatum (NAc) and the olfactory tubercle. DRD2 and DRD3,
however, are the only receptors that are also expressed presynaptically in the SN
and VTA [Beaulieu & Gainetdinov, 2011]. D4 and D5 receptors exhibit the low-
est expression of all dopamine receptors and are found within a variety of areas,
including cortical areas, hippocampus, hypothalamus and midbrain [Beaulieu &
Gainetdinov, 2011].
Genes of the DRD1 and DRD5 do not have introns and thus these receptors are
not expressed in different splice isoforms [Beaulieu & Gainetdinov, 2011]. DRD2,
DRD3 and DRD4, however, have intronic regions in their respective genes and
several isoforms have been described, the most prominent ones being the DRD2S
(short isoform), that shows preferentially presynaptic expression, and the DRD2L
(long isoform), that is predominantly found postsynpatically [De Mei et al., 2009].
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Dopamine receptors belong to the family of G protein-coupled receptors and as
such their main target is the regulation of the adenylyl cyclase (AC) and cAMP
production [Hyman et al., 2006; Beaulieu & Gainetdinov, 2011]. Whereas D2-like
receptors inhibit the AC via Gαi/o, D1-like receptors increase the activity of AC
via Gαs/ol f and thus increase cAMP levels. As a result of G protein signaling,
dopamine receptors modulate activity of important signaling mediators, such as
protein kinase A (PKA), phospholipase C (PKC) and protein kinase B (AKT) (see
Figure 1.1) [Hyman et al., 2006; Beaulieu & Gainetdinov, 2011].
Despite modulation of AC activity, several other signaling modalities have been
reported for dopamine receptors. Both DRD5 and DRD1 have been implicated in
regulation of phospholipase C (PLC) via Gαq, potentially linking dopamine signal-
ing to intracellular calcium mobilization [Beaulieu & Gainetdinov, 2011]. Whether
this connection is mainly through DRD5 or DRD1 (or DRD1:DRD2 heterodimers),
however, remains to be elucidated. D2-like receptors, on the other hand, have
been demonstrated to activate PLC via Gβγ, while inhibiting L- and N-type cal-
cium channels through the same G protein cascade [Beaulieu & Gainetdinov, 2011].
Moreover, D2-like receptors regulate neuronal activity through Gβγ mediated ac-
tivation of G protein-coupled inwardly rectifying potassium channels (GIRKs),
which hyperpolarize and hence inhibit neurons (Figure 1.1) [Lüscher & Slesinger,
2010]. Following activation by dopamine, dopamine receptor signaling may be ter-
minated through phosphorylation by G protein-coupled receptor kinases (GRKs)
and subsequent internalization. Phosphorylation, however, may also promote a
late signaling event in D2-like receptors that inhibits protein kinase B (AKT/PKB)
in a β-arrestin 2 and protein phosphatase 2A (PP2A) dependent manner (Figure
1.1) [Beaulieu & Gainetdinov, 2011].
1.3.3 Dopamine and reward related behaviors
One of the primary functions of the dopaminergic system is the modulation of be-
havioral responses [Pandit et al., 2011; Volkow et al., 2013; Wise, 2013]. A major
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Figure 1.1: Pre- and postsynaptic dopamine receptor signaling.
Dopamine is synthesized from tyrosine via the tyrosine hydroxylase and subse-
quent decarboxylation via the DOPA decarboxylase. Dopamine receptors are di-
vided into two groups, the D1-like receptors (DRD1 and DRD5) and the D2-like
receptors (DRD2, DRD3 and DRD4). While D1-like receptors are only present
postsynaptically on dopamine target neurons, DRD2 and DRD3 receptors are
also found presynaptically on dopamine neurons. Dopamine receptors are G
protein-coupled receptors, that are able to trigger several responses. DRD1-like
receptors positively regulate the adenylyl cyclase (AC) via Gαs/ol f leading to in-
creasing levels of cAMP and protein kinase A (PKA) activity. Moreover, D1-like
receptors phospholipase C (PLC) activity is increased via Gαq.
D2-like receptors, on the other hand, negatively regulate AC activity (via Gαi/o)
and AKT (in a β-arrestin 2 (βArr2) and protein phosphatase 2A (PP2A) depen-
dent manner). Furthermore, coupling to Gβγ positively regulates PLC and may
lead to opening of G protein-coupled inwardly rectifying potassium channels
(GIRK), while inhibiting L- and N-type calcium channels. Presynaptic coupling
of D2-like receptors to GIRKs has been found to play an important role in the
dopamine autoreceptor feedback loop. Termination of dopaminergic signaling
is finally achieved through reuptake of dopamine via the dopamine transporter
expressed on dopamine neurons.
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aspect of this function is encoding the motivational value, being rewarding or aver-
sive, of substances, such as drugs and food, or behaviors like sexual reproduction
[Kenny, 2011; Kelley & Berridge, 2002]. As a consequence, dopamine signaling ad-
justs the probability for a repetition of a certain behavior, being it e.g. drug abuse
or highly palatable food intake [Schultz, 2010; Volkow et al., 2013; Schultz, 2007].
Hence, underlying these alterations is a learning process that depends on reinforc-
ing experiences that describe the ’liking’ of the performed behaviors [Iversen &
Iversen, 2007; Schultz, 2007].
First evidence for the involvement of dopaminergic pathways in reward related
motivation stem from self stimulation studies. Electrical stimulation of dopami-
nergic afferents along the medial forebrain bundle, the LH that is connecting to
the midbrain dopamine neurons or dopamine neurons themselves (VTA) causes a
favorable sensation that subsequently leads to increasing self stimulation in both
rodents and humans [Wise, 2013; Volkow et al., 2013]. Subsequent studies estab-
lished the role of the dopaminergic system in a complex system of neuronal circuits
shaping motivation and reinforcement of behaviors [Schultz, 2007; Pandit et al.,
2011].
To encode the motivational value, dopamine neurons exhibit episodes of burst
firing that subsequently lead to increased dopamine levels in the synaptic cleft
[Schultz, 2010; Overton & Clark, 1997]. These burst firing events were observed
in response to motivating stimuli, such as ingestion of sweet liquid in monkeys
[Schultz, 2010, 1998]. Moreover, these rewarding stimuli have been successfully
coupled to visual or auditory stimuli that, when preceding the actual reward, elicit
anticipatory dopamine neuron burst firing [Schultz, 1998]. Absence of the reward-
ing stimuli following the conditioned stimulus, however, leads to a paucity in do-
pamine neuron firing, hence encoding the prediction error of the missing motiva-
tional stimulus and adjusting behavior [Schultz, 1998]. The very same mechanism
is furthermore hypothesized to underly the drug taking response and subsequent
craving and seeking for drugs, hallmarks of drug addiction [Pandit et al., 2011;
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Volkow et al., 2013]. Moreover, many addictive drugs directly influence the dopa-
minergic system. Cocaine, for example, blocks the dopamine transporter (DAT)
expressed on dopaminergic neurons and prevents re-uptake of dopamine from the
synaptic cleft and thus attenuates DA signaling shut down [Hyman et al., 2006].
Similarly, amphetamine potentiates dopamine signaling through increasing DA re-
lease from dopaminergic synapses [Hyman et al., 2006]. Despite drug abuse and
addiction, malfunction of the dopaminergic circuitry has been implicated in con-
ditions such as attention deficit/hyperactivity syndrome (ADHD) [Swanson et al.,
2007], Tourette’s syndrome [McNaught & Mink, 2011], schizophrenia [Beaulieu &
Gainetdinov, 2011; Iversen & Iversen, 2007], bipolar disorder and major depression
[Beaulieu & Gainetdinov, 2011].
Dopamine signaling is not causing a fast postsynaptic response, but rather mod-
ulates the properties of postsynaptic neurons [Kauer & Malenka, 2007; Hyman
et al., 2006]. Thus, dopamine is instrumental in synaptic plasticity and adaptations
of synaptic transmission, thought to be the underlying mechanism of learning pro-
cesses [Kauer & Malenka, 2007].
1.3.4 Dopamine and obesity
The dopaminergic system is "the brain’s natural reinforcement system" [Salamone
& Correa, 2002]. As such, it is believed that the motivational value of natural
rewarding stimuli, such as food and the behavior leading to the consumption of
food, are encoded in the dopaminergic system [Pandit et al., 2011; Volkow et al.,
2013]. From an evolutionary perspective, reinforcing food intake was ensuring the
ability to overeat in times of plenty to prepare for times of need [Pandit et al.,
2011; Schwartz et al., 2003]. In fact, food has been demonstrated in some cases
to be preferred over drugs [Lenoir et al., 2007]. Several studies suggest common
alterations of the dopaminergic circuitry in addiction and obesity [Volkow et al.,
2013; Wise, 2013; Bello & Hajnal, 2010; Kenny, 2011].
Drugs of abuse increase extra synaptic levels of dopamine [Kauer & Malenka,
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2007; Di Chiara & Imperato, 1988]. In the same manner, eating and drinking cause
elevated levels of dopamine in the ventral and dorsal striatum [Yoshida et al., 1992;
Small et al., 2003]. Both pharmacological dopamine depletion, as well as genetically
engineered DA-deficiency in mice causes hypophagia [Salamone et al., 1993; Zhou
& Palmiter, 1995]. Moreover, obesity and chronic drug abuse reduce dopamine
type 2 receptor (DRD2) availability in human striatum [Volkow et al., 2002; Wang
et al., 2001]. Consistently, DRD2 levels are reduced in obese rats [Hamdi et al.,
1992; Johnson & Kenny, 2010]. Knock-down of striatal DRD2s, on the other hand,
caused obsessive food seeking in rats [Johnson & Kenny, 2010]. Chronic exposure
to a high fat diet in rats increases the threshold for electric self stimulation in the
LH [Johnson & Kenny, 2010]. The very same is observed in rats after prolonged
cocaine treatment [Ahmed et al., 2002]. Moreover, high fat diet exposure dampens
the preference for amphetamine cues and lowers the operant response to sucrose
[Davis et al., 2008]. Consistently, human obesity has been shown to decrease the
lifetime risk for drug abuse [Simon et al., 2006]. Vice versa, food restriction was
demonstrated to increase the sensitivity for drugs and to reduce the threshold for
lateral hypothalamic self administration [Carroll et al., 1979; Carroll & Meisch, 1981;
Davis et al., 2010; Abrahamsen et al., 1995].
During food restriction, levels of endocrine hormones change. In case of leptin
and insulin, food deprivation decreases circulating levels [Könner et al., 2009]. Food
restriction has been demonstrated to decrease Dat mRNA and activity in the stria-
tum, whereas centrally applied insulin increases Dat mRNA levels in the midbrain
[Patterson et al., 1998; Figlewicz et al., 1994]. Both leptin and insulin receptors are
expressed on dopaminergic neurons and both insulin and leptin potently modulate
dopamine neuron activity [Figlewicz et al., 2003; Fulton et al., 2006; Könner et al.,
2011]. Intracerebroventricular (ICV) injection of leptin inhibited dopamine neuron
firing, reducing food intake and dopamine levels in the ventral striatum. Knock
down of midbrain leptin receptors, on the other hand, increases food intake and
the sensitivity to sucrose and highly palatable food [Hommel et al., 2006; Krügel
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et al., 2003]. Consistently, ICV leptin administration is able to modulate LH self
stimulation [Fulton et al., 2000] and both insulin and leptin decrease sucrose self
stimulation [Figlewicz et al., 2006].
In humans, obesity causes increased brain activity in response to feeding asso-
ciated cues [Volkow et al., 2008]. The same is observed in leptin deficient patients,
however, leptin treatment is able to reduce the increased brain activity, as well as
food liking and caloric intake [Farooqi et al., 2007]. Despite insulin and leptin, sev-
eral other hormones an neuropeptides have been linked to drug abuse and reward
related behavior, including orexin, oxytocin, galanin, melanocortin, neuropeptide
Y (NPY) and peptide YY (PYY), further supporting the connections of homeostatic
and hedonic feeding control [Volkow et al., 2013].
1.3.5 DRD2/DRD3 autoreceptor feedback loop
To regulate dopaminergic synaptic transmission, DA neurons feature an autoin-
hibitory feedback loop that terminates dopamine release [Beaulieu & Gainetdinov,
2011; De Mei et al., 2009; Joseph et al., 2002; Sibley, 1999; Missale et al., 1998]. Both
DRD2 and DRD3, but not D1-like receptors, are presynaptically expressed and
were shown to couple to GIRKs (Figure 1.1) [De Mei et al., 2009; Beaulieu & Gainet-
dinov, 2011; Sibley, 1999; Mercuri et al., 1997]. Upon dopamine release opening of
these channels leads to an inhibition of firing and thus termination of dopamine
release from DA neurons [Paladini et al., 2003]. Findings for presynaptic D3 recep-
tors, however, are in part controversial, showing potent inhibition for VTA, but not
SN dopamine neurons [Davila et al., 2003; Lejeune & Millan, 1995; Kuzhikandathil
et al., 1998; Gainetdinov et al., 1996; Joseph et al., 2002]. In addition to the regulation
of dopamine neuron firing, presynaptic dopamine receptors are implicated in the
direct regulation of dopamine synthesis [Wolf & Roth, 1990; Anzalone et al., 2012;
Joseph et al., 2002].
In mice, loss of DRD2 autoreceptors causes cocaine supersensitivity and increases
motivation for reward, while body weight and food intake remain unaltered [Bello
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et al., 2011]. In humans, reduced dopamine autoreceptor availability is associated
with increased impulsivity [Buckholtz et al., 2010]. Taken together, dopamine au-
toreceptor function is likely to play a critical role in the proper function of the dopa-
minergic system and may lead to elevated DA neuron excitability and aberrant DA
release. Hence, malfunction of the autoinhibitory feedback loop may impinge on
complex human behavior, such as impulsivity, reinforcement or drug abuse [Bello
et al., 2011; Buckholtz et al., 2010].
1.4 The fat mass and obesity-associated protein (FTO)
1.4.1 Genome wide association studies
Associations with obesity-related traits
First identified as one of the genes deleted in the fused toes (Ft) mouse mutant [Pe-
ters et al., 1999; van der Hoeven et al., 1994], general interest in FTO (fat mass and
obesity-associated protein) was triggered through the robust association of a sin-
gle nucleotide polymorphism (SNP, rs9939609) within the FTO gene with obesity-
related traits (Figure 1.2 a) [Frayling et al., 2007; Dina et al., 2007; Scuteri et al., 2007].
These findings, to date, have been replicated in both adults and children in inde-
pendent populations of various, though not all, ethnicities [den Hoed et al., 2009;
Cecil et al., 2008; Fang et al., 2010; Grant et al., 2008; Bollepalli et al., 2010; Liu et al.,
2010; Adeyemo et al., 2010; Chang et al., 2008; Tan et al., 2008; Croteau-Chonka et al.,
2011; Yajnik et al., 2009]. While initially FTO was associated with changes in BMI,
subsequent studies with increased sample size confirmed the associations not only
for BMI, but additionally for e.g. body fat percentage, waist circumference and
obesity risk [Loos, 2012].
To date, the majority of FTO single nucleotide polymorphisms associated with
obesity are situated in the first intron of the human gene, forming a cluster of
SNPs that predisposes to obesity (Figure 1.2 a) [Willer et al., 2009; Jacobsson et al.,
2012]. The overall effect size for the human FTO obesity-associated risk alleles,
16 1 Introduction
0 2 4 6 8 10 12
age [years]
15
16
17
18
BMI vs. Age for FTO genotypes
–
lo
g 1
0 
p–
va
lu
e
 
BM
I
cM
/M
b
BM
I [k
g/
m
2 ]
a b
Position on chromosome 16 [Mb]
FTO
Figure 1.2: Genome wide association studies link FTO to obesity (a) A cluster of single
nucleotide polymorphisms (SNPs) within the first intron of the human FTO
gene is significantly associated with increased BMI. Upstream and in oppo-
site orientation of the FTO gene, the ciliary gene RPGRIP1L is situated (Figure
adapted from Willer et al. [2009]). (b) Before adiposity rebound at the age of 5.5
years in children, an inverse association between FTO genetic variation and BMI
is detected. After the adiposity rebound, the correlation reverses and FTO SNPs
are associated with increased BMI (A = obesity risk allele, T = non-obesity risk
allele; Figure adapted from Sovio et al. [2011]).
however, is relatively small. One copy of the risk allele may account for as much as
1.5 kg increased body mass or approximately 0.4 kg/m2 higher body mass index
[Frayling et al., 2007]. This, however, renders the FTO SNPs not only the genomic
variants with the strongest obesity association, but also the variant with the biggest
effect size [Loos, 2012].
Interestingly, the positive association of FTO genomic variation develops at the
age of 5.5 years and is detectable in adults and elderly (Figure 1.2 b) [Sovio et al.,
2011; Frayling et al., 2007; Dina et al., 2007; Scuteri et al., 2007]. Before the age of
2.5 years, however, an inverse association of FTO genotype and BMI is detected
[Sovio et al., 2011]. The reversal of the relationship seems to coincide with the
adiposity rebound, the time point at which the BMI of children starts to steadily
increase after a period of decline from 2 to 5 years of age. Interestingly, each copy
of the rs9939609 risk-allele accelerates development by 2.4 %, resulting in a shift of
adiposity rebound in children.
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Influence on energy intake
Additional assessment of eating behaviour revealed an increased energy intake
for FTO risk-allele carriers in comparison to controls [Cecil et al., 2008; Timpson
et al., 2008; Speakman et al., 2008; Wardle et al., 2009; Haupt et al., 2009], possibly
due to an increase in fat consumption [Timpson et al., 2008; Tanofsky-Kraff et al.,
2009]. At the point of adiposity rebound (age 4-5) that coincides with the begin-
ning of the positive correlation of FTO variants with BMI, children with the obesity
risk-alleles already show increased consumption of highly palatable food [Wardle
et al., 2009]. Hence, this shift in food preference may represent, at least partly, the
underlying mechanism leading to increased BMIs observed later in life. Further
studies assessing the eating behaviour of children support this notion, reporting
increased food responsiveness (ages 3-4, questionnaire example: “Even if my child
is full, he/she finds room to eat his/her favourite food")[Velders et al., 2012], im-
paired satiety response (age 8-11 years; questionnaire example: “My child cannot
eat a meal if he/she has had a snack just before.“) [Wardle et al., 2008], loss of
control over eating (ages 6-19)[Tanofsky-Kraff et al., 2009] and lower postprandial
responses in hungry or satiated state [den Hoed et al., 2009; Karra et al., 2013].
Further attempts to link FTO variants to changes in energy expenditure have
been inconclusive so far. Both decreased, as well as increased energy expenditure
have been reported [Keller et al., 2011; Jonsson & Franks, 2009]. The majority of
studies, however, failed to find any association between FTO genotypes and en-
ergy expenditure [Speakman et al., 2008; Goossens et al., 2009; Hakanen et al., 2009;
Haupt et al., 2009; Berentzen et al., 2008]. On the contrary, physical activity attenu-
ates the impact of FTO genotypes on BMI [Vimaleswaran et al., 2009; Kilpelaeinen
et al., 2011].
Non obesity-related associations
Despite the robust association with obesity-related traits, FTO SNPs have recently
been associated with non obesity-related conditions. Some of these associations,
however, may indirectly impinge on energy intake. Decreased total consumption of
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alcohol (beer and spirits) independently of BMI is observed for rs9939609 risk-allele
carriers, with the consumption of larger amounts distributed over fewer occasions
as compared to controls [Sobczyk-Kopciol et al., 2011]. Correspondingly, the obesity
risk-allele was inversely correlated with alcohol dependency. Moreover, smokers
amongst obesity risk-allele carriers started tobacco consumption later in life and
smoke less cigarettes during times of heavy smoking [Sobczyk-Kopciol et al., 2011].
Both rs9930609 and rs8050136 FTO SNPs are linked to attention-deficit/ hyper-
activity syndrome (ADHD) [Velders et al., 2012; Choudhry et al., 2013]. Despite the
fact that unmedicated ADHD is associated with increasing risk of childhood obe-
sity [Waring et al., 2008], these FTO variants are inversely correlated with ADHD
independent of BMI. Independent of the assessed ADHD symptoms, rs9930609
carriers furthermore exhibited improved emotional control and increased food re-
sponsiveness [Velders et al., 2012].
First associations between several FTO genomic variations and major depressive
disorder described the modifying effects of this psychiatric disease on the FTO de-
pendent differences in BMI [Rivera et al., 2012]. Subsequently, the inverse relation
between depression and the rs9930609 FTO SNP was demonstrated [Samaan et al.,
2012]. Since depression is known to correlate positively with obesity [Pine et al.,
2001; Dockray et al., 2009], this inverse association is surprising. These findings
suggest a protective effect of the FTO obesity risk-alleles for major depressive dis-
order, with each copy of the allele decreasing the risk to develop depression by
approximately 8% [Samaan et al., 2012].
Despite psychiatric disorders that manifest early in life, FTO genomic variation
was furthermore linked to aging-associated cognitive decline. Reduced verbal flu-
ency is observed for obese male homozygous carriers of the obesity associated
rs9939609 ’A’ allele [Benedict et al., 2011]. Normal weight SNP carriers, as well as
normal and overweight non-carriers, however, retain their verbal capabilities. Cor-
respondingly, elderly subjects in treatment for cardiovascular disease and positive
for the rs8050136 risk-allele perform worse in a memory performance test (Califor-
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nia Verbal Learning Test) [Alosco et al., 2013]. Cognitive decline for FTO genotypes
was further confirmed, independent of age, gender, BMI or diabetes [Bressler et al.,
2013].
Dementia and Alzheimer’s disease are additional aging-associated diseases that
are linked to genotypic variation of the FTO gene. Carrying two copies of the
rs9930609 obesity risk-allele increases the risk to develop dementia and Alzheimer’s,
with no influence of physical activity, cardiovascular disease, BMI or diabetes on
this association [Keller et al., 2011]. Strikingly, the risk for dementia and Alzheimer’s
is almost triplicated by an interaction of FTO and apolipoprotein E (APOE) e4 risk
alleles. In line with these findings, healthy elderly rs3751812 SNP carriers exhibit
structural brain changes with an average reduction in brain volume of 8% (frontal
lobes) to 12% (occipital lobes) [Ho et al., 2010].
Finally, the mortality rate was shown to be increased for rs9939609 SNP carriers,
independent of obesity [Zimmermann et al., 2009]. Non carriers exhibit a 42%
reduced mortality rate, when compared to risk-allele carriers. Of note, diseases
of the nervous system were only found in risk-allele carriers as a cause of death.
These fatalities are, however, not the underlying reason for the overall elevated
mortality rate of risk-allele carriers.
Functional aspects of FTO single nucleotide polymorphisms
To date, the functional outcome of the genetic variation found within human
FTO is unknown. In fact, it still remains elusive, whether FTO is affected by these
variations at all. So far, only few studies tried to address the outcome of single
nucleotide polymorphism in the first intron of the FTO gene on its expression
and found increased FTO expression in peripheral blood cells and fibroblasts of
rs9939609 risk allele carriers [Karra et al., 2013; Berulava & Horsthemke, 2010]. Due
to the small sample size of these studies and the questionable functional relevance
of FTO expression in peripheral blood cells and fibroblasts, however, these results
are not compelling with respect to the biological function of FTO.
Orientated in the opposite direction and close to the first exon of FTO, lies
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the transcriptional start site of the RPGRIP1L gene (retinitis pigmentosa GTPase
regulator-interacting protein-1 like), that may as well be affected by the SNPs sit-
uated within this chromosomal area [Jacobsson et al., 2012; Stratigopoulos et al.,
2008]. Two putative CUX1 (CUTL1; cut-like homeobox 1) binding sites were found
within the SNP cluster, potentially leading to a transcriptional co-regulation of FTO
and RPGRIP1L [Frayling et al., 2007; Stratigopoulos et al., 2008, 2011]. Binding of
the p110 CUX1 isoform was further demonstrated to increase the activity of hu-
man FTO and RPGRIP1L minimal promotors, whereas the p200 isoform decreased
the activity [Stratigopoulos et al., 2011]. Additional evidence gathered in rodent
cell culture experiments points to a role of FTO and RPGRIP1L in leptin receptor
clustering at the ciliary pole. Thus, through increasing Fto and Rpgrip1l expression,
Cux1 may increase leptin receptor trafficking to the ciliary pole and increase leptin
sensitivity [Stratigopoulos et al., 2011]. As a result, FTO and RPGRIP1L may alter
food intake by affecting leptin sensitivity. Interestingly, the binding affinity of the
promoter activity increasing p110 isoform was found to be decreased in carriers of
the obesity-associated rs8050136 SNP. The potential decrease in FTO and RPGRIP1L
expression may in turn lead to a decreased leptin sensitivity, which could be the
underlying reason for the increased energy intake observed in obesity risk-allele
carriers [Stratigopoulos et al., 2011]. How FTO and/or RPGRIP1L would affect
leptin receptor clustering is not known in detail. RPGRIP1L, however, is part of
the basal cilium [Vierkotten et al., 2007; Delous et al., 2007] and is thus a poten-
tial link to ciliopathies, some of which are known to be related to obesity, such as
the Alström and Bardet Biedl syndromes [Berbari et al., 2013; Heydet et al., 2013;
Girard & Petrovsky, 2011; Ansley et al., 2003; Davenport et al., 2007]. Conversely,
though, Ftm-deficient mice (the ortholog of RPGRIP1L) have renal, hepatic and
brain abnormalities and no body weight phenotype [Delous et al., 2007]. Moreover,
patients with the Joubert and Meckel syndromes, both caused by loss-of-function
mutations in RPGRIP1L, are not obese, but suffer from brain and renal malforma-
tions [Devuyst & Arnould, 2008]. Hence, the proposed co-regulatory function of
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both FTO and RPGRIP1L in leptin receptor clustering at the ciliary pole demand
further investigation, to identify the underlying molecular mechanisms.
1.4.2 Human FTO phenotypes
Loss-of-function mutations
The importance of a functional FTO protein for the human organism was indi-
cated by the analysis of a rare loss-of-function mutation in the genomic sequence
of FTO in a palestinian arab family [Boissel et al., 2009]. The mutation, leading
to an amino acid substitution at position 316 of the FTO protein (arginine to glu-
tamine, R316Q), most likely impairs the interaction of FTO with the cosubstrate
2-oxoglutarate and thus renders the protein non-functional. As a result, all of the
eight examined patients born with the autosomal recessive mutation died before
the age of 3 while suffering from a severe phenotype, characterized by postnatal
growth retardation, microcephaly, brain malformations, severe psychomotor delay,
functional brain deficits, facial malformations and cardiac deficits [Boissel et al.,
2009]. Both, cognitive defects and changes in brain structure are also observed in
carriers of the human obesity risk-alleles, however, they do not reach the severity
of the FTO-deficient patients [Ho et al., 2010; Benedict et al., 2011].
FTO trisomy
In contrast to the aforementioned loss-of-function mutation, genomic triplica-
tions (trisomies) including the FTO gene show the other end of altered gene dosage.
Only few cases of partial trisomies of the human chromosome 16q are known so
far. Interestingly however, these cases share some phenotypic characteristics in-
cluding obesity, learning difficulties and aggressive behaviour [Barber et al., 2006;
van den Berg et al., 2010]. Due to the fact that the triplications of the proximal
arm of chromosome 16 include more than just one gene these observations cannot
be unambiguously attributed to FTO. Moreover, not all of the investigated patients
exhibited for example obesity [Barber et al., 2006].
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1.4.3 Murine Fto studies
Fto deficiency
Triggered by the growing interest in FTO and its function in regulation of body
weight, mouse models were employed to investigate the role of murine FTO in
energy homeostasis. Germline deletion of FTO through deletion of exons 2 and
3 of the murine Fto gene causes severe defects. Fto-deficient mice exhibit postna-
tal growth retardation accompanied by a 50% reduction in survival rate [Fischer
et al., 2009]. Furthermore, Fto-deficient mice have both reduced lean and fat mass
compared to wildtype littermates, caused by increased energy expenditure and
increased systemic sympathetic tone and despite reduced homecage activity and
relative hyperphagia. These characteristics, are at least partly in line with human
FTO-deficiency [Boissel et al., 2009], demonstrating again the importance of func-
tional FTO protein for mammalian organisms. Notably, heterozygous loss of FTO
renders mice tolerant to high fat feeding, while severe defects are rescued by one
functional Fto allele [Fischer et al., 2009]. Recently, these findings were confirmed
for the germline deletion of exon 3 in a conditional mouse model [McMurray et al.,
2013]. Furthermore, the conditional model enabled the adult onset, global FTO
deletion in mice through usage of a tamoxifen inducible Cre-recombinase (Cre-ER).
Since FTO expression was only altered after 6 weeks of age, these mice overcame
the postnatal growth retardation and premature death of germline FTO deletion. 3
weeks after tamoxifen treatment, adult onset Fto-deficient mice start loosing weight,
mainly due to a loss of lean mass possibly caused by increased protein utilization
[McMurray et al., 2013]. During the course of the following weeks, this initial loss
of weight was compensated by an increase in fat mass, despite any changes in
absolute food intake or energy expenditure.
Fto overexpression
To this end, the exact function of the single nucleotide polymorphisms in the
human FTO gene are not known. Two studies, however, showed increased FTO
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mRNA expression in peripheral blood cells of homozygous rs9939609 risk-allele
carriers suggesting that FTO genomic variation may cause increased FTO expres-
sion [Karra et al., 2013; Berulava & Horsthemke, 2010].
In mice, global overexpression of FTO causes obesity in a dose dependent man-
ner [Church et al., 2010]. Both on normal chow as well as on high fat diet, these
mice have an increased body weight and fat mass. Since no changes in energy ex-
penditure or locomotor activity are detected, the observed elevated food intake is
the most probable cause for the body weight changes [Church et al., 2010]. The in-
crease in food intake in those mice is in line with the reported alterations of energy
intake in human FTO variants, further supporting the notion that human variation
is associated with increased FTO expression or activity.
Peripheral tissue function
FTO is expressed in peripheral tissues [Gerken et al., 2007; Frayling et al., 2007;
Stratigopoulos et al., 2008]. To date, however, studies on peripheral FTO function
are scarce. In a mouse model of reduced FTO function (point mutation I367F),
gene expression analysis of white adipose tissue (WAT) revealed the downregu-
lation of several genes involved in inflammation, while multiple genes clustering
with the control of fat metabolism were found to be deregulated [Church et al.,
2009]. Several genes with known function in fatty acid metabolism, as well as
carbohydrate metabolism were upregulated in muscle of FTOI367F animals. The
observed gene expression changes may be related to some of the phenotypic obser-
vations for this mouse model, such as increased lean mass, reduced fat mass and
changes in metabolic rate. Cause and effect, as well as the connection between FTO
enzymatic function and expression changes, however, remain unanswered [Church
et al., 2009].
In human visceral and subcutaneous adipose tissue, FTO mRNA levels inversely
correlate with body mass index and age [Kloeting et al., 2008]. Moreover, FTO
mRNA expression is downregulated during human adipocyte differentiation [Tews
et al., 2011]. Furthermore, a reduced lipolytic activity was reported for female
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rs9939609 risk-allele carriers in vivo and in vitro [Wåhlén et al., 2008].
Recently, a reduced de novo lipogenesis was observed for human adipocytes af-
ter lentiviral knock down of FTO [Tews et al., 2013]. More strikingly, however,
was the browning of white adipocytes, both in Fto-deficient mice, as well as in
human adipocytes after shRNA mediated FTO knock down [Tews et al., 2013].
Concomitantly, significant upregulation of UCP-1 was detected in Fto-deficient
mouse adipose tissue and FTO-deficient human adipocytes. In FTO-deficient hu-
man adipocytes, this led to increased mitochondrial uncoupling in comparison
to control cells. Reminiscent of a UCP-1 upregulation in brown adipocytes, Fto-
deficient mice have a higher energy expenditure [Fischer et al., 2009]. Therefore,
loss of FTO and the resulting functional browning of white adipocytes may serve
as an explanation for the increased energy expenditure in Fto-deficient mice.
Fto in the central nervous system
FTO is ubiquitously expressed, however, by far the highest levels of FTO are
detected in the central nervous system [Gerken et al., 2007; Frayling et al., 2007;
McTaggart et al., 2011; Fredriksson et al., 2008]. Within the brain, FTO is found in the
majority of neurons [McTaggart et al., 2011]. Due to the high expression in feeding
related nuclei of the hypothalamus (paraventricular nucleus PVN; arcuate nucleus
ARC; ventromedial nucleus VMH; dorsomedial nucleus DMH), an important role
for FTO in the regulation of energy homeostasis was proposed [Gerken et al., 2007;
Tung et al., 2010].
Brain specific Fto deletion in mice recapitulates several phenotypic characteristics
of whole body Fto-deficiency [Gao et al., 2010; Fischer et al., 2009]. Comparable to
Fto-defcient mice, brain specific loss of FTO leads to postnatal growth retardation,
decreased IGF-1 serum concentrations and reduced body weight due to a reduction
in lean mass. Since the Nestin-cre line used to generate the brain specific knock out
model was reported to suffer from a hypopituitarism phenotype which could po-
tentially cause several of the observed alterations [Galichet et al., 2010], the results
of this study have to viewed cautiously.
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Several studies adressed the role of FTO within the feeding related nuclei of
the hypothalamus through virus mediated manipulation of FTO expression. Over-
expression of FTO in the rat arcuate nucleus resulted in a decreased daily food
intake, while a reduction in FTO caused an increase in food intake [Tung et al.,
2010]. Virus mediated knock out of Fto in the mediobasal hypothalamus of a con-
ditional mouse model, however, led to the opposite result, causing a decrease in
food intake [McMurray et al., 2013]. Since the latter study targeted a larger area
of the hypothalamus, the behavioural outcome of Fto knock down may depend on
the affected neuronal population.
Recently, for the first time, FTO genomic variation was investigated regarding
human brain function. In line with previous findings, carriers of the risk-allele
(rs9939609 ’A’ allele) displayed attenuated suppression of hunger following a stan-
dard test meal [den Hoed et al., 2009; Karra et al., 2013]. Moreover, regardless of
feeding state, neuronal activity assessed by functional MRI in response to food im-
ages was altered in homozygous rs9939609 risk-allele carriers [Karra et al., 2013].
Changes in BOLD signal were detected in homeostatic, as well as hedonic brain ar-
eas. Furthermore, while the neuronal response to pictures of highly palatable food
in control subjects positively covaried with increasing acyl-ghrelin levels, it nega-
tively covaried in risk-allele carriers [Karra et al., 2013]. Acyl-ghrelin is known to
potently stimulate hunger and to increase food intake [Uchida et al., 2013]. Hence,
altered responses to acyl-ghrelin, or changes in acyl-ghrelin levels could potentially
alter energy intake in FTO risk-allele carriers. Postprandialy, rs9939609 SNP carri-
ers show an increased acyl-ghrelin to ghrelin ratio, due to a failure in reduction of
acyl-ghrelin levels after a meal [Karra et al., 2013]. The same increase in acyl-ghrelin
to ghrelin ratio was observed in vitro, if FTO was overexpressed. In Fto-deficient
mice, on the other hand, this ratio is decreased [Karra et al., 2013]. Hence, FTO may
play a critical role in regulating ghrelin and acyl-ghrelin levels. Moreover, it may
modulate the responses of homeostatic, as well as hedonic brain areas and thus
shape hunger and/or satiety responses.
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1.4.4 Molecular function of FTO
Cellular localisation
FTO is ubiquitously expressed [Gerken et al., 2007; Frayling et al., 2007; Fredriks-
son et al., 2008]. The highest levels are, however, reported for the central ner-
vous system and especially for feeding related brain areas [Gerken et al., 2007;
Frayling et al., 2007; Tung et al., 2010; McTaggart et al., 2011; Stratigopoulos et al.,
2008; Fredriksson et al., 2008]. Hence, it was proposed that FTO plays a critical
role in the central nervous system. FTO primarily localizes to the nucleus of a cell
[Gerken et al., 2007; McTaggart et al., 2011]. Only limited evidence so far suggests
the presence of FTO in the cytoplasma depending on feeding state [Vujovic et al.,
2013]. Within the nucleus, it colocalizes in nuclear speckles with splicing factors,
such as SART1 (U4/U6.U5 tri-snRNP-associated protein 1), SC35 (serine/arginine-
rich-splicing factor 2) and Pol II-S2P (RNA polymerase II phosphorylated at Ser2)
[Jia et al., 2011]. Therefore, despite direct evidence for a connection to mRNA pro-
cessing, FTO was proposed to play a role in splicing processes.
In mice, FTO is reported to be coexpressed with the satiety mediator oxytocin
[Olszewski et al., 2009, 2011]. Furthermore, overexpression of FTO in vitro leads to
increased oxytocin mRNA levels [Olszewski et al., 2011].
Since FTO was associated with the development of obesity and aberrant feeding
behaviour [Cecil et al., 2008; Timpson et al., 2008; Speakman et al., 2008; Wardle
et al., 2009; Haupt et al., 2009; Tanofsky-Kraff et al., 2009], FTO expression may vary
with nutritional status. So far, however, findings are contradictory. In rats, fast-
ing (48h) led to increased Fto transcript levels [Fredriksson et al., 2008], whereas
the same 48h fast in mice and long term food restriction in rats (60% of ad libi-
tum) cause decreases in Fto mRNA [Gerken et al., 2007; Wang et al., 2011]. In a
different restriction scheme in mice (food only available from 13:00 to 15:00h each
day), however, Fto transcript levels were significantly increased in the arcuate and
ventromedial hypothalamus [Boender et al., 2012]. Other studies failed to detect
differences for Fto mRNA in mice for both long term (40h) [Stratigopoulos et al.,
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2008] or overnight fasting [McTaggart et al., 2011]. On the protein level, FTO levels
were unchanged in response to a overnight fast [McTaggart et al., 2011], whereas
reduced levels were measured after long term food restriction (60% of ad libitum)
in rat hypothalamus and brainstem [Wang et al., 2011]. Of note, the reduction of
FTO protein caused by food restriction depends on leptin receptors and functional
STAT3 signaling. A reduction of FTO levels due to caloric restriction was not ob-
served on a leptin-deficient background [Wang et al., 2011]. Furthermore, centrally
administered leptin reduced Fto mRNA levels in mouse hypothalamus, a result re-
produced by application of leptin on a hypothalamic slice preparation [Wang et al.,
2011].
Vice versa, FTO was proposed to influence leptin signaling through alteration of
leptin receptor clustering [Stratigopoulos et al., 2011]. Furthermore, overexpression
of FTO in rat arcuate nucleus increased STAT3 mRNA levels by 4-fold [Tung et al.,
2010]. Moreover, global Fto overexpression in mice resulted in reduced fasting
plasma levels of leptin at 8 weeks of age, but not at 20 weeks [Church et al., 2010].
Hence, the relationship between leptin and FTO, as well as the regulation of FTO
expression itself seems to be complex and demands further investigation.
FTO in amino acid sensing
In addition to the aforementioned observations, FTO has been reported to rely on
nutrient availability. Glucose deprivation, as well as total amino acid deprivation
cause both a reduction in Fto mRNA and protein in a hypothalamic cell culture
(N46 cells) [Cheung et al., 2013]. Further experiments have proven that essential
amino acid deprivation is sufficient to downregulate FTO, presenting a potential
link between energy metabolism and FTO expression [Cheung et al., 2013].
Loss of Fto leads to growth defects, both in vitro and in vivo. Postnatal growth
retardation is observed in Fto-deficient mice, while Fto-deficient MEFs (mouse em-
bryonic fibroblasts) have reduced growth rates and translation levels [Gulati et al.,
2013; Fischer et al., 2009]. Further analysis revealed a downregulation of the multi-
synthetase complex (MSC) in knock out MEFs and a physical interaction of FTO
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with several components of the MSC [Gulati et al., 2013]. Through coordination
of aminoacyl-tRNA synthetases, the MSC is taking part in the translational regu-
lation. Hence, failure to assemble the complex would lead to reduced translation.
Re-expression of Fto on a Fto-deficient background, however, restored levels of the
MSC complex and rescued translational rate [Gulati et al., 2013].
Moreover, loss of Fto affects mTORC1 (mammalian target of rapamycin complex
1) signaling, a key-regulatory pathway of translation and growth. Fto deficiency
leads to reduced phosphorylation of the mTOR effector kinase S6K1 (S6-kinase 1)
[Gulati et al., 2013]. Furthermore, the downregulation of mTORC1 in response to
amino acid deprivation, a physiologically relevant process, is prevented by over-
expression of exogenous FTO [Gulati et al., 2013]. Expression of a catalytically
inactive form of FTO (R316Q), however, is not able to block this downregulation of
mTORC1. Hence, mTORC1 depends on the enzymatic activity of Fto [Gulati et al.,
2013]. The apparent amino acid dependent regulation of Fto expression and fur-
ther coupling of FTO activity to the MSC and mTORC1 signaling present a possible
model for the integration of FTO in metabolic processes. The exact mechanisms,
however, demand further investigation.
2-oxoglutarate dependent nucleic acid demethylase
Interestingly, the FTO gene is only present in algae and vertebrates, but is absent
in invertebrates, plants, fungi, bacteria or archaea [Fredriksson et al., 2008; Gerken
et al., 2007; Sanchez-Pulido & Andrade-Navarro, 2007; Robbens et al., 2008]. Using
bioinformatical sequence comparison, FTO was found to be closely related to the
bacterial AlkB (alpha-ketoglutarate-dependent dioxygenase) and human AlkB ho-
mologs (ABH1, ABH2 and ABH3) [Gerken et al., 2007; Sanchez-Pulido & Andrade-
Navarro, 2007; Han et al., 2010]. The FTO protein features the conserved 2-oxogluta-
rate (2-OG) and Fe(II) binding sites, typical for the 2-OG dependent dioxygenases
of the AlkB family of enzymes [Gerken et al., 2007]. Due to its role as an inter-
mediate product of the Krebs-cycle, 2-OG was proposed to link FTO to metabolic
processes. Since the 2-OG Km for FTO (2.88 µM), however, is 10 fold below physi-
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ologically relevant concentrations of 2-OG, FTO is unlikely to convey information
of the current metabolic status through sensing 2-OG levels [Ma et al., 2012].
AlkB and human AlkB homologs (ABH2 and 3) have been described as DNA re-
pair enzymes, which demethylate cytotoxic 1 - methyladenine and 3 - methylcyto-
sine [Trewick et al., 2002; Aas et al., 2003]. Correspondingly, FTO was demonstrated
to demethylate 3 - methylthymine (m3T) in single stranded DNA (ssDNA) and 3
- methyluracil (m3U), as well as N6 - methyladenosine (m6A) in ssRNA [Gerken
et al., 2007; Jia et al., 2008, 2011; Meyer et al., 2012]. A C-terminal loop, unique to
2-OG dependent oxygenases, was identified through solving the crystal structure
of FTO and probably causes its preference for single stranded rather than double
stranded DNA/RNA [Han et al., 2010]. Moreover, its demethylase efficiency is
slightly higher for RNA than DNA and m6A does not occur in DNA, thus suggest-
ing that RNA is the primary target of FTO [Jia et al., 2008; Ratel et al., 2006].
1.5 m6A RNA modification
1.5.1 RNA and RNA modifications
RNA (ribonucleic acid) is a central molecule in any organism that may appear
in many different forms, serving a plethora of different functions. The relatively
short-lived and low-abundant messenger RNA (mRNA) is the carrier molecule
for the genetic information encoded in the genome. Approximately 97% of the
RNA in a cell, however, belongs to the non protein coding RNA families, includ-
ing transfer RNA (tRNA), ribosomal RNA (rRNA), small nuclear RNA (snRNA),
small-interfering RNA (siRNA), micro RNA (miRNA) and long noncoding RNA
(lncRNA) [Sharp, 2009]. The most abundant type of RNA is rRNA, which forms
the catalytic domain in ribosomes and hence is a key component of protein syn-
thesis. During protein synthesis, tRNA molecules are the mediators that match the
correct amino acid to the corresponding base triplet found within the protein cod-
ing mRNA molecule. In both rRNA and tRNA, the secondary and tertiary structure
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is of importance for their correct function. Small nuclear RNAs play an important
role in pre-mRNA splicing in the nucleus [Sharp, 2009]. Small-interfering and mi-
cro RNAs on the other hand, represent the means for silencing gene expression
at the RNA level through translational/transcriptional silencing or mRNA decay
[Sharp, 2009]. Regulation of gene expression is also regulated by long noncoding
RNAs, however, their mode of action most probably involves binding of proteins
such as transcription factors or formation of protein complexes [Rinn & Chang,
2012].
Modification of the four nucleotides enhances the diversity of RNA species and
is needed for the complex functional purposes of RNA. To date, 109 post-tran-
scriptional modifications have been identified in most of the different types of
RNA species [Cantara et al. [2011] and ’The RNA Modification Database’: http:
//mods.rna.albany.edu/, date: 09/20/2013]. Interestingly, the RNA modifications
are dynamic and thus may represent yet another level of epigenetic adjustments
to environmental input [Yi & Pan, 2011]. Most of the modifications have been de-
scribed in tRNA and rRNA. However, 13 modifications are reported for mRNA.
These modifications include N7 - methylguanosine (m7G), 2’-O - methylnucleotide
(Nm), 5 - methylcytosine (m5C), N6 - methyladenosine (m6A), N6-methyl-2’- O
- methyladenosine (m6Am). m7G and 2’-O - methylnucleotide are modifications
found within and being important for the 5’CAP structure of a mRNA molecule
[Jia et al., 2012], thus enabling the recruitment of initiation factors and translation,
nuclear export, as well as promoting mRNA stability [Sonenberg & Hinnebusch,
2009]. m6A and m5C, on the other hand, are internal modifications found within
the 5’UTR, coding sequence (CDS) or 3’ UTR of mRNAs, whose functions so far
are largely unknown [Jia et al., 2012].
1.5.2 N6-methyladenosine (m6A)
Despite the fact that the N6-methyladenosine (m6A) RNA modification has been
known since the 1970s, to date the purpose of this most abundant RNA methyla-
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tion remains largely unknown [Desrosiers et al., 1974; Harper et al., 1990; Jia et al.,
2012]. m6A is present in a variety of organisms, including plants [Nichols, 1979;
Zhong et al., 2008], yeast [Clancy et al., 2002; Bodi et al., 2010], flies [Levis & Pen-
man, 1978] and mammals [Wei et al., 1975; Shatkin, 1976; Desrosiers et al., 1974; Jia
et al., 2011]. Moreover, it has been detected in viral RNA [Krug et al., 1976; Kane
& Beemon, 1985]. m6A has been found in rRNA and tRNA [Saneyoshi et al., 1969;
Iwanami & Brown, 1968]. Despite the scarce knowledge, m6A is suggested to be im-
portant for mRNA processing, export from the nucleus, stability and translational
efficiency [Harper et al., 1990; Pan, 2013; Jia et al., 2012; Niu et al., 2013; Dominissini
et al., 2012; Tuck et al., 1999]. The methylation mark is also found in intronic re-
gions of pre-mRNA, showing that it is present before splicing [Carroll et al., 1990].
Moreover, m6A on RNA may serve as a label for endogenous RNA that helps the
innate immune system to identify foreign RNA molecules [Karikó et al., 2005]. To
date, several putative m6A binding proteins have been reported [Dominissini et al.,
2012]. Two of those proteins are members of the YTH (YT521 homology) family
and have been previously described to be involved in alternative splice site selec-
tion and mRNA degradation [Rafalska et al., 2004; Harigaya et al., 2006]. Indeed,
most recently, YTHDF2 was shown to bind to a subset of m6A methylated mRNA
transcripts and to subsequently shuttle these transcripts to, for example, processing
bodies (p bodies) for RNA degradation [Wang et al., 2013]. Hence, mRNA stability
and lifetime depends on m6A methylation status and thus will limit the pool of
templates available for translation [Wang et al., 2013]. Furthermore, m6A sites are
overrepresented in transcripts that harbor putative miRNA binding sites and highly
expressed miRNAs in the brain have a greater percentage of target transcripts with
m6A sites, suggesting, that miRNA levels may be involved in the methylation pro-
cess itself [Meyer et al., 2012]. Despite mRNA, m6A is also found in long noncoding
RNA, whose mode of action is yet to be finally determined [Meyer et al., 2012].
Before the development of deep sequencing techniques, only two mRNAs were
identified that harbor m6A sites. One was found to be in the 3’UTR of bovine
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Figure 1.3: Reversible N6-methyladenosine modification FTO demethylates N6-
methyladenosine (m6A) in a 2-oxoglutarate and Fe(II) dependent manner.
The reverse reaction of m6A demethylation involves a m6A-methyltransferase
complex that contains several subunits, one of which is METTL3.
prolactin [Horowitz et al., 1984], whereas several sites were identified in the Rous
sarcoma virus RNA [Kane & Beemon, 1985]. Further analysis led to the description
of the consensus site: RRACH (R = G or A, H = A, C or U) [Horowitz et al., 1984;
Harper et al., 1990; Csepany et al., 1990]. Within each mRNA, however, not all m6A
sites are methylated. Prevalence for m6A in the Rous sarcoma virus RNA is within
20 to 90 % of all sites [Kane & Beemon, 1985] and only about 20 % for bovine
prolactin [Horowitz et al., 1984; Narayan et al., 1994].
So far, only one subunit of a nuclear human m6A-methyltransferase complex was
decribed [Bokar et al., 1994, 1997]. METTL3 (or MTA70) is a homolog of the yeast
IME4 (inducer of meiosis), which methylates mRNA in yeast during sporulation
(Figure 1.3) [Clancy et al., 2002; Bodi et al., 2010]. Both in plants, as well as in flies,
the homologs of METTL3 are important regulators of development [Zhong et al.,
2008; Hongay & Orr-Weaver, 2011]. Consistently, knock down of METTL3 affects
HepG2 cells, resulting in deregulation of p53 signaling components and apoptosis
[Dominissini et al., 2012]. METTL3 colocalizes in the nucleus with nuclear speckles.
Hence, the methylation may occur already during transcription [Bokar et al., 1997].
Recently, FTO was shown to demethylate m6A in single stranded RNA and sin-
gle stranded DNA in vitro (Figure 1.3) [Jia et al., 2011]. Since m6A is not detected
in genomic DNA, RNA represents the physiological substrate of FTO [Ratel et al.,
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2006]. Further experiments confirmed the demethylation of m6A in mRNA by FTO
[Jia et al., 2011; Meyer et al., 2012]. Like METTL3, FTO localizes primarily in the
nucleus and was furthermore reported to colocalize with splicing factors such as
SART1 and SC35 in nuclear speckles [Jia et al., 2011; McTaggart et al., 2011; Gerken
et al., 2007]. In addition to FTO, a second m6A demethylase, alkB alkylation re-
pair homolog (ALKBH)5, has been identified [Zheng et al., 2012]. ALKBH5, like
FTO, is ubiquitously expressed, but in contrast to FTO exhibits highest expression
levels in peripheral tissues and relatively low levels in the central nervous system
[Zheng et al., 2012]. Loss of ALKBH5 in mice affects nuclear mRNA export, RNA
metabolism and influences the localization of RNA processing proteins in the nu-
cleus [Zheng et al., 2012]. Alkbh5-deficient mice exhibit impaired fertility due to
increased apoptosis and abnormal spermatogenesis [Zheng et al., 2012].
Taken together, the identification of the m6A methyltransferase METTL3 and the
m6A demethylases FTO and ALKBH5 demonstrates once more that RNA methy-
lation is probably a dynamic process putatively in control of mRNA processing,
nuclear export, turnover, translation and first evidence for a role in mRNA stability
[Wang et al., 2013; Pan, 2013; Jia et al., 2012].
1.5.3 The m6A methylome
The development of next-generation sequencing enabled the thorough analysis of
the whole transcriptome with respect to m6A methylation sites, the m6A methy-
lome [Dominissini et al., 2012; Meyer et al., 2012]. Approximately 100 nucleotide
long RNA fragments were immunoprecipitated with a m6A antibody and sub-
sequently subjected to high-throughput sequencing. Both studies identified the
m6A mark in more than 7000 mRNA transcripts and approximately 300 non cod-
ing RNAs in both humans [Dominissini et al., 2012] and mice [Meyer et al., 2012],
showing that m6A is a common and conserved modification. m6A sites were found
to be enriched in the 3’UTR near the stop codon, coding sequence and to a lesser
extent in the 5’UTR of mRNA transcripts [Dominissini et al., 2012; Meyer et al.,
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2012]. m6A levels are increasing during the course of mouse brain development
and show tissue dependent prevalence [Meyer et al., 2012]. Environmental stimuli,
such as heat shock, UV irradiation or hepatocyte growth factor did not influence
the m6A peak positions, however some dynamic modulation was observed upon
interferon γ treatment [Dominissini et al., 2012]. Levels of m6A-methylation de-
pend on FTO and its enzymatic activity in vitro [Dominissini et al., 2012; Meyer
et al., 2012]. Hence, FTO most probably plays a critical role in what may represent
a novel and dynamic RNA epigenetic process affecting cellular programs important
for e.g. energy homeostasis.
1.6 Objectives
The aim of this study was to investigate the potential role of the fat mass and
obesity-associated gene (Fto) in the dopaminergic system. Since some of the char-
acteristics of Fto-deficient mice resemble features of DRD2-deficient mice [García-
Tornadu et al., 2010; Díaz-Torga et al., 2002; Sibley, 1999; Kelly et al., 1998; Beaulieu
& Gainetdinov, 2011] and as both FTO, and dopamine have been implicated in the
etiology of obesity [Scuteri et al., 2007; Dina et al., 2007; Frayling et al., 2007; Volkow
et al., 2013; Wang et al., 2001], FTO might play a critical role in dopaminergic sig-
naling. To investigate this hypothesis, both whole body, as well as DA neuron
restricted Fto-deficient mice were utilized.
2 Materials and Methods
2.1 Animal care
Mice (Mus musculus, C57Bl/6) were housed in a virus-free facility at 22-24°C on
a 12 h light/ 12 h dark cycle. Animals were either fed standard rodent chow
(Teklad Global Rodent 2018; 53.5% carbohydrates, 18.5% protein, 5.5% fat (12%
calories from fat); Harlan, IN, USA) or a high fat diet (C1057; 32.7% carbohydrates,
20% protein, 35.5% fat (55.2% calories from fat); Altromin, Lage, Germany). All
animals had access to water and food ad libitum, except 16h fasting prior to glu-
cose tolerance test and refeeding experiments. Procedures and euthanasias were
reviewed by the animal care committee, approved by local government authori-
ties (Tierschutzkommission acc. §15 TSchG of the Landesamt für Natur, Umwelt
und Verbraucherschutz North Rhine Westphalia) and were in accordance with NIH
guidelines.
2.2 Experimental mouse models
For the investigation of the effect of global deficiency, mice with a germline dele-
tion of exon 2 and 3 of the Fto gene were employed [Fischer et al., 2009]. For all ex-
periments, whole body Fto deficient mice (homozygous knock outs) and wildtype
littermates were used. To investigate the role of FTO specifically in dopaminergic
neurons, mice expressing the Cre-recombinase under the control of the endogenous
Dat promoter [Ekstrand et al., 2007] were crossed to mice with a loxP site flanked
third Fto exon (provided by EUCOMM). If not otherwise stated, DAT-Cretg/wt;
Fto f l/ f l and their respective littermate controls DAT-Crewt/wt; Fto f l/ f l were used
for experiments.
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2.3 Genotyping
Isolation of genomic DNA
Mouse tail biopsies were taken at weaning age and subsequently digested in 500
µl tail lysis buffer (100 mM Tris-HCl pH 8.5, 5 mM EDTA pH 8.0, 0.2% SDS, 200 nM
NaCl) containing proteinase K (1/100) at 55°C. DNA was precipitated using 500 µl
100% isopropanol and centrifugation at 17.000g. Afterwards, DNA was washed
with 750 µl 70% ethanol, centrifuged at 17.000g and dried. The DNA pellet was
resuspended in TE buffer (10 mM Tris-HCl pH 7.5, 1 mM EDTA) containing RNase
(1/1000) or ddH2O.
Polymerase chain reaction
For genotypic analysis, polymerase chain reaction (PCR) was performed on tail
DNA using the primers given in table 2.1. For PCR DreamTaq PCR MasterMix and
DNA polymerase (Fermentas/Fisher Scientific Germany GmbH, Schwerte, Ger-
many) was used. Standard PCR contained approx. 50 ng DNA, 25 pMol of each
primer, 25 µM dNTP mix and 1 unit DNA polymerase in a 25 µl reaction mix.
Table 2.1: Genotyping Primer
Mouse Line Primer Sequence 5’-3’
DAT-Cre DAT_F3 CATGGAATTTCAGGTGCTTGG
Cre_R2 CGCGAACATCTTCAGGTTCT
DAT_R1 ATGAGGGTGGAGTTGGTCAG
Fto flox (FLP deleted) Fto_5b TCAATCCTGGGCTAACATTTACCA
Fto_3b TTTATGGCCTTCGGCTTCAC
Fto flox (non FLP deleted) Fto_5b TCAATCCTGGGCTAACATTTACCA
Fto_3b_euc GGGATCCTCTAGAGTCCAGAT
Fto_3b_wt CAGCGGCGATCTCAGCCTC
Fto deletion Fto_5b TCAATCCTGGGCTAACATTTACCA
Fto_3a TGGTGACTTCCAACCATTCATC
Fto conventional Fto_5’ ACCCCTCTCCCCCATCTAAATCCT
Fto_3’ AAGCCAAGAACAAGTCCATACCTG
Neo_5’ CTGTGCTCGACGTTGTCACTG
Neo_3’ GTCCCGCTCAGAAGAACTCGT
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2.4 Phenotyping
2.4.1 Body weight
Body weight was assessed weekly for each individual mouse for ages 4-16 (18)
weeks. After weaning, animals were either fed a normal chow diet or high fat diet.
2.4.2 Insulin tolerance test
For insulin tolerance test, baseline blood glucose levels (time point 0 min) were
measured using a glucometer (GlucoMen PC, A.Menarini Diagnostics, Italy). Fol-
lowing intraperitoneal administration of insulin (0.75 units ml−1; 0,75 units kg−1
body weight), blood glucose levels were measured 15, 30 and 60 minutes after
injection. For determination of insulin tolerance, 15, 30 and 60 min values were
calculated relative to baseline blood glucose levels for each individual mouse and
plotted over time.
2.4.3 Glucose tolerance test
Mice were fasted 16h prior to glucose tolerance test. Fasting state blood glucose
levels (time point 0 min) were determined using a glucometer (GlucoMen PC,
A.Menarini Diagnostics, Italy). Following intraperitoneal administration of glu-
cose solution (20%, 10 ml kg−1 body weight), blood glucose levels were measured
at 15, 30, 60 and 120 minutes after injection. For determination of glucose tolerance,
blood glucose levels (in mg dl−1 blood) were plotted over time.
2.4.4 Indirect calorimetry
Energy expenditure was measured using indirect calorimetric measurements in a
PhenoMaster System (TSE systems, Bad Homburg, Germany). Animals were al-
lowed to adapt to the single housing in metabolic chambers (7.1 liter) for a training
phase of 5 days. During that time, animals were monitored daily to ensure proper
adaptation to the drinking and feeding dispensers. Calorimetric measurement was
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conducted at 22-24°C over a period of 48-72 hours, assessing oxygen consumption,
carbon dioxide production and locomotor activity (light barrier frame, TSE sys-
tems). Moreover, water and food intake was assessed using automated measuring
devices (TSE Systems). Indirect calorimetry was performed with great help and
advice of Hella Brönneke and Jens Alber.
2.4.5 Food intake and refeeding response
Daily food intake was either measured automatically during calorimetric measure-
ments (figure 3.15 e and f) or manually using a food hopper (figure 3.17). In either
case, mice were allowed to adapt to single housing and food hoppers for 4-5 days.
Food intake measurements were conducted for at least 3 consecutive days. All food
intake measurements were performed for single caged mice. Refeeding response
was measured after a 16h over night fast. Consumed food was measured manually
1, 2, 4, 8 and 24h after returning the food hopper to the home cage.
2.5 Microarray expression analysis
RNA was isolated from midbrain tissue (VTA/SN) using peqGOLD TriFast and
following the recommended protocols (peqlab, Erlangen, Germany). Quality of
RNA (n=3/genotype) was assessed on a Bioanalyzer chip and subsequently hy-
bridized on GeneChip Mouse Gene 1.0 ST Arrays (Affymetrix, Santa Clara CA,
USA). RNA quality check and array hybridization was performed by the Cologne
Center for Genomics (CCG, Cologne, Germany). Background correction and nor-
malization for the intensity values were performed using the Affymetrix Power-
tools (Affymetrix, Santa Clara CA, USA) and robust multi-array average (RMA).
Fold change of intensity values, as well as statistics (calculation of p-value and
false discovery rate (FDR)) were calculated in R (using the bioconductor software
package). Genes were considered significantly dysregulated for p-values ≤ 0.05
and FDR ≤ 0.25. HeatMap of significantly deregulated genes was generated using
R.
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2.6 Quantitative polymerase chain reaction
2.6.1 Preparation of RNA
Fresh brain samples of different brain areas were prepared using a brain slicer
(Braintree Scientific, Braintree MA, USA) and snap frozen in liquid nitrogen. RNA
was isolated from tissues using peqGOLD TriFast (Peqlab, Erlangen, Germany)
according to the manufacturer’s protocol and RNA pellets were resuspended in
DEPC water. RNA concentrations were assessed by measuring absorption at 260
and 280 nm using a NanoDrop ND-1000 UV-Vis Spectrophotomoter (Thermo Fisher
Scientific Inc., Schwerte, Germany). Afterwards, RNA samples were adjusted to
equal concentrations for further processing.
2.6.2 Reverse transcription and quantitative PCR
RNA (100 to 200 ng µl−1 per sample) was reversely transcribed with High-Capacity
cDNA Reverse Transcription kit (Applied Biosystems, Foster City CA, USA) and
amplified using TaqMan Gene Expression Master Mix with TaqMan Assay-on-
demand kits (Applied Biosystems) following the manufacturer’s protocol. Realtime
probes used for gene expression analysis are listed in table 2.2. Relative expression
was determined for target mRNA and samples were adjusted for total mRNA con-
tent by quantitative PCR for housekeeping genes (Gusb, Hprt, Tfrc). Calculations
were performed by comparative method (2−∆∆CT ) [Livak & Schmittgen, 2001].
Table 2.2: Realtime PCR probes
Symbol Transcript Name Probe
Fos FBJ murine osteosarcoma viral oncogene homolog Mm00487425_m1
Dbh Dopamine beta hydroxylase Mm00460472_m1
Drd2 Dopamine receptor D2 Mm00438545_m1
Drd3 Dopamine receptor D3 Mm00432887_m1
Grin1 glutamate receptor, ionotropic, NMDAR1 (zeta 1) Mm01336437_m1
Gusb Beta-glucuronidase Mm00446953_m1
Hprt Hypoxanthin-phosphoribosyl-transferase Mm00446968_m1
Continued on next page
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Table 2.2 – continued from previous page
Symbol Transcript Name Probe
Kcnj6 potassium inwardly-rectifying channel, subfamily J,
member 6
Mm00440070_m1
Slc6a3 Dopamine transporter Mm00438388_m1
Tfrc Transferrin receptor Mm00441941_m1
Th Tyrosine hydroxylase Mm00447557_m1
2.7 Protein biochemistry
2.7.1 Protein preparation
Tissues, initially frozen in liquid nitrogen, were thawed and homogenized in RIPA
buffer (20 mM Tris-HCl pH 8.0, 150 mM NaCl, 1% NP-40, 10 mM NaF, 1 mM so-
dium vanadate, 1 mM sodium pyrophosphate, 1 protease inhibitor (cOmplete Mini,
Roche Diagnostics, Basel, Switzerland) for 10 ml RIPA buffer and, if necessary, 1
PhosSTOP phosphatase inhibitor (Roche Diagnostics, Basel, Switzerland)) using ei-
ther a Ultra-Turrax homogenizer (IKA Werke, Staufen, Germany) or manually with
a pestle. Following homogenization, samples were incubated for 10 min on ice and
subsequently centrifuged for 20 min at 4°C. Supernatant was transferred to fresh
tubes and kept on -80°C for long term storage.
2.7.2 Western blot
For Western blots, protein samples were boiled for 5 minutes in SDS-PAGE sam-
ple buffer (1:3 dilution in 4x SDS loading buffer: 125 mM Tris-HCl pH 6.8, 5%
SDS, 43.5% glycerol, 100 mM DTT, and 0.02% bromphenol blue). Proteins were
separated by SDS-PAGE and blotted onto PVDF membranes (Bio-Rad, Munich,
Germany). Membranes were incubated for at least 1h with 1% blocking reagent in
TBS/T at room temperature (Roche, Mannheim, Germany) and subsequently with
primary antibody diluted in 0.5% blocking solution for 1 h at room temperature
or over night at 4°C. After three washing steps with TBS/T, membranes were in-
cubated for 1 h at RT with the respective secondary antibodies. Antibodies used
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for Western blot are listed in table 2.3. The signals were visualized after 3 wash-
ing steps with TBS/T using Pierce ECL Western Blotting Substrate (Perbio Science,
Bonn, Germany) and exposition to Amersham Hyperfilm chemiluminescent film
(GE Healthcare, Little Chalfont, UK).
Table 2.3: Antibodies for Western blot
Antibody Cat.No. Supplier
β-ACTIN A5441 Sigma Aldrich Co. LLC.
CALNEXIN 208880 Calbiochem
DAT SC-14002 Santa Cruz Biotechnology, Inc.
DRD2 ab21218 Abcam, Inc.
ab32349 Abcam, Inc.
sc-5303 Santa Cruz Biotechnology, Inc.
DRD3 ab42114 Abcam, Inc.
FTO custom antibody pro-
duced in guinea-pig
provided by U. Rüther/Pineda antibody services,
Berlin, Germany
GIRK2 ab30738 Abcam, Inc.
GNAI1 #5290 Cell Signaling Technology, Inc.
HSC70 sc-7298 Santa Cruz Biotechnology, Inc.
IKK2 #2370 Cell Signaling Technology, Inc.
NMDAR1 #5704 Cell Signaling Technology, Inc.
TH ab112 Abcam, Inc.
2.8 Behavioural experiments
2.8.1 Open Field
Open field experiments were performed in open field box for mice (TSE Systems,
Bad Homburg, Germany). One day before experiments, mice were injected in-
traperitoneally (i.p.) with saline and allowed to explore the open field box for
5 minutes. For baseline locomotor activity, mice were injected i.p. with vehicle
(saline). The following days, mice were administered cocaine hydrochloride (10 or
20 mg kg−1 body weight; C5776, Sigma Aldrich) or (-)-quinpirole (30 or 100 µg
kg−1 body weight; Q102, Sigma Aldrich). The distance for each mouse was mea-
sured over a period of 45 minutes using an automated video-based system in an
open field (50x50 cm, VideoMot 2, TSE Systems, Bad Homburg, Germany). Data
are expressed as relative increase compared to baseline (saline). Absolute values
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are given for baseline locomotor activity.
2.8.2 Conditioned Place Preference
Conditioned place preference (CPP) experiments were performed in the condi-
tioned place preference box for mice (TSE Systems, Bad Homburg, Germany). Ac-
tivity and location in the CPP box were monitored by a video recording system
(VideoMot 2, TSE Systems).
Pre-conditioning test (2 days): To determine whether a pre-existing bias exists, two
single 30 min test sessions (1 session/day) were performed during which mice
were allowed to freely explore the CPP box with doors open. Both sessions were
video-taped to determine the preferred side.
Conditioning phase (6 days): During the conditioning phase mice of different geno-
types received a positive stimulus of 0.5 mg cocaine kg−1 body weight via i.p. in-
jection prior to placement in the non-preferred side of the box (doors closed) and
on the intervening days, all mice received an injection of vehicle (saline) prior to
placement in the preferred side of the box. The six conditioning sessions lasted 30
min each, one session per day.
Drug place preference test (1 day): One single 30 min test session has been per-
formed during which mice were allowed to freely explore the CPP box with doors
open. The session has been video-taped to determine the location of the mice in
the CPP box.
Data analysis: Data are expressed as relative increase compared to baseline (neu-
tral middle part of CPP box excluded). For statistical analysis a paired t-test was
performed.
2.8.3 Sucrose preference
To assess sucrose preference, mice were housed individually and restricted to 75%
of ad libitum food intake. Each cage was fitted with 2 drinking bottles and one
additional cage without experimental animal was set up as a control for handling
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and evaporation water loss. After 2 days of habituation, the following 3 days water
consumption and bottle preference was measured for each mouse. Afterwards,
mice were presented with a choice of one bottle of water and one bottle of sucrose,
with concentrations increasing over the course of the experiment (0.5, 1, 2, 4, 8%).
Each concentration was measured for 2 days, changing the location (bottle 1 or
bottle 2) of the sucrose solution after the first 24h to adjust for bottle preference. In
between different sucrose concentrations, both bottles were changed to water for a
period of 24h. Sucrose preference was calculated as sucrose solution intake relative
to total liquid intake.
2.9 Electronmicroscopy
A tissue block containing the midbrain was dissected from each brain. 50 µm thick
vibratome sections were cut and thoroughly washed in 0.1 M phosphate buffer
(PB). To eliminate unbound aldehydes, sections were incubated in 1% sodiumboro-
hydride for 15 min, then rinsed in PB. Next, sections were incubated with primary
antobody (α-Tyrosine hydroxylase; dilution 1:1000 in PB) for 24 h at room tem-
perature. Subsequently, sections were incubated in biotinylated goat anti-rabbit
immunoglobulin (dilution 1: 250; Vector Laboratories, Burlingame, CA, USA) at
room temperature. After a thorough wash in PB, sections were placed in avidin-
biotin-complex (ABC Elite Kit, Vector Labs) for 2 hr at room temperature. The
tissue-bound peroxidase was visualized by a diaminobenzidine reaction. After the
immunostaining, the sections were osmicated (15 min in 1% osmic acid in PB),
and dehydrated in increasing ethanol concentrations. During the dehydration, 1%
uranyl-acetate was added to the 70% ethanol to enhance ultrastuctural membrane
contrast. Dehydration was followed by flatembedding in Araldite. Ultrathin sec-
tions were cut on a microtome, collected on Formvar-coated single-slot grids and
analyzed with a Tecnai 12 Biotwin (FEI Company) electron microscope. The plasma
membranes of selected cells were outlined on photomicrographs and their length
was measured with the help of a chartographic wheel. Plasma membrane length
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values measured in the individual animals were added and the total length was
corrected to the magnification applied. Section thickness was determined by using
the Small’s minimal fold method.
2.10 Immunohistochemistry
For double immunohistochemical stainings, mice were anesthetized and transcar-
dially perfused with saline. The dissected brains were frozen in tissue-freezing
medium. 7 µm thick coronal sections were fixed in 4% paraformaldehyde (PFA).
Following washing in PBS, slices were incubated in 0.3% glycine (in PBS). Subse-
quently, samples were washed in PBS and treated with 0.03% SDS (in PBS). Prior to
antibody treatment, blocking was performed with donkey serum. Incubation with
the primary antibody was conducted overnight (α-Tyrosine hydroxylase, 1:1000,
ab112, Abcam); α-FTO, 1:1000; custom antibody produced in guinea-pig, provided
by U. Rüther/Pineda antibody services, Berlin, Germany; Fischer et al. [2009]). Pre-
ceding secondary antibody treatment, samples were washed in PBS. Secondary
antobodies used for immunofluorescent stainings were Cy3 α-guinea pig (Jackson
Immuno Research, 706-165-148, donkey, 1:500) and Alexa 488 α-rabbit (Invitrogen,
A11008, goat, 1:500). Finally, following 3 washing steps for 10 min in PBS, brain
slices were embedded in Vectashield (Vector Laboratories, Burlingame, CA, USA)
containing DAPI (4-,6-Diamidin-2-phenylindol).
For staining of c-Fos, mice were anesthetized and transcardially perfused with
saline followed by 4% PFA. Brains were dissected, postfixed in PFA for 4 h, soaked
in 20% sucrose overnight at 4°C, and frozen in tissue-freezing medium. c-Fos im-
munoreactivity was labeled with α-c-Fos antibody (PC38, Calbiochem, EMD Mil-
lipore, Billerica MA, USA) and peroxidase coupled secondary antibody (α-rabbit
).
For β-galactosidase stainings, mice were transcardially perfused with saline, and
dissected brains were frozen in tissue-freezing medium. X-gal staining was per-
formed using standard protocols. Briefly, coronal sections (8 µm thick) were fixed
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in cold 100% EtOH, washed in PBS and subjected to X-gal staining overnight at
37°C (X-gal solution: 5 mM K3Fe(CN)6, 5 mM K4Fe(CN)6, 2 mM MgCl2, 1 mg ml−1
X-gal in PBS, pH 7.4). After staining, sections were rinsed in PBS and counter-
stained with Nuclear Fast Red.
2.11 In situ hybridization
In situ hybridization for GAD67 on fresh frozen sections was performed based on
a protocol described previously [Hommel et al., 2006]. Briefly, brains were sliced
on a cryostat (16µm) and kept at -80°C until usage. Slices from freezer were dried
and subsequently fixed in 4% PFA in PBS for 20 min. After a 3 x 3 minute wash-
ing step in PBS, slices were acetylated (2.38 ml triethanolamine, 0.32 ml HCL, 0.45
ml acetic anhydride ad 180 ml H2O) for 10 minutes on a stirrer. Following 3 x 5
minutes wash in PBS, slices were preincubated for 2h at room temperature with
hybridization solution (50% deionized formamide, 5x SSC, 5x 50x-Denhardt’s solu-
tion, 250 µg ml−1 tRNA bakers yeast, 500 µg ml−1 sonicated salmon sperm DNA).
Afterwards, slices were incubated over night at 72°C in hybridization mixture (150
µl including 400 ng of dig-labeled RNA probe). The following digoxigenin (DIG)-
labeled probe was used: Gad67 bp 1064-2046 of the mouse coding sequence (PCR
amplification primers: 5’GAD67: TGTGCCCAAACTGGTCCT, 3’GAD67: TGGC-
CGATGATTCTGGTT). The next day, slices are washed for 2h in 0.2xSSC at 72°C,
followed by 5 minutes in 0.2xSSC at room temperature. Fluorescent labeling of the
RNA probe was performed using the TSA™ Plus Cyanine 3/Fluorescein System
kit (Perkin Elmer, Inc., Waltham MA, USA), following the manufacturer’s proto-
cols. In situ hybridization was followed by immunostaining for FTO as described
in section 2.10. The fluorescence images were captured with a confocal microscope
(Leica SP8X, Leica, Wetzlar, Germany).
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2.12 Electrophysiology
All electrophysiology experiments were performed by Simon Hess in the lab of
Peter Kloppenburg (University of Cologne, Cologne, Germany). Experiments were
performed on brain slices containing the substantia nigra from 21- to 28-day old
female and male Fto−/− and Fto∆DAT/∆ mice and their respective littermates as
controls. The general experimental procedure has recently been described in detail
with additional information in the following paragraphs [Klöckener et al., 2011].
Brain slices were transferred into carbogenated artificial cerebrospinal fluid (aCSF).
First, they were kept for 20 min in a 35 °C ’recovery bath’ and then stored at room
temperature (24 °C) for at least 30 min prior to recording. aCSF contained (in
mM): 125 NaCl, 2.5 KCl, 2 MgCl2, 2 CaCl2, 1.2 NaH2PO4, 21 NaHCO3, 10 HEPES,
and 5 Glucose adjusted to pH 7.2 (with NaOH) resulting in an osmolarity of 310
mOsm. For voltage-clamp experiments, the patch pipette was tip filled with inter-
nal solution and back filled with gramicidin-containing solution ( 2.5 – 10 µg ml-1;
G5002; Sigma Aldrich) to achieve perforated patch recordings. For stable long-term
current-clamp recordings Amphotericin B ( 200 µg ml-1; A4888; Sigma Aldrich)
was used as poreforming agent. Gramicidin and Amphotericin B were dissolved in
dimethyl sulfoxide (final concentration: 0.4 - 0.5%; DMSO; D8418, Sigma Aldrich)
as described previously [Rae et al., 1991; Kyrozis & Reichling, 1995] and was added
to the modified pipette solution shortly before use. Drugs were bath-applied at a
flow rate of 2 ml min−1. Cocaine hydrochloride (10 µM; C5776; Sigma Aldrich) and
(-)-quinpirole (10 – 1000 nM; Q102; Sigma Aldrich) were added to the normal aCSF
shortly before the experiments. In order to quantify DRD2-dependent GIRK cur-
rents, we used BaCl2 (1 mM) which is known to block GIRK channels [Lacey et al.,
1988; Takigawa & Alzheimer, 1999; Cruz et al., 2004]. Dopaminergic (DA) neurons
in the substantia nigra pars compacta (SNpc) were identified by their slow and
regular firing and the presence of a large Ih-dependent “sag”-potential [Ungless
et al., 2001; Lacey et al., 1989; Richards et al., 1997]. In voltage-clamp experiments,
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dopaminergic neurons were additionally identified by their immunoreactivity for
tyrosine hydroxylase (TH) or the dopamine transporter (DAT). All labelled cells
which were identified using the aforementioned electrophysiological criteria exhib-
ited DAT or TH immunoreactivity. Upon completion of the recordings, perforated-
patch recordings were converted to the whole cell configuration and biocytin (1%;
B4261; Sigma) was allowed to diffuse into the cell for 3 – 5 min. Brain slices were
fixed in Roti-Histofix (P0873; Carl Roth, Karlsruhe, Germany) overnight at 4°C and
rinsed in TBS. Afterwards, the slices were incubated in TBS-T and 10% normal goat
serum (30 min). Brain slices were washed in TBS (3 x 10 min) and subsequently
incubated for 2 days at 4°C in rabbit anti-TH (1:1000; ab112; Abcam, Cambridge,
UK) or rat anti-DAT (1:500; ab5990; Abcam, Cambridge, UK) that was dissolved in
TBS-T and 10% normal goat serum. Afterwards, brain slices were rinsed in TBS (3
x 15 min) and incubated with secondary antibodies: Alexa 633-conjugated strepta-
vidin (1:600; S21375; Invitrogen, Karlsruhe, Germany), dylight 488 anti-rabbit IgG
(1:200; ab96883; Abcam) or dylight 488 anti-rat IgG (1:200; ab96887; Abcam) for 2h
at RT in TBS-T. Brain slices were rinsed in TBS (5 x 10 min), dehydrated, and then
cleared and mounted in Permount. The fluorescence images were captured with
a confocal microscope (LSM 510, Carl Zeiss, Göttingen, Germany). Data analysis
was performed with Spike2 (Cambridge Electronics, Cambridge, UK), Igor Pro 6
(Wavemetrics) and Graphpad Prism (version 5.0b; Graphpad Software Inc., La Jolla,
CA, USA). For each neuron, the firing rate was averaged over a time period of 60s
under control conditions and after the drug treatment had reached a steady-state.
2.13 Microdialysis
The intracerebral microdialysis technique enables concentration measurements of
neurotransmitters in freely moving animals. In these experiments, the effect of a
single cocaine injection on the release of extracellular dopamine levels in the NAc
was investigated. Experimental animals were anesthetized by i.p. injection of Ke-
tamin (Albrecht GmbH, Germany) and Rompun (Bayer HealthCare, Germany) and
48 2 Materials and Methods
were stereotactically provided unilateral with a microdialysis guide cannula (CMA
Microdialysis AB, Sweden). The tip of the microdialysis guide cannula was po-
sitioned just lateral to the NAc (coordinates: 2.0 mm anterior to bregma, 0.9 mm
lateral from midline, and 2.9 mm below the surface of the brain; with toothbar set
to obtain flat skull position). Dental cement was used to secure the microdialysis
guide cannula to two stainless screws inserted in the skull. After surgery, animals
were individually housed and allowed to recover for at least two weeks before
the microdialysis experiment. The day before the start of intracerebral microdial-
ysis, animals were anesthetized as described above, the dummy of the microdial-
ysis guide cannula was retracted and a microdialysis probe (CMA7 probe (Micro-
dialysis AB, Sweden), 6 kD cut-off membrane, 2 mm length) was inserted. After
overnight recovery, the probe was then connected to a microperfusion pump and
perfused with Ringer solution at a rate of 1 µl min−1. After four hours of habitua-
tion to the microdialysis perfusion set-up, perfusion samples were collected every
20 minutes. After collecting six baseline samples, cocaine (20 mg kg−1) was admin-
istered i.p. and another six perfusion samples were collected after drug treatment.
For absolute quantification of dopamine levels, a nano Acquitiy UPLC (Waters) was
connected to a Xevo™ TQ (Waters). An Acquitiy UPLC BEH Phenyl 1.7 µm, 1 mm
x 100 mm column was used at room temperature. Solvent A was 0.1% formic acid
and B acetonitril/0.1% formic acid. A linear gradient from 97% A to 5% in 8 min
at a flow rate of 17 µl min−1 was used. 8 µl of sample were injected. The TQ was
operated in positive ESI MRM (multi reaction monitoring) mode. The source tem-
perature was set at 120°C, desolvation temperature was 200°C and desolvation gas
was set to 400 l h−1. The following MRM transitions were used; m/z 154.1 (M+H+)
to 91.04 (quantifier) collision energy 22V, m/z 154.1 to 64.94 (qualifier) collision
30V, m/z 154.1 to 109.05 (qualifier) collision 18V, m/z 154.1 to 119.01 m/z (quali-
fier) collision 18V, 154.1 to 137.02 (qualifier) collision 10V, cone was in all cases 12V.
As data management software MassLynx 4.1 (Waters) and for data evaluation and
absolute quantification TargetLynx (Waters) were used. As external standard do-
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pamine hydrochloride (Sigma-Aldrich, Germany) was dissolved in Ringer solution
(DeltaSelect, Dreieich, Germany) containing 0.1% perchloric acid. With dopamine
eluting at 6.23 min a standard calibration curve was calculated using concentra-
tions ranging from 2.5 – 100 ng ml−1. Correlation coefficient; r < 0.995, r2 < 0.992;
response type: external standard, area; curve type linear; weighting 1/x. The peak
integrations were corrected manually, if necessary. Quality control standards were
used during sample analysis and showed between 0.5% and 40% deviation respec-
tively. Blanks after the standard, quality control and sample batch proved to be
sufficient. No carry over was detected. For the samples a slight shift in the reten-
tion time at 6.35 was observed due to the matrix. Microdialysis was performed
with help of Linda A.W. Verhagen and Hella S. Brönneke. UPLC measurements of
dopamine was performed by Thomas Franz and Yvonne Masekowitz (Max Planck
Institute for Ageing, Cologne, Germany).
2.14 MeRIP pulldown
MeRIP pulldown of provided Fto-deficient midbrain RNA was performed by Kate
D. Meyer in the lab of Samie R. Jaffrey. Immunoprecipitation of methylated RNAs
was performed as described previously [Meyer et al., 2012] using a rabbit anti-
m6A antibody (Synaptic Systems, Göttingen, Germany). MeRIP-Seq was done us-
ing three biological replicates of midbrain RNA isolated from Fto-deficient and
wild type (WT) littermate mice. Reads were aligned to the genome using the
Burrows-Wheeler Aligner (BWA), and m6A peaks were called as previously de-
scribed [Meyer et al., 2012]. Only the peaks which reached significance in all three
replicates for each sample were included in the final peak analysis.
2.15 GO analysis
GO analysis was performed by Yogesh Saletore and Olivier Elemento (Dept. of
Physiology and Biophysics, Cornell University NY, USA). Peaks were identified
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for Fto-deficient and WT samples as described above, and the genome coordinates
of Fto-deficient peaks were intersected with those of WT peaks to determine the
peaks that were specific to the Fto knockout samples. Pathway analysis was then
performed using iPAGE46 and the GO database. Briefly, iPAGE identifies path-
ways that are informative about the distinction between two or more groups of
genes using mutual information. For all highly informative pathways, it calculates
hypergeometric enrichment and depletion P values in all gene groups considered
and represents these pathways as red-blue heat maps. A similar analysis was per-
formed comparing genes with m6A peaks in WT-expressed genes (reads per kilo-
base per million reads (RPKM) >1) compared to all other expressed genes (RPKM
>1).
2.16 Pathway analysis
Pathway analysis was performed for deregulated transcripts in the microarray ex-
pression analysis (see section 3.1.2) and hypermethylated transcripts identified in
MeRIP pulldown for Fto-deficient mice (see section 3.3.1). For pathway analysis,
Ingenuity Pathway Analysis software (IPA, Ingenuity Systems, Inc., Redwood City
CA, USA) was used.
2.17 Graphical representation of data
If not otherwise mentioned, all graphical representations were created using Graph-
Pad Prism (GraphPad Software, Inc., La Jolla CA, USA) and Adobe Illustrator CS4
(Adobe Systems, San Jose CA, USA). Box plot whiskers indicate the minimum
and maximum values, centerlines indicate the median and plus signs indicate the
means. Sample sizes are indicated in parentheses.
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2.18 Statistics
Statistical calculations were performed using Microsoft Excel (Microsoft Corp.,
Redmond WA,USA) and GraphPad Prism (GraphPad Software, Inc., La Jolla CA,
USA). Details on statistical analysis are given in the respective figure legends.
2.19 Chemicals and Materials
Table 2.4: Chemicals
Chemical Supplier
β-mercaptoethanol Applichem, Darmstadt, Germany
0.9% saline (sterile) AlleMan Pharma GmbH, Pfullingen,
Germany
Acrylamide Roth, Karlsruhe, Germany
Agarose Peqlab, Erlangen, Germany
Agarose (Ultra Pure) Invitrogen, Karlsruhe, Germany
Ammoniumpersulfat (APS) Sigma-Aldrich, Seelze, Germany
Bacillol Bode Chemie, Hamburg, Germany
Bovine serum albumin (BSA) Sigma-Aldrich, Seelze, Germany
Bromphenol blue Merck, Darmstadt, Germany
Chloroform Merck, Darmstadt, Germany
Cocaine hydrochloride Sigma-Aldrich, Seelze, Germany
Denhardt’s Solution Applichem, Darmstadt, Germany
Desoxy-ribonucleotid-triphosphates (dNTPs) Amersham, Freiburg, Germany
Developer G153 AGFA, Mortsel, Belgium
DEPC Applichem, Darmstadt, Germany
Dimethylsulfoxide (DMSO) Merck, Darmstadt, Germany
di-Natriumhydrogenphosphat Merck, Darmstadt, Germany
Enhanced chemiluminescence (ECL) Kit Perbio Science, Bonn, Germany
Ethanol, absolute Applichem, Darmstadt, Germany
Ethidium bromide Sigma-Aldrich, Seelze, Germany
Ethylendiamine tetraacetate (EDTA) Applichem, Darmstadt, Germany
Fixer G354 AGFA, Mortsel, Belgium
Forene (isoflurane) Abbot GmbH, Wiesbaden, Germany
Formamide Applichem, Darmstadt, Germany
Glucose 20% DeltaSelect, Pfullingen, Germany
Glycerol Serva, Heidelberg, Germany
Continued on next page
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Table 2.4 – continued from previous page
Chemical Supplier
Glycine Applichem, Darmstadt, Germany
HEPES Applichem, Darmstadt, Germany
Hydrochloric acid (37%) KMF Laborchemie, Lohmar, Germany
Insulin Novo Nordisk, Bagsvaerd, Denmark
Isopropanol (2-propanol) Roth, Karlsruhe, Germany
Magnesium chloride Merck, Darmstadt, Germany
Methanol Roth, Karlsruhe, Germany
Nitrogen (liquid) Linde, Pullach, Germany
NP-40 Roche Diagnostics GmbH, Mannheim,
Germany
Paraformaldehyde (PFA) Sigma-Aldrich, Seelze, Germany
Phosphate buffered saline (PBS) Gibco BRL, Eggenstein, Germany
Potassium chloride Merck, Darmstadt, Germany
Potassium dihydrogenphosphat Merck, Darmstadt, Germany
Potassium hydroxide Merck, Darmstadt, Germany
(-)-Quinpirole Sigma-Aldrich, Seelze, Germany
Sage tea Bad Heilbrunner Naturheilmittel GmbH
Sodium acetate Applichem, Darmstadt, Germany
Sodium chloride Applichem, Darmstadt, Germany
Sodium citrate Merck, Darmstadt, Germany
Sodium dodecyl sulfate Applichem, Darmstadt, Germany
Sodium fluoride Merck, Darmstadt, Germany
Sodium hydrogen phosphate Merck, Darmstadt, Germany
Sodium hydroxide Applichem, Darmstadt, Germany
Sodium orthovanadate Sigma-Aldrich, Seelze, Germany
Sodium pyrophosphate Sigma-Aldrich, Seelze, Germany
Tetramethylethylenediamine (TEMED) Sigma-Aldrich, Seelze, Germany
Tissue Freezing Medium Jung, Heidelberg, Germany
Tramadolhydrochlorid (Tramal) Grünenthal, Aachen, Germany
Trishydroxymethylaminomethane (Tris) Applichem, Darmstadt, Germany
Triton X-100 Applichem, Darmstadt, Germany
Trizol Applichem, Darmstadt, Germany
Tween 20 Applichem, Darmstadt, Germany
Vectashield Mounting Medium with DAPI Vector, Burlingame, USA
Western Blocking Reagent Roche Diagnostics GmbH, Mannheim,
Germany
3 Results
3.1 Whole body Fto deficiency alters the function of the
dopaminergic circuitry
3.1.1 FTO is expressed in midbrain dopaminergic neurons
FTO is ubiquitously expressed with highest levels detected in the brain, especially
in feeding related nuclei [Gerken et al., 2007; McTaggart et al., 2011]. To test whether
FTO is expressed in dopaminergic neurons, midbrain slices of wildtype C57Bl/6
mice were immunohistochemically stained for FTO and tyrosine hydroxylase, the
rate limiting enzyme in dopamine synthesis and hence a suitable marker for dopa-
mine neurons in the midbrain (Figure 3.1).
Figure 3.1: FTO is expressed in dopaminergic neurons of the midbrain
Double immunofluorescent labeling of tyrosine hydroxylase (TH, green) and
FTO (red) in wildtype C57Bl/6 midbrain slices. Nuclear staining with DAPI
(blue). Representative picture of n >3, scale bar = 10 µm.
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FTO is present in dopaminergic neurons and, consistently with previous reports,
immunoreactivity was found to be primarily localized in the nucleus [Gerken et al.,
2007; McTaggart et al., 2011]. Moreover, a slight cytosolic immunoreactivity was
observed for FTO. Whether this signal is specific to any FTO function remains
elusive.
Furthermore, expression of Fto was investigated using a mouse model carrying
a knock in of the β-galactosidase gene into the endogenous Fto locus (Fto::tm1a-
(EUCOMM)Wtsi, see Section 3.2.1 for further description). X-gal staining of brain
sections confirmed the expression of Fto throughout the central nervous system,
including the hypothalamus (ARC, VMH, DMH, PVN) and midbrain (VTA, SN)(Fi-
gure 6.2 in appendix).
Fto deficiency does not change the number or morphology of midbrain
dopaminergic neurons
Since Fto-deficient mice suffer from a severe phenotype including growth retar-
dation and decreased postnatal survival rate [Fischer et al., 2009], loss of FTO may
potentially impact cell viability. Thus, to test whether the health of dopaminergic
cells is affected by Fto deficiency, cell number and morphology was assessed in
whole body Fto-deficient (Fto−/−) and control (Fto+/+) mice (see Figure 3.2).
No significant differences in cell number as well as cell area and perimeter were
detected for dopamine neurons. Hence, loss of FTO does not alter the general
health of dopaminergic neurons.
3.1.2 Microarray analysis of Fto-deficient midbrain
Expression analysis of Fto-deficient midbrain tissue
To generate a general hypothesis for possible effects of Fto deficiency on dopa-
minergic neuron function, gene expression was compared between Fto-deficient
and control midbrain tissue using microarray analysis. For this purpose, RNA was
isolated from midbrain tissue (RNA integrity number determined by bioanalyzer
chip ≥8.9) and subsequently the RNA was hybridized to an Affymetrix GeneChip
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Figure 3.2: Loss of FTO does not alter cell number or morphology of dopaminergic mid-
brain neurons
(a) Immunohistochemical labeling of FTO and quantification of cells was per-
formed on midbrain sections of control and Fto-deficient mice. Experiments
performed by Marcelo O. Dietrich and Tamas L. Horvath. Sample sizes are in-
dicated in parentheses, no significant differences were detected. (b) Electron
microscopy of wildtype and Fto-deficient dopaminergic neurons. Fto deficiency
does not alter the morphology of dopaminergic neurons as assessed by quan-
tification of cell area and perimeter. Experiments performed by Marcelo O.
Dietrich and Tamas L. Horvath. Sample sizes are indicated in parentheses, no
significant differences were detected.
Mouse Gene 1.0 ST array. Transcripts were considered significantly deregulated for
p-values ≤ 0.05 (t-test) and a false discovery rate (q-value) of ≤ 0.25.
In total, 5785 transcripts were significantly deregulated, of which 2382 were
down- and 3403 were up-regulated. The relative changes in transcript expression,
however, were relatively low, with the highest downregulation observed for Cartpt
(−4.807) and the highest up-regulation for Tdgf1 (+2.774) (see Figure 3.3 and Table
6.2).
Most of the transcripts exhibited minor expression changes (Figure 3.3 fold change
(fc) cut off ±1.80; table 6.2 fc cut off ±1.50). Among the deregulated mRNAs,
several transcripts were identified that are directly or indirectly related to dopami-
nergic signaling. Significantly downregulated transcripts included the dopamine
transporter (Slc6a3, fc = −2.558), tyrosine hydroxylase (Th, fc = −1.880), dopamine
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Figure 3.3: Microarray analysis of Fto-deficient midbrain tissue
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Figure 3.3: Microarray analysis of Fto-deficient midbrain tissue
Microarray analysis was performed for control and Fto-deficient midbrain tis-
sue. Normalized intensities are presented as a heatmap (each row scaled indi-
vidually), key indicates Z-Score for color coding. Fold change (fc), p-value (p)
and false discovery rate (q-value, q) are shown for a selection of significantly
deregulated genes. Highlighted in red are components related to dopaminergic
signaling. n = 3 per genotype
type 2 receptor (Drdr2, fc = −1.301), dopa decarboxylase (Ddc, fc = −1.371) and the
vesicular monoamine transporter (Slc18a2, fc = −1.306). Transcripts of the dopa-
mine type 5 receptor (Drd5, fc = +1.456) and the dopamine beta hydroxylase (Dbh,
fc = +2.391) were found to be upregulated.
Critical components of dopaminergic signaling are deregulated in Fto-deficient
mice
The overlay of deregulated transcripts using pathway analysis revealed that sev-
eral components implicated in dopaminergic function were affected in Fto-deficient
mice (see Figure 3.4). Transcripts of three enzymes involved in the dopamine
synthesis were deregulated. The mRNA levels of both the tyrosine hydroxylase,
converts L-tyrosine to L-DOPA, and the dopa decarboxylase, converts L-DOPA to
dopamine, were reduced in Fto-deficient mice, while the transcript levels of the
dopamine beta hydroxylase, catalyzes the reaction from dopamine to norepine-
phrine, was increased (Figure 3.4). These alterations could potentially affect do-
pamine availability through a reduction in dopamine synthesis and an increase in
conversion of dopamine to norepinephrine.
Additionally, a downregulation of the vesicular monoamine transporter, which
transports monoamines such as dopamine into synaptic vesicles, could lead to a
reduction in dopamine release. On the other hand the downregulation of the do-
pamine transporter via a reduction in dopamine reuptake from the synaptic cleft,
may prolong dopaminergic signaling and thus counteract the potentially decreased
levels of secreted dopamine.
Moreover, dopaminergic neurons express dopamine autoreceptors of the D2-like
dopamine receptor family (DRD2 and DRD3). One of these, the type 2 dopamine
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Synapse
Nerve Terminal
Figure 3.4: Schematic overlay of the microarray expression data and the dopaminergic
signaling pathway
Key components of dopaminergic signaling and dopamine syntheses exhibit
altered expression in midbrain of Fto-deficient mice. TH: tyrosine hydroxy-
lase, DDC: dopa decarboxylase, VMAT: vesicular monoamine transporter, DAT:
dopamine transporter, AC: adenylyl cyclase, COMT: catechol-O-methyl trans-
ferase, MAO: monoamine oxidase. Overlay was created using Ingenuity Path-
way Analysis software. Green indicates downregulation and red indicates up-
regulation of the respective transcripts.
receptor (DRD2), was found to be downregulated on the mRNA level. A reduction
in DRD2 autoreceptor signaling could potentially impinge on the regulation of
dopamine release through attenuation of the autoreceptor feedback loop [Beaulieu
& Gainetdinov, 2011; Bello et al., 2011].
Selected deregulated transcripts are not altered on protein level
To confirm the alterations of transcript levels observed in the microarray analysis,
quantitative PCR was conducted on a selected subset of deregulated transcripts. To
this end, qPCR analysis of Drd2, Th, and Slc6a3 verified the observed downregula-
tions for midbrain tissue of Fto-deficient mice (Figure 3.5 a, b, c).
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Figure 3.5: Selected transcripts deregulated in microarray analysis are not altered on pro-
tein level
Quantitative PCR on selected deregulated transcripts confirmed the microarray
analysis. mRNA levels for (a) Drd2 and (b) Slc6a3 are significantly downregu-
lated, whereas a strong tendency is detected for (c) Th. Western blot analysis,
however, reveals no changes on protein level for DRD2, DAT and TH. Western
blot for DRD2 (a) was performed using three different antibodies. Sample blot
shows α-DRD2 ab21218 (Abcam, Inc.) with two bands corresponding to the
long (DRD2L, 51 kDa) and short form (DRD2S, 47 kDa) of DRD2. Sample sizes
indicated in parentheses, *P<0.05, unpaired two-tailed t-test.
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Since mRNA levels may not necessarily reflect protein levels, western blot analy-
sis was performed for DRD2, TH and DAT. In contrast to the changes on the mRNA
level, no alterations of protein levels were observed (Figure 3.5 a, b, c).
3.1.3 Fto-deficient mice exhibit attenuated responses to cocaine
Cocaine fails to increase locomotor activity in Fto-deficient mice
Many addictive substances affect dopaminergic signaling [Beaulieu & Gainetdi-
nov, 2011; Koob & Volkow, 2010]. One of the most prominent drugs of abuse is
cocaine, which potently blocks the dopamine transporter [Beaulieu & Gainetdinov,
2011]. Due to the resulting prolonged dopaminergic signaling, the primary effect
of cocaine administration is an increase in locomotor activity. For this reason, many
studies use cocaine to test the functionality of the dopaminergic system, utilizing
locomotor activity as the primary readout [Koob & Volkow, 2010; Seale & Carney,
1991].
To test whether the functionality of the dopaminergic system is altered, loco-
motor activity after intraperitoneal (i.p.) cocaine administration was assessed in
Fto-deficient and control mice. After baseline measurement of locomotor activity
(saline injection), mice were challenged with two different cocaine concentrations
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Figure 3.6: Cocaine fails to increase locomotor activity in Fto-deficient mice
Control and Fto-deficient mice were injected i.p. with 10 mg kg−1 and 20 mg
kg−1 cocaine. Data is represented as percent relative to baseline saline injection
(sample sizes indicated in parentheses, *P<0.05, **P<0.01, unpaired two-tailed
t-test).
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(10 mg kg−1 and 20 mg kg−1 body weight). While wildtype control mice signif-
icantly increased their locomotor activity at both 10 mg kg−1 (216±34%) and 20
mg kg−1 (361±47%) cocaine, Fto-deficient mice failed to increase their locomotor
activity (10 mg kg−1: 113±31%, 20mg kg−1: 117±30%, Figure 3.6). These results
indicate that dopaminergic function is severely attenuated, rendering Fto-deficient
mice insensitive to the locomotor stimulatory effect of cocaine.
Cocaine fails to increase Fos expression in Fto-deficient mice
To assess the observed insensitivity to cocaine on the network level, Fto-deficient
mice were treated with 20 mg kg−1 cocaine i.p. and subsequently midbrain, NAc
and CPu tissue was analyzed for Fos expression. Fos, as one of the immediate early
genes, is a widely used marker for neuronal activity [Knight et al., 2012; Dragunow
& Faull, 1989]. As such, cocaine-induced stimulation of dopamine signaling is able
to induce Fos expression as a result of the modulation of neuronal activity.
Fos mRNA expression significantly increased 2h after i.p. cocaine treatment in
wildtype control mice in all brain areas investigated (Figure 3.7). Conversely, in
Fto-deficient mice cocaine failed to increase the Fos mRNA levels (Figure 3.7, also
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Figure 3.7: Cocaine fails to increase Fos expression in Fto-deficient mice
Midbrain, caudate putamen (CPu) and nucleus accumbens (NAc) of control
and Fto-deficient mice were dissected 2h after either saline (Sal) or 20 mg kg−1
cocaine (Coc) i.p. injection. Fos expression was measured using qPCR and is
represented as relative increase compared to saline (Sal) injected control ani-
mals. (*P<0.05, **P<0.01, unpaired two-tailed t-test, sample sizes are indicated
in parentheses).
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confirmed on the protein level see Figure 6.1 in appendix). Of note, Fos mRNA
levels were elevated under baseline conditions (saline) in the NAc of Fto-deficient
mice. Thus, the Fos expression analysis was consistent with the observed failure of
Fto-deficient mice to increase their locomotor activity in response to cocaine.
Cocaine evoked extracellular levels of dopamine are reduced in Fto-deficient
mice
In order to test whether the loss of FTO affected dopamine release and/or reup-
take, extracellular levels of dopamine were measured in the NAc of Fto-deficient
and control mice via implantation of a microdialysis probe and subsequent detec-
tion of dopamine via ultra performance liquid chromatography (UPLC) coupled to
mass spectrometry. During the experiment, mice were challenged with either 10 or
20 mg kg−1 body weight cocaine i.p. injection.
In both Fto-deficient and control mice extracellular levels of dopamine increased
in response to cocaine administration, due to the blockade of the dopamine trans-
porter preventing dopamine reuptake. Comparing Fto-deficient and control mice,
no differences in the relative increase in extracellular dopamine levels were de-
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Figure 3.8: Reduction in cocaine-induced extracellular dopamine in the nucleus accum-
bens of Fto-deficient mice
Levels of extracellular dopamine in response to 10 mg kg−1 (a) and 20 mg kg−1
(b) i.p. cocaine administration were measured in the NAc of control (n=6) and
Fto-deficient (n=7) mice using microdialysis. Dopamine was subsequently de-
tected by ultra performance liquid chromatography (UPLC). Graph shows mean
± s.e.m. for each individual measurement time point (*P<0.05, unpaired two-
tailed t-test).
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tected for the 10 mg kg−1 cocaine treatment (Figure 3.8 a). At a higher cocaine
dosage (20 mg kg−1) however, dopamine levels significantly varied between Fto-
deficient and control mice (Figure 3.8 b). In comparison to the lower cocaine
dosage, control mice had even further elevated dopamine content in the NAc in
response to 20 mg kg−1 cocaine injection. Fto-deficient mice, on the other hand, dis-
played similar relative increases at both cocaine concentrations. Hence, dopamine
release appears to have reached a maximum at 10 mg kg−1 cocaine in Fto-deficient
mice. Unfortunately, whether these differences are due to alterations in dopamine
synthesis rates, dopamine release or dopamine reuptake cannot be addressed using
the microdialysis technique.
3.1.4 Attenuation of the DRD2/DRD3 autoreceptor feedback loop in
Fto-deficient mice
DRD2/DRD3 receptor dependent responses are altered in Fto-deficient mice
To investigate the effects of Fto deficiency on the cellular level, neuronal activity
of single cells was measured in midbrain slices of Fto-deficient and control mice
using the patch-clamp technique. No differences in the general properties of dopa-
minergic neurons were detected, except a slightly reduced conductance density for
Fto-deficient mice (Table 6.1 in appendix). While under baseline conditions, dopa-
minergic neurons fired tonically at a rate of approximately 2 Hz, bath application
of cocaine (10 µM) potently reduced the firing rate of these neurons in control mice
on average by 86% (Figure 3.9 a). In Fto-deficient mice, however, cocaine’s abil-
ity to reduce the firing rate of dopaminergic neurons was significantly attenuated
(reduction by 46%, Figure 3.9 a).
Since dopamine neurons express autoreceptors, blocking of the dopamine trans-
porter by cocaine increases the amount of extracellular dopamine, which then binds
to these D2-like receptors, leading to the activation of an autoinhibitory feedback
loop that silences the neurons in a G protein-coupled inwardly rectifying potassium
channel (GIRK) dependent manner [Lüscher & Slesinger, 2010].
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Figure 3.9: Altered DRD2/DRD3 receptor dependent responses in Fto-deficient mice
(a) Relative firing rate of SNpc dopaminergic neurons in patch clamp record-
ings during bath application of cocaine (10 µM, 10 min). Sample trace shows
recording of firing rate before, during and after bath application of cocaine
(sample sizes indicated in parentheses, *P<0.05, unpaired two-tailed t-test). (b)
Bath application of the D2-D3-receptor agonist quinpirole (10 nM) on control
and Fto-deficient dopamine neurons (sample sizes indicated in parentheses,
*P<0.05, unpaired one-tailed t-test). (c) In line with the attenuated reduction
in firing rate, quinpirole (1 µM) mediated increase in conductance density is
significantly reduced in Fto-deficient mice (sample sizes indicated in parenthe-
ses, *P<0.05, unpaired one-tailed t-test). All electrophysiological experiments
were conducted by Simon Hess.
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To further assess whether the observed alteration in autoinhibition was directly
related to receptor function, the selective DRD2/DRD3 agonist quinpirole (10 nM)
was applied during patch clamp recordings of midbrain dopaminergic neurons.
In line with the previous finding, quinpirole potently inhibited firing in control
neurons, while the response in Fto-deficient neurons was significantly attenuated
(Figure 3.9 b). Consistently, the quinpirole (1 µM) evoked conductance density, a
measure of the membrane’s ability to pass current, was significantly reduced in
Fto-deficient mice (Figure 3.9 c).
Taken together, these results demonstrate that the DRD2/DRD3 dependent au-
toreceptor feedback loop was affected by the loss of FTO. Since the primary func-
tion of the autoreceptor feedback loop is the opening of GIRKs, the attenuated
ability to reduce the firing rate in Fto-deficient mice may be a result of a reduc-
tion in DRD2/DRD3 or GIRK expression. Moreover, malfunction of the intracel-
lular coupling of the dopamine receptors to GIRKs could potentially represent the
underlying cause of the attenuated cocaine and quinpirole-mediated reduction in
firing rate.
Reduced GIRK dependent current density in Fto-deficient mice
To directly assess the GIRK mediated and dopamine autoreceptor dependent
changes in membrane conductance, brain slices were incubated with quinpirole
(300 nM) to fully activate the DRD2/DRD3 autoreceptor feedback loop. Subse-
quently, bath application of barium chloride (1 mM), a potent potassium channel
blocker, was used to measure the change in current density mediated by GIRKs (Fi-
gure 3.10). Confirming the previous results, the increase in quinpirole-dependent
current density was attenuated in Fto-deficient mice. Furthermore, these quinpirole
mediated changes were almost completely reversed by the blockade of GIRK chan-
nels, demonstrating that GIRK currents are the main driver of dopamine autoinhi-
bition. The GIRK dependent current density was significantly lower in Fto-deficient
mice, further supporting the notion that the DRD2-DRD3 dependent feedback loop
depends on GIRK function and FTO expression (Figure 3.10).
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Figure 3.10: Reduced GIRK dependent current density in Fto-deficient mice
DRD2 mediated activation of GIRK channels is attenuated in Fto-deficient do-
pamine neurons. GIRK currents were measured by activation of D2 receptors
by quinpirole (300 nM) and subsequent blocking of GIRKs by BaCl2 (1 mM)
(sample sizes indicated in parentheses, *P<0.05, unpaired two-tailed t-test). All
electrophysiological experiments were conducted by Simon Hess.
Attenuated quinpirole dependent decrease in locomotor activity in
Fto-deficient mice
As on the cellular level, Fto-deficient mice showed an attenuated response to
quinpirole, the ability of quinpirole to reduce locomotor activity was tested in freely
moving animals [Mattingly et al., 1993; Bello et al., 2011]. Intraperitoneal injection
of quinpirole dose dependently decreased locomotor activity in both Fto-deficient,
as well as control mice (Figure 3.11). Fto-deficient mice, however, exhibited an
attenuated response to quinpirole, retaining a higher relative locomotor activity
than control littermates. Locomotor activity was significantly higher at 100 µg
kg−1 i.p. quinpirole injection and showed a tendency for 30 µg kg−1 as compared
to contols (Figure 3.11).
Taken together, Fto-deficient mice displayed a significant attenuation of cocaine
and quinpirole evoked locomotor responses. Furthermore, cocaine’s ability to in-
duce Fos expression was blunted and Fto-deficient mice exhibited a reduction in
cocaine evoked extracellular levels of dopamine in the NAc (20 mg kg−1 cocaine
i.p.). On the cellular level, Fto-deficiency altered the ability of the DRD2/DRD3-
GIRK dependent autoreceptor feedback loop to inhibit dopamine neuron firing.
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Figure 3.11: Attenuated quinpirole dependent decrease in locomotor activity in Fto-
deficient mice
Control and Fto-deficient mice were injected i.p. with 30 µg kg−1 and 100
µg kg−1 quinpirole. Data is represented as percent relative to baseline saline
injection. (*P<0.05, unpaired two-tailed t-test, sample sizes are indicated in
parentheses).
3.2 Dopamine neuron restricted loss of FTO attenuates the
function of the DRD2/DRD3 dependent autoreceptor
feedback loop
3.2.1 Generation of dopamine neuron restricted Fto knock out mice
Conventional whole body deletion of Fto causes a severe phenotype that, with re-
spect to dopaminergic function, affects dopamine neurons as well as target neurons
of the midbrain dopamine system. Hence, the loss of Fto most probably alters pre-
as well as postsynaptic signaling events. Therefore, mice with a dopamine neu-
ron restricted Fto deletion (Fto∆DAT) were generated using the Cre-loxP system, to
investigate the role of FTO specifically in dopaminergic neurons.
Mouse models for dopamine neuron restricted Fto deletion
To generate a dopamine neuron restricted FTO knock out, mice with a loxP
site flanked exon 3 of the Fto gene (knock out first allele EUCOMM, Fto::tm1a-
(EUCOMM)Wtsi; Figure 3.12 a) were crossed to FLP-deleter mice and subsequently
to transgenic mice expressing the Cre recombinase under the control of the endoge-
nous dopamine transporter (Dat) promoter (Figure 3.12 b; Ekstrand et al. [2007]).
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Figure 3.12: Schematics of Cre-dependent deletion of Fto
(a) Fto::tm1a(EUCOMM)Wtsi mice provided by the European Conditional
Mouse Mutagenesis program carry a flippase recognition target (FRT) site
flanked knock in of the β-galactosidase gene in conjunction with a neomycin
resistance cassette (knock out first allele). Furthermore, loxP sites were intro-
duced flanking the third exon of the Fto gene. Prior to FLP deletion, the knock
out first construct was used for β-galactosidase stainings. The conditional al-
lele was generated through crossing of mice with FLP-recombinase, deleting
the β-galactosidase and neomycin cassette and restoring endogenous Fto ex-
pression levels. (b) Subsequent crossing of mice carrying the conditional allele
with mice expressing the Cre recombinase under the control of the endogenous
Dat promoter Ekstrand et al. [2007] led to the generation of dopamine neuron
restricted Fto knock outs (Fto∆DAT) and controls (Ftofl/fl).
The dopamine transporter is regarded as a selective marker for dopaminergic
neurons [Ciliax et al., 1995; Freed et al., 1995]. Therefore, directing the expression of
Cre to DAT expressing neurons caused a dopamine neuron restricted recombina-
tion of loxP sites. Deletion of the loxP site flanked third exon of Fto leads to a frame
shift, causing a premature translational stop signal. Moreover, exon 3 encodes for
approximately 40% of the FTO protein. The remaining truncated Fto mRNA is
likely to undergo degradation via nonsense-mediated decay mechanisms. Hence,
excision of the third Fto exon was expected to efficiently delete FTO.
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Figure 3.13: Validation of DA neuron specific Fto deletion
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Figure 3.13: Validation of DA neuron specific Fto deletion
(a) Midbrain dopaminergic neurons were stained in Fto∆DAT/∆ and Fto+/+ mice
using an antibody directed against the tyrosine hydroxylase (TH), a marker for
dopaminergic neurons in the midbrain. Further labeling of FTO revealed the
absence of FTO in dopamine neuron restricted Fto knock out mice. (b) Quan-
tification of FTO immunofluorescence in TH positive neurons in the midbrain
(n = 3 for each Fto∆DAT and Ftofl/fl, ***P<0.001, unpaired two-tailed t-test). (c)
Western blot analysis of liver, pancreas, skeletal muscle and rest brain (non-
midbrain). (d) Western blot analysis of DAT expression between Fto∆DAT mice
carrying a copy of the Cre recombinase in the endogenous Dat locus and con-
trols.
Validation of DA neuron specific Fto deletion
To verify the efficient and selective loss of FTO in Fto∆DAT mice, immunohisto-
chemical stainings of midbrain sections were performed. To identify the genetically
targeted neurons, tyrosine hydroxylase (TH, Figure 3.13 a, green) was used as a
marker for dopamine neurons in the midbrain. Immunolabeling of FTO confirmed
the presence of FTO in approximately 90% of midbrain TH expressing neurons
of control mice (Figure 3.13 a, b; FTO labeled in red, representative staining shows
midbrain sections of Fto∆DAT/∆ and Fto+/+ mice). In Fto∆DAT mice, FTO immunore-
activity was only observed in 1.14% of TH neurons (Figure 3.13 a, b; quantification
was performed for Fto∆DAT and Ftofl/fl controls).
To exclude unspecific deletion of the loxP-flanked third exon in untargeted pe-
ripheral or remaining brain tissue, Western blot analysis was performed. For anal-
ysis of liver, pancreas and skeletal muscle (SM), tissue derived from Fto∆DAT/∆ was
used, while Western blot of rest brain (non-midbrain) tissue was conducted for
Fto∆DAT mice. No aberrant loss of FTO was observed for all non-targeted tissues
tested. Hence, the targeted deletion of FTO in dopaminergic neurons was consid-
ered efficient and specific (Figure 3.13 c).
In DAT-cre mice the cre-recombinase cDNA was cloned into the endogenous
Dat locus between exon 1 and 2 [Ekstrand et al., 2007]. Using this strategy, the
endogenous transcription site was used for cre expression, while not affecting the
Dat coding region with its translational start codon in exon 2. To ensure that this
strategy was not affecting the endogenous DAT expression, western blot on mid-
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Figure 3.14: Fto deletion in DA neurons does not affect FTO expression in midbrain
GABAergic neurons
Combined in situ hybridization for Gad67 (red), a marker for GABAergic neu-
rons, and immunofluorescent staining of FTO (green) revealed no loss of FTO
in GABAergic neurons of Fto∆DAT mice.
brain lysates of Fto∆DAT and Ftofl/fl was performed. This analysis confirmed no
differences in DAT expression between genotypes (Figure 3.13 d).
Fto deletion in DA neurons does not affect FTO expression in midbrain
GABAergic neurons
To further exclude unspecific deletion of Fto within the midbrain, FTO expres-
sion was assessed in GABAergic neurons of midbrain slices. For this purpose, com-
bined in situ hybridization for Gad67 (glutamat decarboxylase; marker for GABAer-
gic neurons) and FTO immunohistochemistry was performed. No loss of FTO in
GABAergic neurons of the midbrain was observed (Figure 3.14).
Taken together, FTO was shown to be efficiently and specifically deleted in mid-
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brain dopaminergic neurons of Fto∆DAT mice. Neither FTO expression in peripheral
or remaining brain tissue was affected nor was FTO unspecifically deleted in non-
dopaminergic neurons.
3.2.2 Dopamine restricted Fto knock out does not influence basic metabolic
parameters
Dopamine neuron restricted loss of FTO does not affect body weight
Whole body Fto-deficient mice have a lower body weight, due to a reduced lean
and fat mass [Fischer et al., 2009]. Since dopamine signaling is implicated in the
etiology of obesity, alteration of dopaminergic function through loss of FTO may
impact body weight regulation [Volkow et al., 2013]. Therefore, the body weight
of Fto∆DAT and control mice was monitored over the course of 16-18 weeks (Figure
3.15 a, b). No significant differences were detected for both males and females on
either a normal chow diet (NCD) or a high fat diet (HFD).
Consistently, no differences in metabolic rate (depicted as O2-consumption, 12-
13 weeks of age) were found for males on either NCD or HFD (Figure 3.15 c,
d). Moreover, food intake was unchanged for male Fto∆DAT mice as compared to
controls on both NCD and HFD (Figure 3.15 e, f).
Dopamine neuron restricted loss of FTO does not affect insulin and glucose
tolerance
To investigate glucose metabolism in Fto∆DAT mice, insulin and glucose tolerance
tests were performed at 12 weeks (ITT) and 13 weeks (GTT) of age. No differ-
ences in either insulin sensitivity or glucose tolerance were observed between male
Fto∆DAT and control mice on either high fat (Figure 3.16 a, c) or normal chow diet
(Figure 3.16 b, d).
Hence, insulin’s ability to reduce blood glucose levels, as well as the insulin
mediated counter response to elevated glucose levels are not altered in Fto∆DAT
mice. These results are consistent with the paucity of body weight differences for
Fto∆DAT mice.
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Figure 3.15: Basic metabolic parameters are unchanged in Fto∆DAT mice
(a) Body weight of male Fto∆DAT and control mice was monitored until 16
weeks of age on both normal (NCD) and high fat diet (HFD). (b) Body weight
of female Fto∆DAT and control mice was monitored until 18 weeks of age on
both normal (NCD) and high fat diet (HFD). (c) O2 consumption of male
Fto∆DAT and control mice on a HFD. (d) O2 consumption of male Fto∆DAT and
control mice on a NCD. (e) Food intake of male Fto∆DAT and control mice on
a HFD. (f) Food intake of male Fto∆DAT and control mice on a NCD (sample
sizes are indicated in parentheses).
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Figure 3.16: Unchanged insulin and glucose tolerance in Fto∆DAT mice
(a) Insulin tolerance test was performed on male Fto∆DAT (n=24) and control
(n=22) mice fed a HFD. (b) Insulin tolerance test was performed on male
Fto∆DAT (n=18) and control (n=14) mice fed a NCD. (c) Glucose tolerance test
was performed on male Fto∆DAT (n=23) and control (n=24) mice fed a HFD.
(d) Glucose tolerance test was performed on male Fto∆DAT (n=16) and control
(n=12) mice fed a NCD.
Dopamine neuron restricted loss of FTO does not affect food intake and
refeeding responses
In order to further investigate feeding behavior in Fto∆DAT mice, the refeeding
response to a 16h over night fast was assessed. In line with the previous results
(Figure 3.15 e, f), baseline food intake was unaltered between Fto∆DAT and control
mice (Figure 3.17 a).
Following the 16h over night fasting period, the cumulative food intake was
measured 1h, 2h, 4h, 8h and 24h after refeeding. During early hours of refeeding,
Fto∆DAT mice showed a slightly increased food intake as compared to their control
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Figure 3.17: Food intake and refeeding response are unaltered in Fto∆DAT mice
(a) Baseline food intake was unaltered in male Fto∆DAT mice on NCD. (b)
Refeeding behavior was assessed in response to a 16h over night fast. Food
intake was measured 1, 2, 4, 6, and 24h after refeeding in male Fto∆DAT and
control mice fed a NCD (RM two-way ANOVA, F1,14 = 1.06, P = 0.3196).
littermates, however, no significant changes were observed (F1,14 = 1.06, P = 0.3196;
Figure 3.17).
Dopamine neuron restricted loss of FTO does not affect sucrose preference
Both anhedonia and depression are closely related to dopaminergic function
[Nestler & Carlezon, 2006; Krishnan & Nestler, 2008]. To test, whether dopamine
neuron restricted deletion of Fto affected anhedonia in mice, Fto∆DAT and control
mice were subjected to a sucrose preference test, a measure for anhedonia in an-
imals [Strekalova et al., 2004]. With increasing concentrations, both Fto∆DAT and
control mice significantly increased their preference for sucrose (0.5 - 8% sucrose
solution, RM two-way ANOVA, F4,60 = 42.68, P < 0.0001, Figure 3.18). Between
genotypes, Fto∆DAT mice exhibited slightly higher sucrose preference values. How-
ever, these differences were not significant (RM two-way ANOVA, F1,15 = 0.4338, P
= 0.5201), showing that anhedonia is not affected in Fto∆DAT mice (Figure 3.18).
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Figure 3.18: Sucrose preference is unaltered in Fto∆DAT mice
Sucrose preference was assessed for Fto∆DAT and control mice. Sucrose con-
sumption was monitored for each sucrose concentration (0.5, 1, 2, 4 and 8%
sucrose solution) for 2 consecutive days and calculated relative to total liquid
consumption. Ftofl/fl (n = 10); Fto∆DAT (n = 7).
3.2.3 Altered DRD2/DRD3 dependent responses in Fto∆DAT
Attenuated DRD2/DRD3 autoreceptor feedback loop inFto∆DAT mice
To investigate whether Fto∆DAT mice exhibited comparable alterations on the cel-
lular level as Fto-deficient mice, patch-clamp recordings were performed and firing
rate was measured for dopaminergic midbrain neurons challenged with 10 µM co-
caine or 10 nM quinpirole. In line with the results obtained for Fto-deficient mice
(see Figure 3.9 a, b), Fto∆DAT mice exhibited attenuated cocaine and quinpirole de-
pendent reductions in firing rate compared to control mice, demonstrating that the
DRD2/DRD3 mediated autoinhibition was malfunctional (Figure 3.19 a, b). Fur-
thermore, the quinpirole (10 nM) dependent conductance density was reduced,
demonstrating that activation of presynaptic DRD2/DRD3 receptors in Fto∆DAT
mice is not able to elicit the same relative current flow (Figure 3.19 c). Hence, the
loss of FTO in dopaminergic neurons cell autonomously affects the DRD2/DRD3
autoreceptor feedback loop.
Reduced GIRK dependent current density in Fto∆DAT mice
To further assess whether the change in feedback inhibition could be attributed
to GIRK currents, GIRK-dependent current density was measured as described
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Figure 3.19: Attenuated responses of midbrain neurons to cocaine and quinpirole in
Fto∆DAT mice
(a) Relative firing rate of SNpc dopaminergic neurons in patch clamp record-
ings during bath application of cocaine (10 µM, 10 min, sample sizes indicated
in parentheses, *P<0.05, unpaired one-tailed t-test). (b) Bath application of
the D2-D3-receptor agonist quinpirole (10 nM) on control and Fto∆DAT dopa-
mine neurons. (sample sizes indicated in parentheses, **P<0.01, unpaired two-
tailed t-test). (c) In line with the attenuated reduction in firing rate, quinpirole
(10 nM) mediated increase in conductance density is significantly reduced in
Fto∆DAT mice (sample sizes indicated in parentheses, *P<0.05, unpaired two-
tailed t-test). All electrophysiological experiments were conducted by Simon
Hess.
in section 3.1.4. Consistent with the attenuated responses to bath application of
cocaine and quinpirole on firing rate and mirroring the results obtained for Fto-
deficient mice (Figure 3.10), the GIRK dependent current density was significantly
reduced in Fto∆DAT mice (Figure 3.20).
Hence, the autoreceptor feedback loop is malfunctional through the attenuation
of DRD2-DRD3-GIRK dependent changes in conductance. Whether a reduction in
GIRK channel availability or whether attenuated activation of these channels due
to changes further upstream in the signaling pathway are responsible for these
observations remains unclear.
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Figure 3.20: Reduced GIRK dependent current density in Fto∆DAT mice
DRD2 mediated activation of GIRK channels is attenuated in Fto∆DAT dopa-
mine neurons. GIRK currents were measured by activation of D2/D3 receptors
by quinpirole (300 nM) and subsequent blocking of GIRKs by BaCl2 (1 mM)
(sample sizes indicated in parentheses, **P<0.01, unpaired two-tailed t-test).
All electrophysiological experiments were conducted by Simon Hess.
Altered baseline and cocaine evoked locomotor activity in Fto∆DAT mice
Since dopamine is involved in motor control, malfunction of the dopaminergic
autoinhibitory feedback loop may alter locomotor activity. To probe motor func-
tion, baseline and cocaine-induced locomotor activity was assessed for Fto∆DAT
mice in the open field paradigm. For baseline locomotor activity, the distance trav-
elled over the course of 45 minutes was assessed in saline injected mice. These
measurements revealed baseline hyperlocomotion for Fto∆DAT mice as compared
to controls (Figure 3.21 a).
When challenged with cocaine, Fto∆DAT mice exhibited a hypersensitivity to-
wards lower cocaine concentration (10 mg kg−1), while no differences at the higher
concentration (20 mg kg−1) were observed (Figure 3.21 b).
Attenuated quinpirole dependent decrease in locomotor activity in Fto∆DAT
mice
To directly address the impact of the activation of the DRD2/DRD3 autoreceptors
on locomotor activity, Fto∆DAT mice and control mice were challenged with i.p.
injections of 30 and 100 µg kg−1 quinpirole. In line with the previous results
obtained for Fto-deficient mice, Fto∆DAT mice exhibited an attenuated response in
the quinpirole-dependent decrease of locomotor activity (Figure 3.22).
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Figure 3.21: Altered baseline and cocaine evoked locomotor activity in Fto∆DAT mice
(a) Baseline locomotor activity during open field experiments in Fto∆DAT mice
(sample sizes indicated in parentheses, *P<0.05, unpaired two-tailed t-test) (b)
Cocaine induced locomotor activity in the open field paradigm after 10 mg
kg−1 BW and 20 mg kg−1 cocaine i.p. injection in Fto∆DAT compared to control
mice. Cocaine evoked locomotor activity is expressed as percent increase com-
pared to baseline activity following saline injection (sample sizes indicated in
parentheses, *P<0.05, unpaired two-tailed t-test).
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Figure 3.22: Attenuated quinpirole dependent decrease in locomotor activity in Fto∆DAT
mice
Control and Fto∆DAT mice were injected i.p. with 30 µg kg−1 and 100 µg kg−1
quinpirole. Data is represented as percent relative to baseline saline injection
(*P<0.05, unpaired two-tailed t-test, sample sizes are indicated in parentheses).
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After both 30 and 100 µg kg−1 quinpirole administration Fto∆DAT mice retained
significantly more of their locomotor activity. Hence, the ability of the DRD2/
DRD3 agonist quinpirole to reduce activity of the dopaminergic neurons and there-
by reducing the dopaminergic network tone was significantly attenuated. These re-
sults are consistent with the proposed cell autonomous reduction in DRD2/DRD3-
GIRK dependent autoinhibition in Fto∆DAT mice and are in line with the results
obtained for Fto-deficient mice.
Hypersensitivity of Fto∆DAT mice to cocaine in the conditioned place
preference
Finally, to assess the function of the dopaminergic system with respect to pro-
cessing reward-related behavior, Fto∆DAT mice were tested in the conditioned place
preference paradigm. Fto∆DAT mice featured several aspects of the previously re-
ported DRD2 autoreceptor knock out mouse, including increased baseline and
cocaine-induced locomotor activity and the attenuated responses to quinpirole both
on the cellular as well as the behavioral level [Bello et al., 2011]. Therefore, the con-
ditioned place preference was performed with a very low dose cocaine bait (0.5 mg
kg−1), a concentration that was able to affect place preference in DRD2 autorecep-
tor knock out mice [Bello et al., 2011]. While this concentration failed to show any
effect in control mice, place preference in Fto∆DAT mice was significantly enhanced
(Figure 3.23).
This result is in line with the concept that decreased inhibitory tone in do-
paminergic neurons would result in enhanced responses to conditioned stimuli
and again supports the notion that loss of FTO cell autonomously attenuates the
DRD2/DRD3-GIRK-dependet autoinhibitory feedback loop.
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Figure 3.23: Low dosage of cocaine shifts preference of Fto∆DAT mice in conditioned
place preference
Reward processing was assessed in the conditioned place preference paradigm
for Fto∆DAT and control mice using a low dose cocaine bait (0.5 mg kg−1, sam-
ple size indicated in parenthesis, *P<0.05, paired two-tailed t-test).
3.3 N6-methyladenosine in mRNA depends on FTO
demethylase function
3.3.1 Methylated RNA immunoprecipitaion (MeRIP) sequencing identifies
demethylation targets of FTO
On the molecular level, FTO was identified as a Fe(II) and 2-oxoglutarate dependent
demethylase that is able to demethylate 3 - methyluracil and N6 - methyladenosine
(m6A) in vitro [Jia et al., 2011; Gerken et al., 2007]. Recently, the m6A mark was
identified in over 7600 mRNA transcripts in vivo [Meyer et al., 2012; Dominissini
et al., 2012]. To investigate the potential role of this enzymatic capability of FTO
with respect to dopaminergic function, the m6A methylation profile was assessed
in Fto-deficient mice. To this end, mRNA of midbrain and striatal (CPu and NAc)
tissue was isolated and subsequently processed using established methylated RNA
immunoprecipitaion (MeRIP) protocols, followed by next generation sequencing
[Meyer et al., 2012]. In total, 42.000 m6A peaks were found, and 5000 peaks in
over 1500 transcripts were unique to Fto-deficient mice (Table 6.3). In line with
previously published results, one or more m6A marks were found in the 5’ UTR,
CDS or 3’UTR of individual transcripts (Table 6.3, Meyer et al. [2012]).
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Figure 3.24: Gene ontology analysis of transcripts with m6A hypermethylation in Fto-
deficient mice
Gene ontologies of m6A hypermethylated midbrain and striatal mRNA tran-
scripts cluster in categories of synaptic transmission and cell-cell signaling in
Fto-deficient mice. Gene ontology analysis was performed by Yogesh Saletore
and Olivier Elemento
.
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Gene ontology analysis of transcripts hypermethylated in Fto-deficient mice
Since the loss of FTO leads to a hypermethylation of a subset of m6A modi-
fied mRNAs, gene ontology analysis was performed to investigate the potential
connection between the observed phenotype of Fto-deficient mice and the hyper-
methylated transcripts. This analysis showed that in comparison to the whole tran-
scriptome, gene ontologies related to synaptic transmission and cell-cell signaling
were overrepresented in Fto-deficient mice (Figure 3.24).
In wildtype control mice, however, enrichment of these categories identified in
Fto-deficient mice were not found, suggesting that FTO targets a functionally dis-
tinct subset of transcripts (Figure 3.25).
3.3.2 m6A in mRNA influences translation of methylated transcripts
To identify putative candidate transcripts, whose m6A methylation in Fto-deficient
mice might be functionally implicated in dopamine signaling, pathway analysis
was performed to generate an overlay of dopaminergic signaling and hypermethy-
lated mRNAs (Table 6.3, Figure 3.26). A number of hypermethylated transcripts in
Fto-deficient mice encode for proteins that are components of dopaminergic signal-
ing, including DRD3, GIRK2, NMDAR1, GNAO1 and SYN1 (Figure 3.26). Several
of these components were selected for further analysis.
The type 3 dopamine receptor (DRD3) is expressed both pre- and postsynapti-
cally [Beaulieu & Gainetdinov, 2011]. MeRIP-seq identified a m6A methylation site
within the coding sequence of the Drd3 transcript (Figure 3.27 a, Table 6.3). Using
quantitative PCR, significant upregulation of Drd3 mRNA levels were detected in
Fto-deficient midbrain and CPu (Figure 3.27 b). On the protein level, however, a
significant downregulation was observed for DRD3 in Fto-deficient mice (Figure
3.27 c, d).
Comparable results were obtained for the G protein coupled inwardly rectify-
ing potassium channel 2, whose transcript was m6A methylated within the 5’UTR
(Figure 3.28 a). This 5’ UTR, however, is only present in the Girk2A and Girk2B,
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Figure 3.25: Gene ontology analysis of transcripts m6A methylated in control mice
m6A methylated mRNA transcripts, isolated from wildtype midbrain and
striatum, do not cluster in gene ontologies of synaptic transmission or cell-
cell signaling. Gene ontology analysis was performed by Yogesh Saletore and
Olivier Elemento
.
but not Girk2C transcripts. qPCR analysis of total Kcnj6 revealed a significant up-
regulation of mRNA levels in Fto-deficient midbrain tissue (Figure 3.28 b; isoform
unspecific Kcnj6 qPCR probe). Consistent with the previous results for DRD3,
GIRK2 protein levels were significantly downregulated in both midbrain and CPu
of Fto-deficient mice (Figure 3.28 c, d).
For the N-methyl-D-aspartate (NMDA) receptor subunit 1, hypermethylated m6A
3 Results 85
Figure 3.26: Pathway analysis of m6A hypermethylated transcripts in Fto-deficient mice
Overlay of dopaminergic signaling and m6A hypermethylated transcripts iden-
tified via MeRIP-Seq in Fto-deficient midbrain and striatal tissue was per-
formed to identify putative candidates functionally related to the phenotype
observed in Fto-deficient mice
sites were detected in both the 5’ and 3’ UTR of Fto-deficient mice (Figure 3.29 a,
only 3’ UTR shown). Grin1 transcripts showed significant upregulation in Fto-
deficient midbrain but not CPu (Figure 3.29 b), while protein levels were signifi-
cantly downregulated in both midbrain and CPu (Figure 3.29 c, d).
Whilst the upregulation of m6A hypermethylated on mRNA level was detected
for additional transcripts (Gnai1, Ikbkb, Gnao1, Gnb5; Figure 3.30 a, 3.31 a, 3.32),
downregulation of the protein level was not confirmed for GNAI1 nor IKK2 (Figure
3.30 b, c, 3.31 b, c), suggesting a more complicated mechanism through which m6A
methylation functionally impacts specific transcripts.
86 3 Results
DRD3
CALNEXIN
Midbrain
DRD3
CALNEXIN
a
c
b
d
1kb
5’ 3’
50
50
1
1
CPu
0
50
100
150
200
250
R
e
la
tiv
e
 
m
R
N
A 
e
xp
re
ss
io
n
 
[%
]
R
e
la
tiv
e
 
in
te
n
si
ty
 [%
]
Midbrain
Midbrain
CPu
CPu
Fto +/+
Fto–/–
Fto +/+
Fto–/–
*
(10)
(8)(10)
(9)
Drd3
DRD3
**
**
***
0
50
100
150
Drd3
Fto+/+
Fto –/–
Fto+/+ Fto –/–
Fto+/+ Fto –/–
(4)
(4)
(6)
(6)
Figure 3.27: FTO demethylation target Drd3
(a) MeRIP-Seq identified a hypermethylated m6A site in the coding sequence
of the Drd3 mRNA transcript of Fto-deficient mice. MeRIP pulldown was per-
formed by Kate Meyer. (b) Quantitative PCR of Drd3 mRNA isolated from
Fto-deficient and control midbrain and dorsal striatum (CPu). (c) Western
blot analysis of DRD3 protein in Fto-deficient and control midbrain and CPu
lysates. (d) Quantification of DRD3 western blot analysis. (*P<0.05, **P<0.01,
***P<0.001; unpaired two-tailed t-test, sample sizes are indicated in parenthe-
sis).
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Figure 3.28: FTO demethylation target Kcnj6
(a) MeRIP-Seq identified a hypermethylated m6A site in the 5’ UTR of Kcnj6
mRNA transcripts of Fto-deficient mice. MeRIP pulldown was performed by
Kate Meyer. (b) Quantitative PCR of Kcnj6 mRNA isolated from Fto-deficient
and control midbrain and dorsal striatum (CPu). (c) Western blot analysis of
GIRK2 protein in Fto-deficient and control midbrain and CPu lysates (bands
in blot correspond to GIRK2A and GIRK2B isoforms). (d) Quantification of
GIRK2 western blot analysis. (*P<0.05, **P<0.01; unpaired two-tailed t-test,
sample sizes are indicated in parenthesis).
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Figure 3.29: FTO demethylation target Grin1
(a) MeRIP-Seq identified hypermethylated m6A sites in the 5’ and 3’ UTR of
Grin1 (glutamate receptor, ionotropic, N-methyl-D-aspartate 1) mRNA tran-
scripts of Fto-deficient mice (5’ UTR not depicted). MeRIP pulldown was per-
formed by Kate Meyer. (b) Quantitative PCR of Grin1 mRNA isolated from
Fto-deficient and control midbrain and dorsal striatum (CPu). (c) Western
blot analysis of NMDAR1 (N-methyl-D-aspartate receptor subunit 1) protein in
Fto-deficient and control midbrain and CPu lysates. (d) Quantification of NM-
DAR1 western blot analysis. (*P<0.05, ***P<0.001; unpaired two-tailed t-test,
sample sizes are indicated in parenthesis).
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Figure 3.30: FTO demethylation target Gnai1
MeRIP-Seq identified a hypermethylated m6A site in the 5’ UTR of Gnai1
mRNA transcripts of Fto-deficient mice. (a) Quantitative PCR of Gnai1 mRNA
isolated from Fto-deficient and control midbrain and dorsal striatum (CPu).
(b) Western blot analysis of GNAI1 protein in Fto-deficient and control CPu
lysates. (c) Quantification of GNAI1 western blot analysis. (*P<0.05, **P<0.01;
unpaired two-tailed t-test, sample sizes are indicated in parenthesis).
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Figure 3.31: FTO demethylation target Ikbkb
MeRIP-Seq identified hypermethylated m6A sites in the coding sequence and
3’ UTR of Ikbkb mRNA transcripts of Fto-deficient mice. (a) Quantitative PCR
of Ikbkb mRNA isolated from Fto-deficient and control midbrain and CPu. (b)
Western blot analysis of IKK2 protein in Fto-deficient and control CPu lysates.
(c) Quantification of IKK2 western blot analysis. (***P<0.001; unpaired two-
tailed t-test, sample sizes are indicated in parenthesis).
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Figure 3.32: FTO demethylation targets Gnao1 and Gnb5
MeRIP-Seq identified hypermethylated m6A sites in the coding sequence and
5’ UTR of Gnao1 and the 5’ UTR of Gnb5 mRNA transcripts of Fto-deficient
mice. (a) Quantitative PCR of Gnao1 mRNA isolated from Fto-deficient and
control midbrain and dorsal striatum (CPu). (b) Quantitative PCR of Gnb5
mRNA isolated from Fto-deficient and control midbrain and CPu. (*P<0.05,
***P<0.001; unpaired two-tailed t-test) Sample sizes are indicated in parenthe-
sis.
4 Discussion
The worldwide increase in prevalence of obesity is going to be one of the major
challenges of modern society, causing a plethora of health problems and placing
a burden on health care systems [Cawley & Meyerhoefer, 2012; Finkelstein et al.,
2009; Caballero, 2007]. The reason for the increase in obesity which started in the
middle of the 20th century, is unlikely to be caused by rare mutations. It is rather
a cause of environmental changes including sedentary life style and the constant
availability of highly palatable food in conjunction with a genetic susceptibility to
gain weight in such conditions [Swinburn et al., 2011; Caballero, 2007].
This susceptibility is believed to be shaped by common genetic variations and the
sum of their individual effects on body weight [Loos, 2012]. Hence, identification
of these single nucleotide polymorphisms (SNPs) underlying common obesity has
become a primary goal. Some of the SNPs can directly impact the function of
genes through changes in the coding sequence, while others are situated in intronic
regions and may indirectly affect gene function.
In 2007, a cluster of SNPs was identified within the first intron of the human
FTO gene and these SNPs were subsequently the targets of extensive studies, due
to their robust association with obesity related traits [Frayling et al., 2007; Dina et al.,
2007; Scuteri et al., 2007]. To date, the exact function of these SNPs within the first
intron as well as the exact function of the FTO gene product are not known. Hence,
the aim of this thesis was the investigation of FTO by means of genetic manipu-
lations in mice to identify FTO’s function and depending pathways, to ultimately
shed light on the connection between FTO genomic variation and common obesity.
Whole body FTO deletion in mice causes a severe phenotype that partly resem-
bles the phenotype of Drd2-deficient mice, including growth retardation, reduced
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IGF-1 levels, lean phenotype, increased energy expenditure and reduced voluntary
locomotor activity [Fischer et al., 2009; Klinker et al., 2013; Kim et al., 2010; García-
Tornadu et al., 2010; Díaz-Torga et al., 2002; Sibley, 1999; Kelly et al., 1998; Beaulieu
& Gainetdinov, 2011]. Moreover, both FTO and DRD2 are linked to the etiology
of obesity [Scuteri et al., 2007; Dina et al., 2007; Frayling et al., 2007; Volkow et al.,
2013; Wang et al., 2001]. For this reason, the potential role of FTO in dopaminergic
signaling was investigated.
4.1 Fto deficiency alters D2-like receptor–dependent responses
4.1.1 FTO is expressed in midbrain dopaminergic neurons
Although Fto is ubiquitously expressed, it’s highest levels are detected within the
central nervous system [Gerken et al., 2007; McTaggart et al., 2011]. In line with
these results, endogenous Fto expression in midbrain dopaminergic neurons was
confirmed using a mouse model with a knock in of the β-galactosidase gene into
the endogenous Fto locus (Section 3.1.1). Moreover, FTO immunoreactivity was
demonstrated for midbrain dopaminergic neurons (Section 3.1.1). Hence, FTO po-
tentially plays a role in dopaminergic neurons and dopaminergic signaling.
Since the loss of FTO leads to increased mortality in both men and mice, Fto
deficiency may affect cell viability [Fischer et al., 2009; Boissel et al., 2009]. In Fto-
deficient mice, however, no changes in number or morphology of dopaminergic
neurons were observed, showing that viability of dopamine neurons is not affected
by the loss of FTO (Section 3.1.1).
4.1.2 Whole body Fto-deficiency attenuates responses to cocaine
To investigate the function of the dopaminergic circuitry, Fto-deficient mice were
challenged with cocaine injections. Cocaine is a potent psychostimulatory sub-
stance, whose primary effect is the blockade of the dopamine transporter and hence
many of its effects impinge on dopaminergic signaling [Beaulieu & Gainetdinov,
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2011; Hyman et al., 2006; Nestler, 2001]. Loss of FTO had severe impacts on the co-
caine evoked responses in mice. Firstly, the cocaine mediated increase in locomotor
activity was blunted (Section 3.1.3). Secondly, cocaine-induced Fos expression in
midbrain and striatal tissue was attenuated (Section 3.1.3). And thirdly, although
cocaine was able to stimulate increases in extracellular dopamine in the NAc, sig-
nificant differences were detected between control and Fto-deficient mice at higher
cocaine dosages (Section 3.1.3). Since all neurons are affected in Fto-deficient mice,
the individual contributions of pre- and postsynaptic loss of FTO in these exper-
iments are not known. Failure to increase locomotor activity and Fos expression
may stem from a failure of cocaine to block the dopamine transporter and would
resemble aspects of a dopamine transporter mutant mouse insensitive to cocaine
[Chen et al., 2006]. The fact that dopamine levels increased in response to cocaine
in Fto-deficient mice, however, suggests that other factors may contribute to the
observed cocaine insensitivity, though not ruling out an alteration of dopamine
transporter function. As DAT protein levels were demonstrated to be unchanged
in Fto-deficient mice, loss of FTO might indirectly affect DAT function.
4.1.3 Impairment of D2-like autoreceptor signaling
Dopaminergic neurons express D2 and D3 autoreceptors that are activated by do-
pamine and trigger a feedback loop that subsequently terminates dopamine signal-
ing through the activation of GIRK channels and hyperpolarization of dopamine
neurons [Beaulieu & Gainetdinov, 2011; Lüscher & Slesinger, 2010]. While dopa-
mine neurons fire tonically in a slice preparation, cocaine administration leads to
a decrease in firing by increasing extracellular dopamine levels and activating the
autoinhibitory feedback loop. Consistently, cocaine decreased the firing rate of do-
pamine neurons in the midbrain of control mice (see Section 3.1.4). In Fto-deficient
mice, however, the ability of cocaine to reduce firing of dopamine neurons was
significantly attenuated (Section 3.1.4).
Since cocaine acts indirectly via increasing extracellular levels of dopamine, the
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DRD2/DRD3 selective agonist quinpirole was used to directly address the func-
tion of the autoinhibitory feedback loop. In line with the previous experiments,
activation of the feedback loop by quinpirole potently reduced the firing rate of
dopamine neurons in control mice, while this response was significantly atten-
uated in Fto-deficient mice (Section 3.1.4). Consistently, the quinpirole and GIRK
dependent conductance density was decreased in Fto-deficient mice. On the behav-
ioral level, injection of quinpirole in control mice caused a reduction in locomotor
activity via inhibiting dopamine neuron activity. Consistently with the impairment
observed on the cellular level, quinpirole’s ability to reduce locomotor activity was
significantly attenuated in Fto-deficient mice, demonstrating that the impaired au-
toinhibitory feedback directly translates into a behavioral phenotype.
Taken together, Fto deficiency led to a malfunction of the DRD2-DRD3-GIRK-
dependent autoinhibitory feedback loop of dopaminergic neurons and impaired, in
conjunction with postsynaptic alterations, responses of the dopaminergic circuitry
to cocaine and quinpirole.
4.2 Conditional loss of Fto resembles D2 autoreceptor
deficiency
4.2.1 Successful generation of dopamine neuron specific knock out mice
To investigate the role of FTO in altering the dopaminergic circuitry, dopamine neu-
ron restricted knock out mice were utilized in addition to whole body Fto-deficient
mice. To generate a specific deletion of FTO in dopaminergic cells, mice carry-
ing the Cre recombinase under the control of the endogenous Dat promoter were
crossed to mice with a loxP site flanked third exon of Fto (Section 3.2.1). Successful
generation of Fto∆DAT mice was confirmed using immunohistochemical investiga-
tion of midbrain slices. Here, tyrosine hydroxylase (TH) immunolabeling was used
to identify dopaminergic neurons. These experiments showed that the majority of
dopamine cells in the VTA/SN of mice expressed FTO (approximately 90%). After
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Cre-mediated recombination in Fto∆DAT mice, however, only 1.14% of TH positive
neurons were found to express FTO, demonstrating the efficient deletion of FTO
in dopaminergic neurons. Using Western blot analysis on peripheral tissues, the
specificity of FTO deletion was further confirmed (Section 3.2.1).
4.2.2 Cell-autonomous impairment of D2-like autoreceptor signaling
On the cellular level, the responses of Fto∆DAT to cocaine and quinpirole mirrored
those obtained in Fto-deficient mice. The ability of both cocaine and quinpirole
to inhibit the firing of midbrain dopamine neurons was significantly attenuated
(Section 3.2.3). Moreover, the GIRK channel-dependent conductance density was
reduced in Fto∆DAT as compared to control mice. These results show that the do-
pamine neuron restricted knock out resembled whole body FTO deletion on the
cellular level and that the autoinhibitory feedback loop was cell-autonomously af-
fected by loss of FTO.
The duration of dopamine signaling is limited by the presynaptic autoinhibition.
Hence, attenuation of the feedback loop that terminates dopamine signaling, pro-
longs synaptic dopamine transmission [Bello et al., 2011]. Targeted disruption of D2
autoreceptors in mice demonstrated that blunted autoreceptor function results on
the single cell level in comparable loss of inhibitory currents in response to quin-
pirole bath application as observed for Fto-deficient and Fto∆DAT mice [Bello et al.,
2011]. In addition, D2 autoreceptor knock out mice displayed increased baseline
and cocaine-induced locomotor activity, whereas quinpirole failed to reduce loco-
motor activity. Moreover, increased conditioned place preference in response to
very low dose cocaine injections was observed in D2 autoreceptor knock out mice,
showing that these mice are hypersensitive to the locomotor and rewarding effects
of cocaine [Bello et al., 2011].
In comparison, Fto∆DAT mice displayed increased baseline as well as cocaine in-
duced locomotor activity at low concentrations, while no significant difference were
detected at higher concentrations. Hypersensitivity to cocaine in Fto∆DAT mice was
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further assessed in the conditioned place preference paradigm, challenging the
mice with a very low dose of cocaine (0.5 mg kg−1, Section 3.2.3). While control
mice were indifferent to the treatment, Fto∆DAT mice responded to the subthreshold
dosage by increasing their preference for the baited side. Hence, in line with the
assumption that dopamine neuron restricted loss of FTO resembles the hypersen-
sitivity observed in D2 autoreceptor knock out mice, very low dosages of cocaine
were able to elicit a response in the conditioned place preference paradigm. Fur-
thermore, dopamine neuron restricted knock out of FTO significantly attenuated
quinpirole’s ability to inhibit locomotor activity (Section 3.2.3). In contrast to D2
autoreceptor knock out mice, quinpirole still retained a portion of its agonist po-
tential and markedly decreased locomotor activity in Fto∆DAT mice as compared to
baseline levels [Bello et al., 2011]. Therefore, Fto∆DAT mice share several features
of D2 autoreceptor deficiency, but are not a phenocopy of the D2 autoreceptor-
deficient mice. Dopamine neuron restricted loss of FTO rather leads to a loss
of autoinhibition through more complex mechanisms as compared to loss of D2
autoreceptors. In line with this notion, no differences in DRD2 expression were
detected in Fto-deficient mice, showing that attenuation of autoinhibition would
involve other components of the feedback loop or may indirectly affect DRD2 au-
toreceptor function.
Dopamine signaling has been implicated in the etiology of obesity [Volkow et al.,
2013; Wang et al., 2001], hence, attenuation of dopamine autoinhibitory feedback
may impact body weight regulation. Since Fto-deficient mice suffer from a com-
plex phenotype, alterations of body weight regulation in these mice may stem
from multiple sources, thereby making it impossible to draw unambiguous con-
clusions [Fischer et al., 2009]. Therefore, basic metabolic parameters were assessed
in Fto∆DAT mice. To this end, no alterations in body weight, food intake, insulin sen-
sitivity, glucose tolerance, re-feeding response or sucrose preference were detected,
demonstrating that loss of FTO specifically in dopaminergic neurons, while affect-
ing dopamine autoinhibition, does not impact energy homeostasis. These results
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are consistent with the findings obtained for D2 autoreceptor-deficient mice, that
do not exhibit changes in body weight [Bello et al., 2011]. Both of these findings
suggest that D2 autoreceptor function is not critical for body weight regulation.
Possibly, postsynaptic adaptations at the network level compensate in every day
life for the aberrant autoreceptor function, thereby preventing malfunctional body
weight regulation. Only as the dopaminergic circuitry is pushed by non-natural
stimuli, such as cocaine, the attenuated autoinhibtory feedback leads to behavioral
alteration. In contrast, in whole body Fto-deficient mice loss of FTO affects postsy-
naptic sites of dopamine action as well. Hence, these mice share several phenotypic
characteristics of whole body Drd2-deficient mice, such as growth retardation, re-
duced IGF-1 levels, lean phenotype, increased energy expenditure and reduced
voluntary locomotor activity [Fischer et al., 2009; Klinker et al., 2013; Kim et al.,
2010; García-Tornadu et al., 2010; Díaz-Torga et al., 2002; Sibley, 1999; Kelly et al.,
1998; Beaulieu & Gainetdinov, 2011].
Taken together, loss of FTO in dopaminergic neurons attenuates function of the
DRD2-DRD3-GIRK-dependent autoinhibitory feedback loop that ensures termina-
tion of dopamine synaptic transmission. While this led to a hypersensitivity to
locomotor and reward stimulating effects of cocaine in Fto∆DAT mice, Fto-deficient
mice were insensitive to cocaine. Therefore, in addition to control of presynaptic
dopamine signaling, FTO is likely to affect postsynaptic signaling events in target
neurons of the dopaminergic system as well.
4.2.3 Relation of whole body and dopamine restricted FTO deficiency to D2
receptor studies
Although DRD2 was not downregulated on the protein level in Fto-deficient mice
(Section 3.1.2), FTO deficiency resembles several aspects of DRD2 deficiency. In
addition to the previously described similarities, both Fto- and Drd2-deficient mice
exhibit comparable loss of cocaine-induced locomotor activity and Fos induction
[Welter et al., 2007]. Likewise, Fto∆DAT mice resemble characteristics of DRD2
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autoreceptor-deficient mice [Bello et al., 2011]. Hence, the phenotypic differences
between Fto-deficient and Fto∆DAT mice mirrors the differences between DRD2
whole body knock out and DRD2 autoreceptor-deficient mice [Bello et al., 2011;
Welter et al., 2007; Chausmer et al., 2002; Kelly et al., 1998].
Despite the paucity of DRD2 protein downregulation in Fto-deficient mice, the
striking similarities to loss of DRD2s suggests to view loss of FTO in the context
of D2 receptor studies. Postsynaptic DRD2 receptor availability influences drug
abuse, with increased levels of DRD2 corresponding with lower self administration
in monkeys and rodents and decreased levels of DRD2 observed in human drug
abusers [Volkow et al., 2009; Morgan et al., 2002; Thanos et al., 2001]. Decreased post-
synaptic DRD2 availability was suggested to cause repetitive drug abuse to com-
pensate for the decreased postsynaptic dopamine signaling [Volkow et al., 1999].
Similarly, obese subjects exhibit decreased DRD2 levels in the striatum and are be-
lieved to compensate for the decreased receptor availability and decreased down-
stream activation of striatal DRD2 signaling via compulsive increase in intake of
highly palatable food that stimulates dopamine release [Volkow et al., 2013; Stice
et al., 2008; Wang et al., 2001]. Consistently, rapid development of compulsive
overeating in rats has been observed after virus-mediated knock down of striatal
DRD2 [Johnson & Kenny, 2010]. A different theory suggests downregulation of
postsynaptic DRD2s as a compensatory response to increased dopaminergic trans-
mission [Bello et al., 2011; Stice et al., 2008]. In line with this notion, reduced levels
of DRD2/DRD3 in human midbrain are associated with higher impulsivity and in-
creased stimulant craving due to increased substance-mediated DA release [Buck-
holtz et al., 2010]. Moreover, DRD2 autoreceptor-deficient mice exhibit increased
responses to the rewarding properties of cocaine [Bello et al., 2011]. Although,
cause and consequence of the changes in D2 receptor expression are still a mat-
ter of debate, both obesity and addiction share deregulations of DRD2 availability
[Volkow et al., 2013]. Therefore, FTO, via regulating presynaptic dopamine autore-
ceptor feedback and/or postsynaptic dopamine signaling, may impinge on obesity
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or addictive behavior. Consistently, Fto∆DAT mice exhibited cocaine supersensitiv-
ity in the conditioned place preference paradigm. Dopamine neuron restricted loss
of FTO, however, had no influence on body weight or food intake, which is consis-
tent with the paucity of body weight differences for DRD2 autoreceptor-deficient
mice. Hence, in detail investigation of postsynaptic loss of FTO is warranted, that
ultimately may affect food intake via attenuation of dopamine signaling in striatal
dopamine target neurons, thereby resembling downregulation of DRD2 in human
drug abusers and obese subjects [Volkow et al., 2009; Wang et al., 2001].
4.3 FTO demethylates m6A in messenger RNA
To date, the exact molecular function of FTO is not known. Growing evidence
suggests that FTO demethylates N6-methyladenosine in messenger RNA [Meyer
et al., 2012; Dominissini et al., 2012; Jia et al., 2011]. First evidence demonstrated
a role for m6A in mRNA stability [Wang et al., 2013]. Whether this modification
serves additional functions in mRNA processing, splicing, translation and/or other
cellular functions remains elusive. Moreover, additional enzymatic functions of
FTO, other than m6A demethylation, cannot be excluded at this point.
4.3.1 FTO acts as a m6A demethylase in vivo
To investigate whether FTO demethylates m6A in mRNA in vivo and thereby poten-
tially impacts dopaminergic signaling, the m6A methylation pattern was assessed
for Fto-deficient and control mice. In line with previous studies, a total of 42.000
m6A peaks were identified in mRNA isolated from midbrain and striatal tissue
[Meyer et al., 2012; Dominissini et al., 2012]. This widespread occurrence of m6A
in brain tissue is in line with previously reported results [Meyer et al., 2012]. In
comparison to control tissue over 5000 additional m6A peaks in over 1500 tran-
scripts were identified in Fto-deficient mice, demonstrating that FTO demethylates
m6A in mRNA in vivo. Moreover, loss of FTO only affected a subset of m6A sites
and consequently only a subset of all methylated transcripts. For this reason, it
4 Discussion 101
seems that FTO is acting only on specific transcripts and potentially affects specific
pathways or cellular functions. Indeed, gene ontology analysis of those transcripts
hypermethylated in Fto-deficient mice (FTO demethylation targets) revealed an en-
richment of categories related to synaptic transmission and cell-cell signaling, while
methylated transcripts in control mice did not cluster within these categories. This
supports the notion that FTO plays a critical role in the central nervous system
and is in line with the severe brain malformations observed for loss of FTO in hu-
mans [Gao et al., 2010; Boissel et al., 2009; Gerken et al., 2007]. FTO demethylase
activity was directed against a specific subset of transcripts, however, this analysis
only included specific parts of the brain. Hence, different transcripts may be af-
fected in other brain areas. Moreover, other demethylases may act in parallel on
yet different subsets of mRNA in a tissue specific manner. Supporting this concept
is the recent identification of AlkBH5, a second m6A demethylase, that is highly
expressed in peripheral tissues rather than the central nervous system [Zheng et al.,
2012]. Hence, FTO, AlkBH5 and yet unidentified demethylases may alter methyla-
tion status and as a consequence mRNA function in a tissue specific manner.
Albeit the yet unknown function of the m6A mark, hypermethylated transcripts
in Fto-deficient midbrain and striatal tissue were further investigated for a potential
involvement in the dopamine signaling related phenotype observed in Fto-deficient
and Fto∆DAT mice. Overlay of hypermethylated transcripts with dopaminergic sig-
naling using pathway analysis revealed several transcripts encoding proteins im-
portant for neuronal signaling in general, such as GNAO1 and NMDAR1(zeta-1),
and dopaminergic signaling specifically, such as DRD3, GIRK2, GNAO1, PDE1b,
CACNA1A -1C -1D and SYN1 (Section 3.3.2).
4.3.2 Selected candidate transcripts are affected on protein level
Following the identification of hypermethylated transcripts that putatively impact
dopaminergic signaling, several candidates were selected for further investigation.
All investigated candidates showed no differences or minor increases on the tran-
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script level. Several candidates, however, were downregulated on the protein level
(DRD3, GIRK2, NMDAR1), suggesting a role for the m6A mark in regulating trans-
lation. These observations are in line with a reduced global translation reported for
Fto-deficient cells and the loss of lean mass in adult onset Fto-deficient mice [Gulati
et al., 2013; McMurray et al., 2013]. Furthermore, downregulated protein levels are
in agreement with the recent finding that m6A affects mRNA stability via binding
of YTHDF2 to methylated transcripts and subsequent recruitment to RNA decay
sites [Wang et al., 2013]. Thereby, the pool of available mRNA templates is lim-
ited and would subsequently lead to a reduction in translation and protein levels.
Hypermethylation as caused by loss of FTO would thus lead to decreased mRNA
stability and lifetime and as a consequence reduced protein levels as observed for
DRD3, GIRK2 and NMDAR1 in Fto-deficient mice.
Since not all investigated hypermethylated transcripts exhibited downregulation
on protein level, the m6A modification does not necessarily influence translation,
suggesting complex mechanisms underlying the role of m6A in mRNA. Binding
of YTHDF2 was reported to only occur for a subset of m6A methylated transcripts
and therefore the YTHDF2-dependent regulation of mRNA stability does not affect
all m6A modified mRNAs [Wang et al., 2013]. Both GNAI1 and IKK2 transcripts
were hypermethylated in Fto-deficient mice, but showed normal protein expres-
sion. Hence, these candidates may represent transcripts that, although they exhibit
m6A hypermethylation, are not bound by YTHDF2 and are not removed from
the mRNA translation pool. Moreover, it cannot be ruled out that the observed
downregulations merely present indirect effects through downregulation of pro-
teins involved in RNA processing, metabolism or translation. Furthermore, m6A
may influence splicing patterns, thus affecting expression and protein levels of cer-
tain isoforms.
Since only midbrain and striatal tissue were analyzed in these experiments, it re-
mains to be determined whether the hypermethylated transcripts identified in this
study reflect a general population that is demethylated by FTO or whether different
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subsets of transcripts are affected in different brain areas. Furthermore, detailed
investigation of the role of m6A in regulating mRNA stability and translation is
warranted in order to define the exact context of FTO action.
With respect to dopaminergic signaling, the downregulation of DRD3, GIRK2
and NMDAR1 protein levels may, at least partly, explain the mechanism underlying
the attenuation of the DRD2-DRD3-GIRK dependent autoinhibitory feedback loop
in Fto-deficient and Fto∆DAT mice.
The dopamine D3 receptor
The DRD3, like the DRD2, is found presynaptically on dopamine neurons [Diaz
et al., 2000]. While the D2 receptor is known to reduce firing rate of dopaminergic
neurons through coupling to potassium channels of the GIRK family and subse-
quent membrane hyperpolarization [Bello et al., 2011; Lacey et al., 1987], evidence
on D3 receptors with regards to this function are so far contradictory. Both the
coupling and the paucity of coupling to GIRKs has been reported for DRD3 autore-
ceptors [Kuzhikandathil et al., 1998; Davila et al., 2003]. Nevertheless, both DRD3
and DRD2 may share the ability to reduce dopamine neuron firing as a mean of
feedback inhibition.
Furthermore, the whole body deletion of DRD3 in mice led to increased loco-
motor activity, increased grooming and enhanced reactivity to drug-paired cues
[Accili et al., 1996; Xu et al., 1997; Le Foll et al., 2005; Narita et al., 2003; Francès
et al., 2004]. All of these behaviors are related to dopamine levels and consistently,
DRD3-deficient mice have higher levels of extracellular dopamine [Koeltzow et al.,
1998; Joseph et al., 2002]. In contrast, DRD2-deficient mice have unaltered dopa-
mine levels, suggesting that control of basal dopamine levels depends on DRD3
rather than DRD2 function [Dickinson et al., 1999]. Fto-deficient mice are hypoac-
tive, whereas Fto∆DAT mice were relatively hyperactive [Fischer et al., 2009]. As
baseline locomotor activity would partialy depend on baseline dopamine levels,
detailed investigation of absolute dopamine values may aid in further outlining
the exact outcome of conditional and whole body loss of FTO [Giros et al., 1996;
104 4 Discussion
Zhou & Palmiter, 1995]. Taken together, decreased availability of DRD3 autorecep-
tors due to FTO deficiency may directly affect the feedback loop, leading to the
attenuation of dopamine neuron autoinhibition in Fto-deficient and Fto∆DAT mice.
In humans variation within the DRD3 gene affecting dopamine binding affinity
has been linked to impulsivity and substance abuse [Agrawal et al., 2013; Huang
et al., 2008; Limosin et al., 2005; Retz et al., 2003; Krebs et al., 1998; Duaux et al., 1998].
Moreover, DRD3 variation was linked to some aspects of ADHD related to violent
behavior [Retz et al., 2003]. Therefore, FTO may likewise impinge on behaviors such
as impulsivity through affecting DRD3 transcript methylation. In line with this no-
tion, first associations of genomic variation in FTO with ADHD have been reported
[Choudhry et al., 2013; Velders et al., 2012]. Thus, investigation of Fto-deficient mice
led to the identification of a putative candidate transcript, Drd3, linking human
FTO genotypes to psychiatric diseases such as ADHD. Consequently, investigation
of human FTO and DRD3 genotypes may hold the potential to identify synergistic
or antagonistic actions with respect to psychiatric and obesity related traits.
G protein-coupled inwardly rectifying potassium channel 2
G protein-coupled inwardly rectifying potassium channels (GIRK) are mediat-
ing slow inhibitory currents, both pre- and postsynaptically [Lüscher & Slesinger,
2010]. Furthermore, they shape the resting membrane potential and thus influence
the excitability of neurons [Mark & Herlitze, 2000]. The four known GIRK subunits
(GIRK1-4) form homo- or heterotetrameric channels [Lüscher & Slesinger, 2010].
Within the brain, the dominant form of this channel is compromised by GIRK1
and GIRK2. Knock out studies in mice have demonstrated that GIRK2 (Kcnj6) is
the primary channel subunit mediating inhibitory currents [Lüscher & Slesinger,
2010]. Hence, one of the consequences of the downregulation of GIRK2 in Fto-
deficient mice is the reduction of dopamine autoreceptor-mediated inhibitory cur-
rents. Furthermore, Girk2-deficient mice exhibited reduced anxiety, increased ac-
tivity, reduced cocaine self-administration and reduced conditioned taste aversion
[Arora et al., 2010; Pravetoni & Wickman, 2008; Hill et al., 2003; Morgan et al., 2003].
4 Discussion 105
While a reduction in cocaine self-administration is reminiscent of the cocaine insen-
sitivity in Fto-deficient mice, increased activity of Girk2-deficient mice is opposing
the hypoactivtiy of whole body FTO knock out mice [Fischer et al., 2009]. There-
fore, Fto-deficient mice do not resemble all aspects of GIRK2 deficiency, but are
rather subject to a number of alterations (including DRD3, NMDAR1 and GIRK2)
shaping their phenotype. GIRKs are not only coupling to autoreceptors, but also to
other non-dopaminergic receptors in dopamine neurons, thereby representing one
of the major factors controlling dopamine neuron function [Lüscher & Slesinger,
2010]. Widely expressed, both pre- and postsynaptic, GIRKs are important me-
diators of long term depression (LTD) and long term potentiation (LTP), synaptic
mechanisms underlying various forms of learning behaviors [Lüscher & Slesinger,
2010]. Hence, the reduced GIRK availability in midbrain dopaminergic neurons
of Fto-deficient and Fto∆DAT mice would not only affect autoreceptor inhibition of
dopamine neurons, but also impact the responsiveness of dopaminergic neurons
to various other synaptic inputs (e.g. GABAergic). Additionally, postsynaptic loss
of GIRKs in target neurons of the dopamine circuitry in Fto-deficient mice would
attenuate LTD and/or LTP and thus prevent the encoding of motivational value by
dopaminergic signaling [Volkow et al., 2013; Kauer & Malenka, 2007; Hyman et al.,
2006].
In humans, GIRK channels are implicated in diseases such as epilepsy, Down’s
syndrome, Parkinson’s disease and addiction, demonstrating their importance for
neuronal function [Lüscher & Slesinger, 2010].
Taken together, FTO dependent regulation of GIRK2 availability would not only
affect dopamine neuron function via coupling of GIRKs to both DRD2 and DRD3
autoreceptors, but may also represent a possible reason for the strong contrast
between whole body and dopamine neuron restricted FTO deficiency, via postsy-
naptic alterations of GIRK expression.
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N-methyl-D-aspartate receptor subunit 1
The NMDAR1 (Grin1) subunit is a critical component of N-methyl-D-aspartate
receptors, which belong to the family of voltage-gated ionotropic receptors [Pao-
letti et al., 2013; Kauer & Malenka, 2007]. NMDARs are activated by membrane
depolarization in conjunction with co-binding of the excitatory neurotransmitters
glutamate and either glycine or D-serine [Paoletti et al., 2013]. Within the brain,
NMDARs are important mediators of LTD and LTP. Opening of NMDARs leads
to an influx of sodium and importantly calcium, which triggers intracellular sig-
naling molecules, such as the CamKII protein kinase (in LTP) or phosphatases (in
LTD) [Paoletti et al., 2013; Kauer & Malenka, 2007]. Both LTP and LTD depend on
changes in α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AM-
PAR) availability, which is regulated by NMDAR signaling [Kauer & Malenka,
2007]. Deletion of the critical NMDAR1 subunit caused a complete loss of NMDA
receptor function [Forrest et al., 1994; Tsien et al., 1996]. Hence, reduced availabil-
ity of NMDAR1 in Fto-deficient mice would lead to an attenuation of the synaptic
alterations in LTP and LTD underlying dopaminergic signaling, thereby impairing
fundamental mechanisms of synaptic plasticity [Kauer & Malenka, 2007; Hyman
et al., 2006]. Once again, loss of these mechanisms may represent one possible cause
for the insensitivity of Fto-deficient mice to cocaine-induced increases in synaptic
dopamine levels. Since NMDARs are also expressed on dopaminergic neurons
[Wang et al., 2010; Paquet et al., 1997], dopamine neuron restricted FTO knock out
mice may also exhibit a deregulation of NMDAR1 signaling in DA neurons, impli-
cated in synaptic plasticity and addiction [Zweifel et al., 2008].
In humans, malfunctional NMDAR dependent synaptic plasticity has been linked
to various psychiatric diseases, including schizophrenia, mood disorders, Hunt-
ington’s and Alzheimer’s disease [Lakhan et al., 2013]. Therefore, malfunctional
FTO-dependent regulation of NMDA receptor availability may play a role in these
neuropsychiatric diseases and could possibly represent a link to the observed asso-
ciations of human FTO variants with major depressive disorder or ADHD [Samaan
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et al., 2012; Rivera et al., 2012; Velders et al., 2012; Choudhry et al., 2013]. Further-
more, the importance of NMDA receptors for synaptic plasticity, poses the ques-
tion, whether human FTO variation affects learning and memory. Limited evidence
suggests that FTO risk alleles worsen memory performance and negatively impact
cognitive decline [Alosco et al., 2013; Bressler et al., 2013].
Taken together, via its proposed function as a m6A demethylase, FTO may regu-
late Grin1 transcript methylation, reducing NMDAR1 availability and thus would
downregulate a major component of the mechanistic machinery needed for synap-
tic plasticity in learning, memory and addiction [Zweifel et al., 2008; Kauer &
Malenka, 2007].
Most probably, additional hypermethylated transcripts not covered by the cur-
rent study are affected on protein level in Fto-deficient mice. Therefore, it is
likely that, in addition to DRD3, GIRK2 and NMDAR1, other components in-
volved in the function of dopaminergic signaling participate in the attenuation of
the DRD2-DRD3-GIRK-dependent autoreceptor function observed for Fto-deficient
and Fto∆DAT mice. Moreover, it cannot be ruled out at this point that loss of FTO
affects processes involved in the development of the central nervous system in
general and formation of synapses in particular. Adult onset loss of FTO in mice
overcomes many of the aspects of the germline Fto knock out phenotype, includ-
ing postnatal growth retardation [McMurray et al., 2013; Fischer et al., 2009]. The
first three postnatal weeks of life in mice (third trimester of pregnancy in humans)
are known as the critical time frame for central nervous system development, dur-
ing which circuits are wired and/or rewired [Bouret, 2010]. Hence, developmental
defects observed for growth may also affect the development of the neuronal cir-
cuitry and hypermethylation of transcripts leading to deregulation on the protein
level may underly these developmental alterations.
So far, all of the above described observations on FTO-dependent m6A hyper-
methylation and subsequent alterations of protein levels have been conducted in
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Fto-deficient mice. Further experiments will need to address whether comparable
results are observed for dopamine neuron restricted loss of FTO and hence dissect
pre- and postsynaptic effects of FTO demethylase activity.
4.4 Relation to studies of human FTO genomic variation
Genomic variation of FTO in humans is associated with obesity related traits. To
date the mechanisms causing this relation remain elusive. Although the exact func-
tion of the N6-methyladenosine modification in mRNA is largely unknown, a puta-
tive regulation of expression through demethylation by FTO may represent a mech-
anism by which physiological networks such as the homeostatic and hedonic cir-
cuitry are controlled. FTO expression has been demonstrated to depend on amino
acid availability [Cheung et al., 2013]. Hence, environmental changes e.g. leading
to starvation could affect FTO expression and subsequently change the methyla-
tion pattern in a given tissue or neuronal circuitry affecting a whole set of genes
simultaneously. These changes in methylation and subsequent expression changes
may alter network properties, setting a new baseline for the responsiveness of for
example the hedonic circuitry, potentially rendering an organism more susceptible
to e.g. rewarding stimuli. Fto-deficient as well as dopamine neuron restricted FTO
knock out mice exhibited alterations of the dopaminergic circuitry. FTO expression
decreases with a reduction of amino acid availability [Cheung et al., 2013; Gulati
et al., 2013]. Hence, starvation may reflect a knock down of FTO that would poten-
tially lead to an attenuation of the dopamine autoinhibitory feedback loop, subse-
quently hypersensitizing dopaminergic pathways and setting a new baseline that
could increase the responsiveness to rewarding stimuli. Further supporting this
hypothesis are studies of human FTO ’risk-allele’ carriers demonstrating altered
responsiveness of different brain areas, including nuclei of the reward circuitry,
to food representations [Karra et al., 2013]. Hence, FTO may be an important re-
lay enzyme, conveying environmental changes to hedonic and energy homeostasis
centers in the brain, finally leading to an adaptation of behavior.
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The human FTO phenotype is predominately related to energy intake, with FTO
’risk-allele’ carriers showing elevated consumption of highly palatable food [Haupt
et al., 2009; Speakman et al., 2008; Cecil et al., 2008; Timpson et al., 2008]. More-
over, ’risk-allele’ carriers display deviant food responsiveness and satiety [Wardle
et al., 2009, 2008; Velders et al., 2012]. Despite the robust associations with obesity
related traits, FTO variants were furthermore associated with addictive behavior,
ADHD and depression [Sobczyk-Kopciol et al., 2011; Velders et al., 2012; Choudhry
et al., 2013; Rivera et al., 2012; Samaan et al., 2012]. These, however, are inverse as-
sociations rendering the obesity ’risk-allele’ protective against depression, certain
addictive behavior and ADHD. Earlier studies established that ADHD and depres-
sion are associated with increased body weight [Luppino et al., 2010; Cortese &
Vincenzi, 2012]. Therefore, the inverse associations of FTO variants with these
conditions are surprising. Malfunction of the dopaminergic circuitry has been
previously linked to psychiatric disorders such as addictive behavior, ADHD and
depression [Swanson et al., 2007; Beaulieu & Gainetdinov, 2011; Koob & Volkow,
2010]. Intake of highly palatable food and the concomitant pleasure felt by its con-
sumption affect the dopaminergic circuitry as well. Hence, Velders and colleagues
proposed a mechanism through which overeating and enjoyment of food represent
self-medication that ameliorates the symptoms of ADHD, addiction and depres-
sion [Velders et al., 2012]. As a result, carriers of the obesity risk allele for FTO
would benefit from protective aspects of the increased intake of highly palatable
food via rewarding stimulation of the dopaminergic circuitry and attenuation of
psychiatric symptoms such as depression.
4.5 Conclusions
In summary, loss of FTO leads to the attenuation of the DRD2-DRD3-GIRK-de-
pendent autoreceptor feedback loop in both Fto-deficient and Fto∆DAT mice. While
this leads to a cocaine hypersensitivity in Fto∆DAT mice, Fto-deficient mice are in-
sensitive to the stimulatory effects of cocaine. On the molecular level, FTO was
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demonstrated to act as a m6A demethylase in midbrain and striatal tissue, act-
ing only on a subset of all m6A methylated transcripts and thus suggesting that
FTO acts on specific pathways implicated in neuronal signaling. As a consequence
of loss of FTO and m6A hypermethylation, protein levels of DRD3, GIRK2 and
NMDAR1 were found to be downregulated and would, at least partly, explain
malfunction of the autoreceptor feedback loop in dopaminergic neurons. More-
over, this finding is in perfect agreement with the recent demonstration that m6A
mRNA methylation leads to shuttling of transcripts to mRNA degradation sites
in a YTHDF2-dependent manner and hence limiting the template pool of mRNA
transcripts [Wang et al., 2013].
Despite the yet unknown consequence of human FTO genomic variation on FTO
function and/or expression, the malfunction of the dopaminergic circuitry in Fto-
deficient and Fto∆DAT mice warrants the detailed investigation of dopaminergic
function in human Fto SNP carriers. Aberrant function of the dopaminergic cir-
cuitry may underly the associations of human FTO variation with addictive be-
havior, ADHD and depression [Sobczyk-Kopciol et al., 2011; Velders et al., 2012;
Choudhry et al., 2013; Rivera et al., 2012; Samaan et al., 2012]. Moreover, malfunc-
tion of dopaminergic signaling could represent a major component causing changes
in food responsiveness and preference, thereby influencing eating behavior and, at
least partly, causing the increase in energy intake described for human FTO risk
allele carriers [Karra et al., 2013; Velders et al., 2012; Wardle et al., 2009; Haupt et al.,
2009; Cecil et al., 2008; Timpson et al., 2008; Speakman et al., 2008].
Importantly, this study defined molecular targets (DRD3, GIRK2 and NMDAR1)
and a pathway (dopamine signaling and dopamine autoreceptor function) for FTO
demethylase activity in mice, indicating potential targets for human FTO studies.
This warrants the broadening of the scientific scope for FTO investigation beyond
obesity and towards reward processing, reward based decision making and psy-
chiatric diseases such as depression, ADHD and addiction.
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4.6 Perspectives
The investigation of both whole body Fto-deficient and dopamine neuron restricted
knock out mice revealed a FTO-dependent alteration of the DRD2-DRD3-GIRK-
dependent autoinhibitory feedback loop of midbrain dopaminergic neurons. Com-
parison of both mouse models suggests that in addition to the changes in dopamine
neuron function, loss of FTO may attenuate postsynaptic signaling events as well.
Hence, conditional deletion of FTO in both pre- and postsynaptic sites of dopa-
minergic signaling through usage of Cre lines expressing the recombinase under
the control of the Drd1, Drd2 or Adora2a (targeting DRD2 expressing neurons in
striatum and not dopaminergic neurons, [Durieux et al., 2009]) promoters may aid
in further delineating the effect of FTO on the dopaminergic circuitry. Further-
more, a double knock out of FTO in both DRD1 and DRD2 expressing neurons,
leading to a loss of FTO in almost every pre- and postsynaptic dopamine signal-
ing site, would be best suited to investigate FTO’s function in the reward circuitry
and may restore features of Fto-deficient mice with respect to dopamine network
function. Since human FTO phenotypes are associated with increased energy in-
take, additional studies could address FTO function in other feeding related nuclei,
such as the PVN and LH. Especially the LH, as it represents an integrative center
for homeostatic and hedonic pathways, may prove a viable target for specific FTO
manipulations [Berthoud, 2011; Simerly, 2006; Saper et al., 2002]. In addition, these
investigations should be used to assess the putative tissue specificity of FTO by
comparison of methylation patterns identified in different brain areas.
To date, human studies addressing FTO phenotypes have focused primarily on
its associations with obesity related traits. However, it becomes more and more
evident that FTO may play a role in more than just homeostatic, feeding related
nuclei. Therefore, the notion that the loss of FTO in mice alters dopamine neuron
function cell autonomously as well as on the network level should aid in gener-
ating hypotheses for the study of human FTO phenotypes. Based on this notion,
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investigation of human FTO ’risk-allele’ carriers should be expanded to reward
processing and reward based decision making, developing the appropriate behav-
ioral tests and functional MRI paradigms. Moreover, identification of pathways
altered by the loss of FTO in rodents may aid in selecting additional risk factors
for polygenic obesity for a combined investigation with FTO variants. Thus, the
combined effects, being synergistic or opposing, could be investigated to better un-
derstand the complex interplay of risk factors for polygenic obesity shaping each
individual’s susceptibility to gain weight.
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Figure 6.1: Reduction in cocaine-induced c-Fos immunoreactivity in Fto-deficient mice
Immunohistochemistry of cortical areas (a, cingulate and sec. motor cortex) and
the CPu (b) revealed blunted cocaine induced c-Fos expression in Fto-deficient
mice (20 mg kg−1 cocaine). No increase in c-Fos immunoreactivity is observed
in Fto-deficient mice following cocaine injection, whereas the number of c-Fos
positive cells markedly increased in control mice when challenged with cocaine.
Scale bar = 200 µm.
Table 6.1: Electrophysiological properties of Fto-deficient dopamine neurons
Whole-cell capacitance [pF] Firing rate [Hz] Conductance density [S F−1]
Fto+/+ 49.5±1.0 2.1±0.1 55.3±2.6
(n=37) (n=41) (n=34)
Fto+/+ 49.7±1.4 1.8±0.2 48.1±2.4*
(n=34) (n=31) (n=31)
Asterisk indicates significant difference (*P<0.05)
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Figure 6.2: Confirmation of Fto expression by β-galactosidase staining
β-galactosidase staining of animals with a knock-in of the ?-galactosidase cDNA
into the endogenous Fto locus (EUCOMM, Ftotm1a(EUCOMM)Wtsi) confirmed Fto
expression in murine midbrain. In addition, expression was detected in numer-
ous other brain regions including the paraventricular nucleus (PVN), arcuate
nucleus (ARC), ventromedial hypothalamus (VMH) and dorsomedial hypotha-
lamus (DMH).
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Table 6.2: List of transcripts deregulated in Fto-deficient midbrain microarray analysis
Assignment fc pv qv
Cartpt -4.806744101 0.012692641 0.107723281
Slc6a3 -2.557829322 0.035206712 0.11387349
Hist1h1c -2.354640266 0.019199099 0.107876683
Aldh1a2 -2.205333231 0.02848494 0.111774003
Gm5921 -2.184485203 0.023360363 0.110058377
4930467E23Rik -2.179599905 0.002514206 0.105745966
4930467E23Rik -2.169801901 0.000476167 0.105745966
E430024C06Rik -2.169055047 0.005632106 0.105745966
E430024C06Rik -2.169055047 0.005632106 0.105745966
Txnip -2.157234981 0.018610818 0.107723281
Tipin -2.138669175 0.009482251 0.107723281
A530053G22Rik -2.133077919 0.025041702 0.110291413
4930467E23Rik -2.110614846 0.00183584 0.105745966
4930467E23Rik -2.087399395 0.000895549 0.105745966
Opalin -2.08488335 0.015322035 0.107723281
Hbb-b1 -2.06195093 0.010209248 0.107723281
Unc13c -2.034451658 0.012459516 0.107723281
D3Ertd751e -2.02987844 0.006774102 0.105745966
Fto -2.020632093 0.000627479 0.105745966
Hbb-b1 -1.988793289 0.007844134 0.107008823
Mgp -1.970365583 0.046597259 0.119725282
Gm12643 -1.970128867 0.016207701 0.107723281
Lphn2 -1.919383949 0.011715228 0.107723281
Frzb -1.896180978 0.010925845 0.107723281
Th -1.879714211 0.040934926 0.116939704
Upp2 -1.873942475 0.008795025 0.107600372
Dcn -1.863080485 0.000779499 0.105745966
Sgk1 -1.861067007 0.021007515 0.109360201
Hdx -1.857029414 0.001708938 0.105745966
Tcf7l2 -1.856506029 0.040466175 0.116683307
4922502B01Rik -1.8471999 0.00595778 0.105745966
Gas5 -1.846158816 0.02126643 0.109523432
D4Wsu53e -1.843239238 0.027718953 0.111732284
Cnn3 -1.834080125 0.004454321 0.105745966
Aga -1.82793318 0.024429234 0.110161209
Hmgb1 -1.819993545 0.03966157 0.116331753
BC049635 -1.81539061 0.013824254 0.107723281
Tdrd6 -1.806916702 0.027600802 0.111732284
Acyp1 -1.806157036 0.043072694 0.117869507
Parl -1.80278831 0.043949741 0.118614199
Tdrd3 -1.796613401 0.033004575 0.112848689
Cdkn1b -1.794493462 0.007520488 0.107008823
Zfp455 -1.789487749 0.032329567 0.112482754
Card6 -1.786765124 0.00206798 0.105745966
Ano3 -1.772890377 0.015209411 0.107723281
Cox17 -1.765185743 0.033412781 0.113287933
Gm10507 -1.761722466 0.028696391 0.11178848
Dnajc13 -1.756877173 0.022868371 0.109894243
Ufc1 -1.754885213 0.02467576 0.110291413
Gstm6 -1.748252215 0.027838164 0.111732284
LOC100047986 -1.743033141 0.009610351 0.107723281
Gabarapl2 -1.739488732 0.041565615 0.117112093
Chrna6 -1.73527783 0.045425046 0.119390455
Resp18 -1.728870729 0.014473351 0.107723281
Chrna5 -1.724064003 0.010583339 0.107723281
Gm7827 -1.721265922 0.02038427 0.109083258
Gm8959 -1.716690546 0.011695995 0.107723281
Syt17 -1.708207619 0.030382594 0.111930776
Ufsp2 -1.707315875 0.000899751 0.105745966
2810021G02Rik -1.706984549 0.043497794 0.118218066
Ranbp3l -1.704600113 0.002316895 0.105745966
Ak5 -1.704107877 0.026516801 0.111072282
Armcx5 -1.701255705 0.008016321 0.107008823
Ret -1.700214379 0.041955542 0.117112093
Trappc2l -1.696020177 0.006509535 0.105745966
Zfp759 -1.691187556 0.002369892 0.105745966
Mettl4 -1.689613578 0.001158299 0.105745966
Eif2s3y -1.689113961 0.004339189 0.105745966
Sumo1 -1.688251688 0.015576743 0.107723281
Npy2r -1.681831689 0.015062172 0.107723281
1110058L19Rik -1.679505671 0.01920112 0.107876683
Pdgfra -1.677144119 0.01222553 0.107723281
Itih2 -1.673617683 0.011343841 0.107723281
Sfrs3 -1.672628055 0.008945402 0.107600372
Gm5512 -1.672067783 0.006677079 0.105745966
Rpa3 -1.667642448 0.047670409 0.120024917
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Chordc1 -1.665182152 0.000454042 0.105745966
Ddx3x -1.664705144 0.013079526 0.107723281
Atp5h -1.663740006 0.000977462 0.105745966
Hspa8 -1.659467069 0.021507654 0.10956964
Efemp1 -1.659298373 0.020800948 0.109317531
Rmnd1 -1.657164324 0.016447891 0.107723281
Lphn2 -1.656440827 0.004199498 0.105745966
Hspa8 -1.646885209 0.020553272 0.109270814
Mettl5 -1.644569525 5.15E-05 0.051083022
Gm10726 -1.642037035 0.002339226 0.105745966
Psma5 -1.637343101 0.018383415 0.107723281
Cstad -1.629911163 0.007196357 0.107008823
Arpc5 -1.627382445 0.004144678 0.105745966
Tomm22 -1.626653159 0.04662033 0.119728073
Kcnc2 -1.62426084 0.004395858 0.105745966
Psmd10 -1.622996625 0.021328229 0.10956964
Gba -1.621913261 0.025599605 0.110565417
Nrip3 -1.61672765 0.000649478 0.105745966
1810030N24Rik -1.615846328 0.035022634 0.113799868
Gjb2 -1.615431974 0.004410946 0.105745966
2410017P09Rik -1.611990602 0.047576823 0.119963923
Ttc39b -1.610780598 0.045932051 0.119506979
Gm5521 -1.60743084 0.019470211 0.108210826
Adamts1 -1.607133751 0.039423927 0.116024248
1810020D17Rik -1.605845764 0.039139568 0.115957022
Sp140 -1.605408009 0.002438355 0.105745966
Snord87 -1.604836881 0.014667822 0.107723281
Polr1d -1.604607004 0.017318098 0.107723281
Dhrs7 -1.601621597 0.045150506 0.119126063
Rpl9 -1.596947259 0.009028466 0.107600372
Chrnb3 -1.596744336 0.011044687 0.107723281
Ano3 -1.596626284 0.002484819 0.105745966
Mrpl50 -1.596552506 0.011287585 0.107723281
D630004N19Rik -1.595505225 0.0121444 0.107723281
Hdac3 0.004199016 0.105745966
Rpl5 -1.592190912 0.007986224 0.107008823
D430042O09Rik -1.590617189 0.039335141 0.116024248
Sept4 -1.587360708 0.007660099 0.107008823
Agxt2l1 -1.585242261 0.014482225 0.107723281
Gtpbp8 -1.577634858 0.00610951 0.105745966
2610017I09Rik -1.577208437 0.022324734 0.10956964
Gabra5 -1.575977204 0.017252598 0.107723281
Gstm1 -1.573303134 0.001694706 0.105745966
Lphn2 -1.573299499 0.001358544 0.105745966
Gm8304 -1.572914226 0.000231863 0.101410316
Rps12 -1.572521781 1.78E-05 0.025735818
Fgf13 -1.572114904 0.023355478 0.110058377
Parl -1.570640859 0.006944363 0.106431423
Lmo3 -1.567921503 0.002091215 0.105745966
Arpc3 -1.567736757 0.028249369 0.111732284
Gm5778 -1.566896623 0.022209946 0.10956964
4930455F23Rik -1.563107138 0.009395818 0.107723281
Txnl4b -1.562930183 0.037845173 0.11559365
Bckdhb -1.561767829 0.007945643 0.107008823
Gm447 -1.560180918 0.040030257 0.116437995
Gm12176 -1.559153893 0.043559463 0.118285272
Gnpnat1 -1.558170745 0.015155721 0.107723281
Ctbs -1.556303393 0.010220326 0.107723281
Rnpep -1.555954637 0.016161944 0.107723281
Hba-a2 -1.554919616 0.038424211 0.115781817
Atp11b -1.5539535 0.001252108 0.105745966
Camta1 -1.552234652 0.017024474 0.107723281
Hist2h2be -1.551556966 0.030689347 0.111930776
Klhl32 -1.550915409 0.035360611 0.114141972
D16H22S680E -1.547836766 0.013802924 0.107723281
Rpl9 -1.547786699 0.011246319 0.107723281
Nkiras1 -1.54777597 0.02829242 0.111732284
B230380D07Rik -1.547736634 0.019609717 0.10830935
Lepr -1.547650811 0.023290941 0.110058377
Hist1h2bc -1.547475605 0.027972056 0.111732284
Atp5h -1.54715385 0.000460279 0.105745966
Ndufaf2 -1.54661774 0.018397514 0.107723281
Psma5 -1.545074782 0.02139651 0.10956964
Hba-a1 -1.545071212 0.036604766 0.114852466
Cpne2 -1.543540496 0.034294926 0.113722583
BC057170 -1.542560065 0.013751163 0.107723281
Dennd4a -1.542314164 0.03968435 0.116339767
Rbbp8 -1.541124413 0.00696665 0.106431423
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Fmn1 -1.540636667 0.02809123 0.111732284
Eef1b2 -1.539853748 0.034471601 0.113740124
Josd1 -1.538630345 0.047207309 0.119852203
Ndufa9 -1.538584131 0.036587997 0.114852466
Aqp11 -1.537972812 0.000888799 0.105745966
LOC433762 -1.536928446 0.002508739 0.105745966
LOC433762 -1.536928446 0.002508739 0.105745966
Nov -1.535785431 0.006190693 0.105745966
Mcts1 -1.535558349 0.003462 0.105745966
Dennd4a -1.534965965 0.007340758 0.107008823
Rnf160 -1.53411149 0.009000027 0.107600372
Arhgef6 -1.533353144 0.006350713 0.105745966
Gm3258 -1.533261034 0.024351585 0.110161209
Fech -1.531561536 0.015369054 0.107723281
Slc38a2 -1.531016679 0.001777778 0.105745966
Eif3e -1.530376544 0.003841968 0.105745966
Tmem68 -1.530058344 0.011458463 0.107723281
Tfam -1.52977909 0.014987079 0.107723281
March11 -1.529369138 0.024346116 0.110161209
Gm5113 -1.529213668 0.004848662 0.105745966
Ctla2a -1.526925846 0.041629591 0.117112093
Nudt11 -1.526322686 0.012813399 0.107723281
1700019N12Rik -1.524733038 0.002666831 0.105745966
Rbm3 -1.524338526 0.002400175 0.105745966
Nfib -1.522022831 0.025682835 0.110565417
Llph -1.52070467 0.044438795 0.118749173
Zfp595 -1.519756301 0.022119974 0.10956964
Tarsl2 -1.519696608 0.021504193 0.10956964
Id2 -1.518433086 0.029227683 0.11178848
Fbxo2 -1.517759637 0.008420158 0.107008823
5830433M19Rik -1.516732501 0.021631357 0.10956964
Exosc1 -1.516546779 0.036559224 0.114852466
Ppp2r5c -1.516403124 0.022015579 0.10956964
Tmem19 -1.5160528 0.021336181 0.10956964
Six6os1 -1.51546444 0.012259311 0.107723281
Snca -1.514277908 0.034200692 0.113722583
Tprkb -1.51378117 0.003835751 0.105745966
Sf4 -1.513200684 0.041596492 0.117112093
2210012G02Rik -1.513053849 0.030136803 0.111919493
Mcf2 -1.51130691 0.014388809 0.107723281
6720456B07Rik -1.510259715 0.034086418 0.113722583
Cfh -1.510092231 0.005958455 0.105745966
4933407N01Rik -1.509729413 0.016716185 0.107723281
Plk2 -1.509286474 0.007120453 0.106791948
Dennd4a -1.509126072 0.003010194 0.105745966
Trappc2 -1.508651939 0.024886374 0.110291413
Styx -1.506095584 0.002901863 0.105745966
Nrn1 -1.505431085 0.004819841 0.105745966
Atp5h -1.505125027 0.008302634 0.107008823
Ublcp1 -1.505069387 0.036027498 0.114754442
Bccip -1.502689219 0.016251217 0.107723281
Rbm3 -1.501981108 0.00244685 0.105745966
Prdx1 -1.501099907 0.020859811 0.109349143
Ephx4 -1.50032668 0.004548999 0.105745966
Dnahc3 1.50016723 0.036831604 0.114929658
Cpb1 1.500226156 0.016737207 0.107723281
Ssty2 1.500454946 0.01011183 0.107723281
Nt5dc1 1.501436368 0.018676895 0.107723281
D19Ertd652e 1.501804132 0.041969526 0.117112093
H1fnt 1.502362891 0.004715492 0.105745966
Gm9961 1.502442731 0.027302579 0.111732284
Gm6219 1.502553819 0.007119362 0.106791948
Igsf1 1.502779492 0.010904827 0.107723281
1110018H23Rik 1.503366401 0.022627987 0.10956964
Anxa10 1.503769383 0.02715305 0.111732284
Gm9891 1.504255884 0.038643638 0.115781817
Tgm4 1.504499194 0.016539445 0.107723281
Acss3 1.504568718 0.02755261 0.111732284
Olfr157 1.504944204 0.005740396 0.105745966
Tlx2 1.50651322 0.039012757 0.115781817
Gm7112 1.506875265 0.021615993 0.10956964
Gper 1.508240679 0.002312487 0.105745966
Vmn2r22 1.508753028 0.008314445 0.107008823
Gm10883 1.508951741 0.026642406 0.111072282
Gnpda1 1.509317859 0.035025006 0.113799868
Lck 1.510346953 0.025058454 0.110291413
Gvin1 1.510483055 0.037375221 0.115180202
LOC100041256 1.510856527 0.018154611 0.107723281
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Scd4 1.510929836 0.000260222 0.101410316
LOC382133 1.511638673 0.004771573 0.105745966
Gm8780 1.511701542 0.023846022 0.110058377
Tnfsf15 1.511974002 0.040741112 0.116858776
Fsd2 1.512267477 0.049386388 0.120564663
Wfdc15b 1.513141249 0.011827764 0.107723281
Pla2g2d 1.513392989 0.019476121 0.108210826
Sycp1 1.51412747 0.008983301 0.107600372
Olfr129 1.515082828 0.008194267 0.107008823
Aldh3b2 1.516157889 0.010035598 0.107723281
Olfr156 1.51652926 0.012222092 0.107723281
Iqcf1 1.516662415 0.034733848 0.113740124
Gm6280 1.517577296 0.008084406 0.107008823
Fam181a 1.518029682 0.013977435 0.107723281
Txlnb 1.519233195 0.021743322 0.10956964
Gsc 1.519872181 0.016979061 0.107723281
Casp1 1.521273975 0.015807825 0.107723281
Capn10 1.524465323 0.015176888 0.107723281
Try4 1.525525892 0.020950188 0.109360201
Clca6 1.525783218 0.009220906 0.107600372
Bace2 1.525973597 0.042447478 0.117395681
Gm9405 1.526396745 0.00701645 0.106630285
Ssty2 1.527801027 0.00668459 0.105745966
Neb 1.527843388 0.00117393 0.105745966
Gm7455 1.528171719 0.008054475 0.107008823
Olfr875 1.528397709 0.034141174 0.113722583
Tnfrsf17 1.528574286 0.03041327 0.111930776
Col10a1 1.529217201 0.031673294 0.112100718
Gm9198 1.529471616 0.021076947 0.1095063
Gm10863 1.529959362 0.008695036 0.107600372
LOC635992 1.53043312 0.040195503 0.116563227
BC028471 1.530998992 0.010155286 0.107723281
Phldb3 1.531193559 0.018349155 0.107723281
Myo18b 1.531409381 0.029182837 0.11178848
Mrgpra6 1.532276512 0.04921693 0.120446832
Trpd52l3 1.533225609 0.007353349 0.107008823
Il28b 1.533572813 0.04819322 0.120254373
Cd96 1.533664942 0.01476872 0.107723281
Serpine3 1.533909464 0.008654149 0.107600372
Eya4 1.53466454 0.004249565 0.105745966
1700025H01Rik 1.535466106 0.044631074 0.118853184
Mia1 1.536016095 0.035992784 0.114754442
Il20rb 1.53627519 0.035961668 0.114754442
Asb10 1.537034982 0.010671635 0.107723281
Gm2524 1.538420615 0.007346535 0.107008823
V1ri9 1.538449051 0.003781961 0.105745966
Ssty2 1.53974346 0.007896418 0.107008823
Vmn2r9 1.542043361 0.009675699 0.107723281
Prtn3 1.542228642 0.009293127 0.107723281
Olfr1034 1.543722389 0.027238765 0.111732284
Ptger2 1.545078352 4.99E-05 0.051083022
Fam183b 1.545717494 0.025976152 0.110694341
Ssty2 1.546006802 0.012650682 0.107723281
LOC100134980 1.547725905 0.002384134 0.105745966
Gm10008 1.547854647 0.005245391 0.105745966
Gm4814 1.548816972 0.028922704 0.11178848
1700007I08Rik 1.549028119 0.012227636 0.107723281
Trim8 1.549973267 0.012401341 0.107723281
Ooep 1.550252626 0.013686233 0.107723281
Dmkn 1.550542783 0.028195496 0.111732284
Ssty2 1.550961993 0.006116264 0.105745966
Gm10751 1.551008579 0.044212592 0.118683725
Olfr350 1.552848051 0.031172925 0.111930776
Dub2a 1.552909046 0.010372972 0.107723281
Defb3 1.553888874 0.005774571 0.105745966
Hormad1 1.554815433 0.006273066 0.105745966
Zfp42 1.55628901 0.006131402 0.105745966
Gm10787 1.556447233 0.006364826 0.105745966
Oit3 1.557458081 0.047096735 0.119837811
A730076H11Rik 1.558365165 0.047236835 0.119852203
Olfr113 1.559031416 0.017323599 0.107723281
Gm10421 1.559161098 0.000534002 0.105745966
Prrg4 1.561471964 0.003614507 0.105745966
Gm414 1.565854323 0.00492997 0.105745966
Acrv1 1.567512195 0.045219369 0.119147006
Dao 1.56791788 0.003992695 0.105745966
Itln1 1.568530229 0.003557167 0.105745966
Cyp2w1 1.571512049 0.046244957 0.119506979
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Fgl1 1.572122169 0.0084568 0.107111315
Lrrc25 1.57302689 0.008288377 0.107008823
Lce1b 1.573379473 0.023872966 0.110058377
1700066B19Rik 1.574885198 0.028852974 0.11178848
Gm16432 1.575642242 0.008976243 0.107600372
Gal 1.575813355 0.005823011 0.105745966
Olfr1165 1.576042748 0.0219427 0.10956964
Hsn2 1.57665827 0.000877596 0.105745966
Duxbl 1.577798896 0.030748514 0.111930776
Duxbl 1.577798896 0.030748514 0.111930776
Gm10755 1.578936699 0.01878801 0.107723281
Krtap4-7 1.579505908 0.00640548 0.105745966
Olfr1410 1.579900096 0.044601259 0.118853184
LOC100046350 1.580049767 0.002956233 0.105745966
Snhg7 1.581715359 0.035756495 0.114628526
Ces1 1.581737287 0.017489869 0.107723281
Tex19.2 1.581901752 0.009247774 0.107693259
4930539E08Rik 1.582888901 0.000634382 0.105745966
Olfr983 1.583748588 0.033070248 0.112932239
Spef2 1.585854047 0.010807988 0.107723281
Cyp8b1 1.58817879 0.028230097 0.111732284
Ceacam19 1.59209159 0.004352944 0.105745966
Gm9949 1.594852866 0.008157327 0.107008823
Phldb3 1.597312584 0.013206027 0.107723281
Tmem86b 1.597655844 0.013972651 0.107723281
Olfr149 1.597906877 0.011513302 0.107723281
Mybl2 1.598253958 0.024121558 0.110084646
LOC100040031 1.598257651 0.020556124 0.109270814
LOC100041207 1.600145765 0.046417443 0.119506979
LOC100041207 1.600145765 0.046417443 0.119506979
LOC674930 1.60248035 0.03091859 0.111930776
Fam83c 1.605964497 0.017140047 0.107723281
Ccl28 1.606090662 0.040676563 0.11680661
6430601O08Rik 1.608712665 0.015753118 0.107723281
Ppef1 1.611033693 0.011613052 0.107723281
A930012O16Rik 1.611942185 0.027626529 0.111732284
Olfr481 1.614950561 0.00759182 0.107008823
Dnahc3 1.615405847 0.01357696 0.107723281
Defb26 1.617362799 0.002965037 0.105745966
Olfr448 1.619591526 0.004400433 0.105745966
Lce3c 1.620332622 0.002225063 0.105745966
Slc7a13 1.620568496 0.007980409 0.107008823
Megf6 1.622258059 0.003015354 0.105745966
2610528A11Rik 1.624561095 0.033008578 0.112848689
2310034G01Rik 1.627265888 0.001232438 0.105745966
Duxbl 1.628119582 0.007985305 0.107008823
Il20rb 1.628789312 0.025021131 0.110291413
Gm8994 1.632360833 0.033946059 0.113699285
Krtap5-3 1.633341732 0.04781024 0.12020897
Bglap1 1.639341779 0.006207674 0.105745966
LOC380994 1.643562896 0.000882866 0.105745966
Tex22 1.64789768 0.008335281 0.107008823
Dynlrb2 1.661776853 0.010216646 0.107723281
H2-M10.2 1.664839769 0.003971442 0.105745966
Ccr7 1.665717024 0.002467486 0.105745966
LOC100040329 1.665870976 0.00844197 0.107008823
Hpse 1.671086794 0.00303465 0.105745966
Megf6 1.672809701 0.005319785 0.105745966
Gm6795 1.672991366 0.006377413 0.105745966
Gabre 1.673432083 0.001889628 0.105745966
E330013P04Rik 1.678384586 0.027657487 0.111732284
Gm1968 1.6861739 0.015634537 0.107723281
Enkur 1.696890338 0.016821788 0.107723281
A130066N16Rik 1.701487635 0.034111594 0.113722583
Gm6219 1.718095225 0.017938156 0.107723281
Gm6648 1.720152731 0.005798953 0.105745966
Bhmt 1.728966601 0.032687015 0.112593722
LOC100039614 1.744475497 0.02324076 0.110058377
Olfr26 1.753284358 0.018990394 0.107723281
Gm10748 1.770221635 0.004823396 0.105745966
Pppde1 1.771158512 0.046895142 0.119728073
Olfr495 1.780550474 0.045857091 0.119506979
Cpa6 1.799916525 0.008284509 0.107008823
Hsd11b1 1.804184234 0.041100764 0.117072249
Bclp2 1.804184234 0.02714435 0.111732284
Olfr328 1.807843759 0.015964933 0.107723281
Gm10534 1.820952555 0.014456206 0.107723281
Klk1b11 1.852735156 0.016132265 0.107723281
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Gm5841 1.879101939 0.042109656 0.117171004
Ccl12 1.907720741 0.032423673 0.112503534
Spef2 1.969400687 0.002857891 0.105745966
Tnnt2 1.991460227 0.000830242 0.105745966
A730020M07Rik 2.011906602 0.001976607 0.105745966
Spef2 2.035570704 0.007990949 0.107008823
Spef2 2.074111329 0.04059774 0.116749128
Ccl17 2.318518653 0.019034701 0.107723281
Olfr161 2.354123487 0.009348122 0.107723281
Dbh 2.39085505 0.008901351 0.107600372
Tdgf1 2.774036301 0.000560319 0.105745966
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Transcript Symbol Transcript Name Location
0610037L13Rik CDS
1110012J17Rik 5’UTR
1110014N23Rik protein fat-free homolog CDS
1110032F04Rik hypothetical protein LOC68725 precursor CDS
1110034B05Rik 5’UTR
1110051M20Rik hypothetical protein LOC228356 CDS
1300018J18Rik 3’UTR
1700001K19Rik hypothetical protein LOC66323 3’UTR
1700001O22Rik CDS
1700017B05Rik hypothetical protein LOC74211 3’UTR
1700020L24Rik hypothetical protein LOC66330 CDS
1700030J22Rik hypothetical protein LOC69528 3’UTR
1700037H04Rik hypothetical protein LOC67326 3’UTR
1700106N22Rik hypothetical protein LOC73582 5’UTR
1810011H11Rik hypothetical protein LOC69069 3’UTR
1810037I17Rik hypothetical protein LOC67704 CDS
1810043G02Rik hypothetical protein LOC67884 CDS
2010109K11Rik hypothetical protein LOC72123 CDS
2210018M11Rik protein EMSY 3’UTR
2310021P13Rik hypothetical protein LOC268721 5’UTR
2310022B05Rik hypothetical protein LOC69551 CDS
2310022B05Rik hypothetical protein LOC69551 3’UTR
2310061I04Rik hypothetical protein LOC69662 3’UTR
2410001C21Rik hypothetical protein LOC66404 5’UTR
2610002I17Rik transmembrane protein 103 CDS
2610002M06Rik charged multivesicular body protein 1b-2 5’UTR
2610015P09Rik CDS
2700078E11Rik hypothetical protein LOC78832 isoform 3 CDS
4632415K11Rik hypothetical protein LOC74347 CDS
4930420K17Rik hypothetical protein LOC652925 5’UTR
4930452B06Rik hypothetical protein LOC74430 CDS
4930539E08Rik hypothetical protein LOC207819 3’UTR
4932411E22Rik hypothetical protein LOC214604 CDS
4932412H11Rik hypothetical protein LOC242838 5’UTR
4933413G19Rik hypothetical protein LOC71149 3’UTR
5330417C22Rik hypothetical protein LOC229722 CDS
5430411K18Rik 3’UTR
6330545A04Rik miro domain-containing protein C1orf89 homolog CDS
6430548M08Rik hypothetical protein LOC234797 isoform c 5’UTR
9130011E15Rik hypothetical protein LOC71617 CDS
9430016H08Rik hypothetical protein LOC68115 precursor 5’UTR
9430038I01Rik hypothetical protein LOC77252 3’UTR
9930111J21Rik1 interferon-inducible GTPase family member 3’UTR
A830018L16Rik hypothetical protein LOC320492 isoform 4 5’UTR
A830093I24Rik hypothetical protein LOC207921 5’UTR
Aamp angio-associated migratory cell protein isoform 3’UTR
Aamp angio-associated migratory cell protein isoform 5’UTR
Aars alanyl-tRNA synthetase, cytoplasmic CDS
Abcb8 ATP-binding cassette sub-family B member 8, CDS
Abhd2 abhydrolase domain-containing protein 2 3’UTR
Ablim2 actin-binding LIM protein 2 isoform 6 3’UTR
Abr active breakpoint cluster region-related protein 5’UTR
Abtb2 ankyrin repeat and BTB/POZ domain-containing 5’UTR
Acads short-chain specific acyl-CoA dehydrogenase, CDS
Acadvl very long-chain specific acyl-CoA dehydrogenase, CDS
Acap3 arf-GAP with coiled-coil, ANK repeat and PH 5’UTR
Acbd6 acyl-CoA-binding domain-containing protein 6 5’UTR
Accn4 amiloride-sensitive cation channel 4 5’UTR
Acot2 acyl-coenzyme A thioesterase 2, mitochondrial CDS
Acrbp acrosin-binding protein isoform 2 CDS
Actb actin, cytoplasmic 1 5’UTR
Actn4 alpha-actinin-4 5’UTR
Actr2 actin-related protein 2 5’UTR
Actr3 actin-related protein 3 5’UTR
Actr3b actin-related protein 3B 5’UTR
Actr8 actin-related protein 8 5’UTR
Adam23 disintegrin and metalloproteinase 5’UTR
Adamtsl1 ADAMTS-like protein 1 CDS
Adcyap1r1 pituitary adenylate cyclase-activating CDS
Add1 alpha-adducin isoform 2 CDS
Add1 alpha-adducin isoform 2 3’UTR
Add2 beta-adducin 3’UTR
Adra1a alpha-1A adrenergic receptor CDS
Adra1a alpha-1A adrenergic receptor 5’UTR
Adra2a alpha-2A adrenergic receptor CDS
Adra2b alpha-2B adrenergic receptor CDS
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Adrb3 beta-3 adrenergic receptor CDS
Aebp2 zinc finger protein AEBP2 isoform 1 CDS
Aff1 AF4/FMR2 family member 1 isoform 1 3’UTR
Aff3 AF4/FMR2 family member 3 3’UTR
Agap2 arf-GAP with GTPase, ANK repeat and PH 5’UTR
Agbl5 cytosolic carboxypeptidase-like protein 5 CDS
Agpat9 glycerol-3-phosphate acyltransferase 3 5’UTR
Ahctf1 protein ELYS 5’UTR
Ahr aryl hydrocarbon receptor CDS
AI593442 hypothetical protein LOC330941 isoform 2 5’UTR
Ak3 GTP:AMP phosphotransferase, mitochondrial CDS
Ak5 adenylate kinase isoenzyme 5 3’UTR
Akap12 A-kinase anchor protein 12 3’UTR
Akap13 A kinase (PRKA) anchor protein 13 3’UTR
Akna AT-hook-containing transcription factor CDS
Akt2 RAC-beta serine/threonine-protein kinase 3’UTR
Aldh16a1 aldehyde dehydrogenase family 16 member A1 CDS
Aldh7a1 alpha-aminoadipic semialdehyde dehydrogenase 3’UTR
Alg2 alpha-1,3-mannosyltransferase ALG2 CDS
Alk ALK tyrosine kinase receptor precursor CDS
Alkbh3 alpha-ketoglutarate-dependent dioxygenase alkB CDS
Alkbh5 probable alpha-ketoglutarate-dependent 5’UTR
Amigo1 amphoterin-induced protein 1 isoform 1 5’UTR
Ampd2 AMP deaminase 2 3’UTR
Angptl2 angiopoietin-related protein 2 precursor 5’UTR
Ank progressive ankylosis protein 5’UTR
Ank2 ankyrin-2 isoform 3 CDS
Ankrd13b ankyrin repeat domain-containing protein 13B 3’UTR
Ankrd13d ankyrin repeat domain-containing protein 13D 5’UTR
Ankrd56 ankyrin repeat domain-containing protein 56 5’UTR
Anks1 ankyrin repeat and SAM domain-containing protein CDS
Ano6 anoctamin-6 5’UTR
Anp32e acidic leucine-rich nuclear phosphoprotein 32 3’UTR
Aoc2 retina-specific copper amine oxidase precursor 3’UTR
Ap1b1 AP-1 complex subunit beta-1 5’UTR
Apba1 amyloid beta (A4) precursor protein binding, 5’UTR
Apc adenomatous polyposis coli protein 5’UTR
Apitd1 centromere protein S CDS
Aplp1 amyloid-like protein 1 5’UTR
App amyloid beta A4 protein 5’UTR
Arap1 arf-GAP with Rho-GAP domain, ANK repeat and PH 3’UTR
Arcn1 coatomer subunit delta 5’UTR
Arf3 ADP-ribosylation factor 3 5’UTR
Arfgap2 ADP-ribosylation factor GTPase-activating 3’UTR
Arhgap26 rho GTPase-activating protein 26 CDS
Arhgap33 rho GTPase-activating protein 33 CDS
Arhgap44 3’UTR
Arhgef11 rho guanine nucleotide exchange factor 11 CDS
Arhgef17 rho guanine nucleotide exchange factor 17 5’UTR
Arhgef18 rho guanine nucleotide exchange factor 18 CDS
Arhgef2 rho guanine nucleotide exchange factor 2 CDS
Arhgef33 rho guanine nucleotide exchange factor 33 CDS
Arhgef37 rho guanine nucleotide exchange factor 37 3’UTR
Arid1a AT-rich interactive domain-containing protein 3’UTR
Arl6ip6 ADP-ribosylation factor-like protein 5’UTR
Armc7 armadillo repeat-containing protein 7 CDS
Arpc1a actin-related protein 2/3 complex subunit 1A 5’UTR
Arsk arylsulfatase K 3’UTR
Arvcf armadillo repeat protein deleted in CDS
Arx homeobox protein ARX CDS
Arx homeobox protein ARX 3’UTR
Asb3 ankyrin repeat and SOCS box protein 3 5’UTR
Ascc2 activating signal cointegrator 1 complex subunit 3’UTR
Ascl1 achaete-scute homolog 1 5’UTR
Atf5 CDS
Atg2b autophagy-related protein 2 homolog B 3’UTR
Atg3 ubiquitin-like-conjugating enzyme ATG3 5’UTR
Atg9a autophagy-related protein 9A 3’UTR
Atg9b autophagy-related protein 9B 3’UTR
Atn1 atrophin-1 CDS
Atoh8 protein atonal homolog 8 CDS
Atp10b probable phospholipid-transporting ATPase VB CDS
Atp13a2 probable cation-transporting ATPase 13A2 isoform CDS
Atp1a3 sodium/potassium-transporting ATPase subunit 3’UTR
Atp1a3 sodium/potassium-transporting ATPase subunit 5’UTR
Atp2a2 5’UTR
Atp5d ATP synthase subunit delta, mitochondrial CDS
Atp5d ATP synthase subunit delta, mitochondrial 5’UTR
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Atp5sl ATP synthase subunit s-like protein CDS
Atp6v0a1 V-type proton ATPase 116 kDa subunit a isoform 3’UTR
Atp6v0c V-type proton ATPase 16 kDa proteolipid subunit 5’UTR
Atp6v1g2 V-type proton ATPase subunit G 2 CDS
Atpaf2 ATP synthase mitochondrial F1 complex assembly 3’UTR
Atxn10 ataxin-10 5’UTR
Atxn7l1 ataxin-7-like protein 1 isoform 1 CDS
Atxn7l1 ataxin-7-like protein 1 isoform 1 3’UTR
AU040320 dyslexia susceptibility 2-like isoform 2 3’UTR
Avl9 late secretory pathway protein AVL9 homolog 5’UTR
B230208H17Rik putative GTP-binding protein Parf 3’UTR
B230208H17Rik putative GTP-binding protein Parf 5’UTR
B3gat1 galactosylgalactosylxylosylprotein CDS
B3gat2 galactosylgalactosylxylosylprotein 5’UTR
B3gnt8 UDP-GlcNAc:betaGal CDS
Bach2 transcription regulator protein BACH2 CDS
Bag3 BAG family molecular chaperone regulator 3 3’UTR
Baiap2l2 brain-specific angiogenesis inhibitor 3’UTR
Baiap3 BAI1-associated protein 3 CDS
Barhl2 barH-like 2 homeobox protein 3’UTR
Baz2a bromodomain adjacent to zinc finger domain 3’UTR
BC005764 5’UTR
BC006779 PPAR gamma-DNA-binding domain interacting CDS
BC013712 protein THEMIS2 CDS
BC021891 mitogen-activated protein kinase kinase kinase CDS
BC068157 hypothetical protein LOC73072 CDS
Bcl10 B-cell lymphoma/leukemia 10 CDS
Bcl6 B-cell lymphoma 6 protein homolog CDS
Bcor BCL-6 corepressor isoform d 5’UTR
Bhlha9 class A basic helix-loop-helix protein 9 CDS
Bhlhe22 class E basic helix-loop-helix protein 22 CDS
Bhlhe40 class E basic helix-loop-helix protein 40 5’UTR
Bmf bcl-2-modifying factor CDS
Bmp1 5’UTR
Bmp6 bone morphogenetic protein 6 precursor 5’UTR
Bmp7 bone morphogenetic protein 7 precursor 3’UTR
Brd4 bromodomain-containing protein 4 isoform 1 CDS
Brms1 breast cancer metastasis-suppressor 1 homolog 5’UTR
Brsk1 BR serine/threonine-protein kinase 1 isoform 2 CDS
Btbd11 ankyrin repeat and BTB/POZ domain-containing 5’UTR
Btrc F-box/WD repeat-containing protein 1A isoform b CDS
C130074G19Rik hypothetical protein LOC226777 CDS
C1qtnf1 complement C1q tumor necrosis factor-related CDS
C1qtnf1 complement C1q tumor necrosis factor-related 3’UTR
C1qtnf4 complement C1q tumor necrosis factor-related 5’UTR
C230096C10Rik hypothetical protein LOC230866 isoform 2 CDS
C2cd2l C2 domain-containing protein 2-like CDS
C2cd2l C2 domain-containing protein 2-like 3’UTR
C2cd2l C2 domain-containing protein 2-like 5’UTR
C2cd3 C2 domain-containing protein 3 CDS
C2cd4d C2 calcium-dependent domain-containing protein CDS
C330005M16Rik iron/zinc purple acid phosphatase-like protein 3’UTR
C330019G07Rik hypothetical protein LOC215476 3’UTR
C630004H02Rik hypothetical protein LOC217310 3’UTR
C77080 hypothetical protein LOC97130 CDS
C77080 hypothetical protein LOC97130 3’UTR
Cachd1 VWFA and cache domain-containing protein 1 CDS
Cacna1a voltage-dependent P/Q-type calcium channel CDS
Cacna1c voltage-dependent L-type calcium channel subunit 3’UTR
Cacna1d voltage-dependent L-type calcium channel subunit 3’UTR
Cacnb1 voltage-dependent L-type calcium channel subunit 5’UTR
Cacng4 voltage-dependent calcium channel gamma-4 CDS
Cadps calcium-dependent secretion activator 1 isoform 5’UTR
Caly neuron-specific vesicular protein calcyon 3’UTR
Camta2 calmodulin-binding transcription activator 2 CDS
Camta2 calmodulin-binding transcription activator 2 3’UTR
Cand2 cullin-associated NEDD8-dissociated protein 2 CDS
Capn5 calpain-5 3’UTR
Caprin2 caprin-2 5’UTR
Capzb F-actin-capping protein subunit beta isoform a 3’UTR
Card10 caspase recruitment domain-containing protein CDS
Card6 caspase recruitment domain family, member 6 CDS
Casp9 caspase-9 CDS
Cass4 cas scaffolding protein family member 4 isoform CDS
Casz1 zinc finger protein castor homolog 1 isoform 1 CDS
Cbfa2t3 protein CBFA2T3 isoform 2 CDS
Cbfa2t3 protein CBFA2T3 isoform 2 3’UTR
Cblb E3 ubiquitin-protein ligase CBL-B 3’UTR
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Ccbe1 collagen and calcium-binding EGF CDS
Ccbp2 chemokine-binding protein 2 3’UTR
Ccdc102a coiled-coil domain-containing protein 102A CDS
Ccdc120 coiled-coil domain containing 120 CDS
Ccdc142 coiled-coil domain-containing protein 142 CDS
Ccdc48 coiled-coil domain-containing protein 48 CDS
Ccdc88a girdin 5’UTR
Ccdc88b coiled-coil domain-containing protein 88B CDS
Ccdc96 coiled-coil domain-containing protein 96 3’UTR
Ccng1 cyclin-G1 5’UTR
Ccnl1 cyclin-L1 5’UTR
Cd248 endosialin precursor CDS
Cd248 endosialin precursor 3’UTR
Cd33 myeloid cell surface antigen CD33 isoform 1 CDS
Cd40 3’UTR
Cd93 complement component C1q receptor CDS
Cd93 complement component C1q receptor 3’UTR
Cdan1 codanin-1 CDS
Cdc25b M-phase inducer phosphatase 2 isoform b CDS
Cdc42bpb serine/threonine-protein kinase MRCK beta 5’UTR
Cdc42se1 CDC42 small effector protein 1 isoform 2 CDS
Cdh13 cadherin-13 precursor CDS
Cdh2 cadherin-2 precursor 5’UTR
Cdh22 cadherin-22 precursor 5’UTR
Cdh24 cadherin-24 precursor CDS
Cdh5 cadherin-5 precursor CDS
Cdh5 cadherin-5 precursor 3’UTR
Cdhr1 cadherin-related family member 1 precursor CDS
Cdk12 cell division protein kinase 12 isoform 2 5’UTR
Cdk18 cell division protein kinase 18 3’UTR
Cdkl3 cyclin-dependent kinase-like 3 isoform 6 5’UTR
Cdkn1a cyclin-dependent kinase inhibitor 1 CDS
Cds2 phosphatidate cytidylyltransferase 2 CDS
Celf3 CUGBP Elav-like family member 3 3’UTR
Celsr1 cadherin EGF LAG seven-pass G-type receptor 1 CDS
Celsr1 cadherin EGF LAG seven-pass G-type receptor 1 3’UTR
Celsr3 cadherin EGF LAG seven-pass G-type receptor 3 3’UTR
Cenpm centromere protein M isoform 2 3’UTR
Cep350 centrosome-associated protein 350 5’UTR
Cftr cystic fibrosis transmembrane conductance 3’UTR
Chadl chondroadherin-like CDS
Chd4 chromodomain-helicase-DNA-binding protein 4 5’UTR
Chga chromogranin-A precursor 3’UTR
Chmp2b charged multivesicular body protein 2b 5’UTR
Chrm3 muscarinic acetylcholine receptor M3 5’UTR
Chrna3 neuronal acetylcholine receptor subunit alpha-3 CDS
Chrnb2 neuronal acetylcholine receptor subunit beta-2 5’UTR
Chst1 carbohydrate sulfotransferase 1 5’UTR
Chst14 carbohydrate sulfotransferase 14 CDS
Chst3 carbohydrate sulfotransferase 3 CDS
Chst5 carbohydrate sulfotransferase 5 CDS
Cit citron Rho-interacting kinase CDS
Cited4 cbp/p300-interacting transactivator 4 CDS
Clcn1 chloride channel protein 1 CDS
Clcn4-2 H(+)/Cl(-) exchange transporter 4 5’UTR
Clcn7 H(+)/Cl(-) exchange transporter 7 3’UTR
Cldn11 claudin-11 CDS
Cldn26 5’UTR
Cldn3 claudin-3 CDS
Clec16a protein CLEC16A 5’UTR
Clip3 CAP-Gly domain-containing linker protein 3 5’UTR
Clk3 dual specificity protein kinase CLK3 CDS
Clmn calmin isoform b CDS
Clnk cytokine-dependent hematopoietic cell linker 3’UTR
Cltb clathrin light chain B 5’UTR
Cmpk2 UMP-CMP kinase 2, mitochondrial precursor CDS
Cmtm3 CKLF-like MARVEL transmembrane domain-containing CDS
Cmya5 cardiomyopathy-associated protein 5 CDS
Cnga3 cyclic nucleotide-gated cation channel alpha-3 CDS
Cnksr3 connector enhancer of kinase suppressor of ras CDS
Cnnm1 metal transporter CNNM1 3’UTR
Cnr1 cannabinoid receptor 1 5’UTR
Cntn2 contactin-2 precursor 5’UTR
Cntnap1 contactin-associated protein 1 precursor CDS
Cntnap5c contactin-associated protein like 5-3 precursor CDS
Cobra1 negative elongation factor B 3’UTR
Cobra1 negative elongation factor B 5’UTR
Cog7 conserved oligomeric Golgi complex subunit 7 3’UTR
Continued on next page
6 Appendix 151
Table 6.3 – continued from previous page
Transcript Symbol Transcript Name Methylation site
Col27a1 collagen alpha-1(XXVII) chain precursor CDS
Col5a1 collagen alpha-1(V) chain precursor 3’UTR
Col6a2 collagen alpha-2(VI) chain precursor CDS
Commd8 COMM domain-containing protein 8 CDS
Cops6 COP9 signalosome complex subunit 6 3’UTR
Cops7a COP9 signalosome complex subunit 7a isoform 1 CDS
Cops7a COP9 signalosome complex subunit 7a isoform 1 3’UTR
Cops7a COP9 signalosome complex subunit 7a isoform 1 5’UTR
Coro1b coronin-1B 5’UTR
Coro2b coronin-2B CDS
Cox8a cytochrome c oxidase subunit 8A, mitochondrial CDS
Cpne5 copine-5 3’UTR
Cpne6 copine-6 isoform a 5’UTR
Cpne7 copine-7 CDS
Cpne8 copine-8 isoform 1 3’UTR
Cpox coproporphyrinogen-III oxidase, mitochondrial CDS
Cpsf4 cleavage and polyadenylation specificity factor 5’UTR
Cpxm1 probable carboxypeptidase X1 precursor 3’UTR
Crebl2 cAMP-responsive element-binding protein-like 2 5’UTR
Creg1 protein CREG1 CDS
Crim1 cysteine-rich motor neuron 1 protein precursor 5’UTR
Crtc1 CREB-regulated transcription coactivator 1 3’UTR
Crtc2 CREB-regulated transcription coactivator 2 CDS
Cry2 cryptochrome-2 CDS
Cryab alpha-crystallin B chain CDS
Crybg3 beta/gamma crystallin domain-containing protein 3’UTR
Csdc2 cold shock domain-containing protein C2 3’UTR
Csf1r macrophage colony-stimulating factor 1 receptor 3’UTR
Csf2ra granulocyte-macrophage colony-stimulating factor 3’UTR
Csnk1d casein kinase I isoform delta isoform 1 5’UTR
Cspg4 chondroitin sulfate proteoglycan 4 precursor 3’UTR
Ctdspl CTD small phosphatase-like protein CDS
Ctnnb1 catenin beta-1 5’UTR
Ctnnd2 catenin delta-2 CDS
Ctps2 CTP synthase 2 isoform a 5’UTR
Cttnbp2nl CTTNBP2 N-terminal-like protein CDS
Cuedc1 CUE domain-containing protein 1 isoform 2 5’UTR
Cyfip1 cytoplasmic FMR1-interacting protein 1 isoform 5’UTR
Cyfip2 cytoplasmic FMR1-interacting protein 2 CDS
Cyp2d22 cytochrome P450, family 2, subfamily d, CDS
Cyp2d22 cytochrome P450, family 2, subfamily d, 5’UTR
Cyp2s1 cytochrome P450 2S1 CDS
Cyp2s1 cytochrome P450 2S1 3’UTR
Cyp4f16 cytochrome P450, family 4, subfamily f, 3’UTR
D16Ertd472e protein EURL homolog 5’UTR
D430042O09Rik hypothetical protein LOC233865 CDS
D630003M21Rik hypothetical protein LOC228846 isoform 2 CDS
D630045J12Rik hypothetical protein LOC330286 CDS
D630045J12Rik hypothetical protein LOC330286 3’UTR
Daam2 disheveled-associated activator of morphogenesis 5’UTR
Dab2 disabled homolog 2 isoform b CDS
Dag1 dystroglycan precursor 5’UTR
Dap death-associated protein 1 3’UTR
Darc Duffy antigen/chemokine receptor CDS
Dbn1 drebrin isoform 2 CDS
Dcaf12l1 DDB1- and CUL4-associated factor 12-like protein 5’UTR
Dcaf12l2 DDB1- and CUL4-associated factor 12-like protein CDS
Dcbld2 discoidin, CUB and LCCL domain-containing 3’UTR
Dclk1 serine/threonine-protein kinase DCLK1 isoform 3 CDS
Dctn1 dynactin subunit 1 CDS
Ddx17 probable ATP-dependent RNA helicase DDX17 5’UTR
Ddx39b 5’UTR
Ddx54 ATP-dependent RNA helicase DDX54 CDS
Dennd1a DENN domain-containing protein 1A CDS
Dennd1a DENN domain-containing protein 1A 3’UTR
Dennd3 DENN domain-containing protein 3 CDS
Dennd3 DENN domain-containing protein 3 3’UTR
Dgke diacylglycerol kinase epsilon 5’UTR
Dhcr24 24-dehydrocholesterol reductase precursor CDS
Dhx38 pre-mRNA-splicing factor ATP-dependent RNA 3’UTR
Diap1 protein diaphanous homolog 1 3’UTR
Dimt1 probable dimethyladenosine transferase CDS
Dio2 type II iodothyronine deiodinase 5’UTR
Dio3 type III iodothyronine deiodinase 3’UTR
Dip2c disco-interacting protein 2 homolog C 5’UTR
Dis3l DIS3-like exonuclease 1 isoform 2 5’UTR
Disp2 protein dispatched homolog 2 CDS
Disp2 protein dispatched homolog 2 5’UTR
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Dlgap1 disks large-associated protein 1 isoform 4 3’UTR
Dlx2 homeobox protein DLX-2 3’UTR
Dmp1 dentin matrix acidic phosphoprotein 1 precursor 3’UTR
Dnahc9 dynein heavy chain 9, axonemal CDS
Dnajb5 dnaJ homolog subfamily B member 5 CDS
Dnm1 dynamin-1 CDS
Dnm1 dynamin-1 3’UTR
Dock9 dedicator of cytokinesis protein 9 isoform 4 CDS
Dopey2 protein dopey-2 isoform 2 3’UTR
Dopey2 protein dopey-2 isoform 2 5’UTR
Dot1l histone-lysine N-methyltransferase, H3 lysine-79 3’UTR
Dpp6 dipeptidyl aminopeptidase-like protein 6 isoform 5’UTR
Dpp9 dipeptidyl peptidase 9 3’UTR
Dpysl2 dihydropyrimidinase-related protein 2 5’UTR
Dpysl5 dihydropyrimidinase-related protein 5 5’UTR
Drd3 D(3) dopamine receptor CDS
Dscaml1 Down syndrome cell adhesion molecule-like CDS
Dscaml1 Down syndrome cell adhesion molecule-like 3’UTR
Dse dermatan-sulfate epimerase precursor 5’UTR
Dtx3 protein deltex-3 CDS
Dtx3l E3 ubiquitin-protein ligase DTX3L CDS
Dtx4 protein deltex-4 5’UTR
Dus1l tRNA-dihydrouridine synthase 1-like CDS
Dusp4 dual specificity protein phosphatase 4 CDS
Dvl3 segment polarity protein dishevelled homolog CDS
Dzip1 zinc finger protein DZIP1 3’UTR
E130308A19Rik hypothetical protein LOC230259 isoform 2 3’UTR
E130309D14Rik hypothetical protein LOC432582 CDS
Ebf2 transcription factor COE2 3’UTR
Ece1 endothelin-converting enzyme 1 CDS
Ece1 endothelin-converting enzyme 1 3’UTR
Ece2 endothelin-converting enzyme 2 isoform e 5’UTR
Edf1 endothelial differentiation-related factor 1 5’UTR
Edil3 EGF-like repeat and discoidin I-like 5’UTR
Efhd1 EF-hand domain-containing protein D1 CDS
Efnb1 ephrin-B1 precursor 3’UTR
Egr3 early growth response protein 3 3’UTR
Egr4 early growth response protein 4 CDS
Egr4 early growth response protein 4 3’UTR
Ehd4 EH domain-containing protein 4 CDS
Eif1ad probable RNA-binding protein EIF1AD 5’UTR
Eif4g3 eukaryotic translation initiation factor 4 gamma 5’UTR
Elac2 zinc phosphodiesterase ELAC protein 2 CDS
Elfn2 leucine-rich repeat and fibronectin type-III 5’UTR
Elk3 ETS domain-containing protein Elk-3 isoform a CDS
Elmo1 engulfment and cell motility protein 1 isoform 5’UTR
Elovl4 elongation of very long chain fatty acids 5’UTR
Emilin2 EMILIN-2 precursor CDS
En1 homeobox protein engrailed-1 CDS
Enho adropin precursor 5’UTR
Eno2 gamma-enolase 5’UTR
Entpd3 ectonucleoside triphosphate diphosphohydrolase 3’UTR
Entpd5 ectonucleoside triphosphate diphosphohydrolase 5 3’UTR
Entpd6 ectonucleoside triphosphate diphosphohydrolase 3’UTR
Epas1 endothelial PAS domain-containing protein 1 CDS
Epb4.1l1 band 4.1-like protein 1 isoform b 5’UTR
Epha8 ephrin type-A receptor 8 precursor 3’UTR
Ephb1 ephrin type-B receptor 1 isoform 2 5’UTR
Ephb3 ephrin type-B receptor 3 precursor CDS
Ephb3 ephrin type-B receptor 3 precursor 5’UTR
Eps15l1 epidermal growth factor receptor substrate CDS
Eps8 epidermal growth factor receptor kinase CDS
Erbb2 receptor tyrosine-protein kinase erbB-2 3’UTR
Ercc1 DNA excision repair protein ERCC-1 isoform b 3’UTR
Espn espin isoform 2 CDS
Esrra steroid hormone receptor ERR1 CDS
Esrrb steroid hormone receptor ERR2 isoform 2 CDS
Etfdh electron transfer flavoprotein-ubiquinone 5’UTR
Etl4 sickle tail protein isoform e CDS
Etnk2 ethanolamine kinase 2 CDS
Ets1 protein C-ets-1 isoform 2 3’UTR
Ets1 protein C-ets-1 isoform 2 5’UTR
Etv6 transcription factor ETV6 CDS
Evpl envoplakin CDS
Exoc1 exocyst complex component 1 CDS
Exoc6b SEC15-like 2 5’UTR
F2r proteinase-activated receptor 1 precursor CDS
Faim fas apoptotic inhibitory molecule 1 Faim-L CDS
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Faim2 fas apoptotic inhibitory molecule 2 isoform 1 CDS
Faim2 fas apoptotic inhibitory molecule 2 isoform 1 3’UTR
Faim2 fas apoptotic inhibitory molecule 2 isoform 1 5’UTR
Fam100a hypothetical protein LOC207740 CDS
Fam100b hypothetical protein LOC319370 CDS
Fam102a family with sequence similarity 102, member A 5’UTR
Fam120c constitutive coactivator of PPAR-gamma-like 5’UTR
Fam135a hypothetical protein LOC68187 5’UTR
Fam159b membrane protein FAM159B 5’UTR
Fam160a1 hypothetical protein LOC229488 CDS
Fam160b2 family with sequence similarity 160, member B2 CDS
Fam163b hypothetical protein LOC109349 CDS
Fam163b hypothetical protein LOC109349 3’UTR
Fam164c family with sequence similarity 164, member C 3’UTR
Fam167a hypothetical protein LOC219148 CDS
Fam167b hypothetical protein LOC230766 CDS
Fam174b membrane protein FAM174B precursor CDS
Fam178a hypothetical protein LOC226151 5’UTR
Fam179b hypothetical protein LOC328108 5’UTR
Fam184b hypothetical protein LOC58227 CDS
Fam184b hypothetical protein LOC58227 3’UTR
Fam184b hypothetical protein LOC58227 5’UTR
Fam189a2 hypothetical protein LOC381217 CDS
Fam189b hypothetical protein LOC68521 5’UTR
Fam190a hypothetical protein LOC232035 5’UTR
Fam196a hypothetical protein LOC627214 3’UTR
Fam199x hypothetical protein LOC245622 5’UTR
Fam203a CDS
Fam65a hypothetical protein LOC75687 CDS
Fam78a hypothetical protein LOC241303 3’UTR
Fam78a hypothetical protein LOC241303 5’UTR
Fam82a2 regulator of microtubule dynamics protein 3 CDS
Fam89a family with sequence similarity 89, member A CDS
Fam89b CDS
Fancl E3 ubiquitin-protein ligase FANCL CDS
Farp1 FERMRhoGEF (Arhgef) and pleckstrin domain CDS
Fat1 FAT tumor suppressor homolog 1 3’UTR
Fat2 protocadherin Fat 2 CDS
Fbrs fibrosin-1 CDS
Fbrsl1 fibrosin-like 1 isoform 1 CDS
Fbxl12 F-box/LRR-repeat protein 12 isoform a CDS
Fbxl17 F-box/LRR-repeat protein 17 5’UTR
Fbxl6 F-box/LRR-repeat protein 6 CDS
Fbxl7 F-box/LRR-repeat protein 7 CDS
Fbxl8 F-box/LRR-repeat protein 8 5’UTR
Fbxo10 F-box only protein 10 3’UTR
Fbxo42 F-box only protein 42 3’UTR
Fbxw7 F-box/WD repeat-containing protein 7 isoform 2 5’UTR
Fchsd2 FCH and double SH3 domains protein 2 isoform 2 5’UTR
Fcrlb Fc receptor-like B CDS
Fdxr NADPH:adrenodoxin oxidoreductase, mitochondrial CDS
Fen1 flap endonuclease 1 5’UTR
Fgd5 FYVE, RhoGEF and PH domain-containing protein 5 CDS
Fgd5 FYVE, RhoGEF and PH domain-containing protein 5 3’UTR
Fgf1 heparin-binding growth factor 1 precursor CDS
Fgf13 fibroblast growth factor 13 5’UTR
Fgfbp3 fibroblast growth factor-binding protein 3 CDS
Flad1 FAD synthase CDS
Flt1 vascular endothelial growth factor receptor 1 5’UTR
Fmod fibromodulin precursor CDS
Fn3k fructosamine-3-kinase isoform b 3’UTR
Fnbp1 formin-binding protein 1 isoform e 5’UTR
Fndc1 fibronectin type III domain-containing protein 3’UTR
Fndc3b fibronectin type III domain-containing protein CDS
Fos proto-oncogene c-Fos 5’UTR
Fosl2 fos-related antigen 2 CDS
Foxa1 hepatocyte nuclear factor 3-alpha CDS
Foxc1 forkhead box protein C1 CDS
Foxd1 forkhead box protein D1 3’UTR
Foxk1 forkhead box protein K1 CDS
Foxp4 forkhead box protein P4 isoform 2 CDS
Foxp4 forkhead box protein P4 isoform 2 3’UTR
Foxq1 forkhead box protein Q1 CDS
Fras1 extracellular matrix protein FRAS1 precursor 5’UTR
Frem2 FRAS1-related extracellular matrix protein 2 CDS
Frem2 FRAS1-related extracellular matrix protein 2 3’UTR
Frmd4a FERM domain-containing protein 4A isoform 1 CDS
Frmd8 FERM domain-containing protein 8 CDS
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Fscn1 fascin 3’UTR
Fto alpha-ketoglutarate-dependent dioxygenase FTO 3’UTR
Fut4 alpha-(1,3)-fucosyltransferase CDS
Fyco1 FYVE and coiled-coil domain-containing protein CDS
Fyn tyrosine-protein kinase Fyn isoform a CDS
Fyn tyrosine-protein kinase Fyn isoform a 5’UTR
Fzd1 frizzled-1 precursor 5’UTR
Fzd10 frizzled-10 precursor 3’UTR
G3bp2 ras GTPase-activating protein-binding protein 2 5’UTR
G6pdx glucose-6-phosphate 1-dehydrogenase X 3’UTR
Gaa lysosomal alpha-glucosidase precursor 3’UTR
Gaa lysosomal alpha-glucosidase precursor 5’UTR
Gab1 GRB2-associated-binding protein 1 5’UTR
Gabbr2 gamma-aminobutyric acid type B receptor subunit CDS
Gabra2 gamma-aminobutyric acid receptor subunit alpha-2 5’UTR
Gad1 glutamate decarboxylase 1 5’UTR
Gadd45g growth arrest and DNA damage-inducible protein CDS
Gal3st3 galactose-3-O-sulfotransferase 3 CDS
Gal3st3 galactose-3-O-sulfotransferase 3 5’UTR
Galnt14 polypeptide N-acetylgalactosaminyltransferase 5’UTR
Galntl2 polypeptide CDS
Gapvd1 GTPase-activating protein and VPS9 5’UTR
Gas1 growth arrest-specific protein 1 5’UTR
Gas7 growth arrest-specific protein 7 isoform b 3’UTR
Gata2 endothelial transcription factor GATA-2 CDS
Gatsl2 GATS-like protein 2 3’UTR
Gbp7 3’UTR
Gbx2 homeobox protein GBX-2 CDS
Gcap14 granule cell antiserum positive 14 isoform 2 5’UTR
Gck glucokinase CDS
Gdap1l1 ganglioside-induced differentiation-associated CDS
Gdf7 growth/differentiation factor 7 CDS
Gga3 ADP-ribosylation factor-binding protein GGA3 3’UTR
Gimap1 GTPase IMAP family member 1 CDS
Git1 ARF GTPase-activating protein GIT1 CDS
Gli2 GLI-Kruppel family member GLI2 3’UTR
Gli3 zinc finger protein GLI3 CDS
Gli3 zinc finger protein GLI3 5’UTR
Glt8d1 glycosyltransferase 8 domain-containing protein 5’UTR
Glud1 glutamate dehydrogenase 1, mitochondrial 5’UTR
Gm13476 hypothetical protein LOC433424 isoform 1 CDS
Gm347 hypothetical protein LOC241289 3’UTR
Gm4951 hypothetical protein LOC240327 CDS
Gm4980 CDS
Gm5151 hypothetical protein LOC381582 5’UTR
Gm52 envelope glycoprotein syncytin-A CDS
Gm6320 hypothetical protein LOC622408 CDS
Gm6537 3’UTR
Gm7694 CDS
Gm98 myelin gene regulatory factor CDS
Gm98 myelin gene regulatory factor 3’UTR
Gmip GEM-interacting protein CDS
Gnai1 guanine nucleotide binding protein, alpha 5’UTR
Gnao1 guanine nucleotide-binding protein G(o) subunit CDS
Gnao1 guanine nucleotide-binding protein G(o) subunit 5’UTR
Gnas 5’UTR
Gnb5 guanine nucleotide-binding protein subunit 5’UTR
Got1 aspartate aminotransferase, cytoplasmic 5’UTR
Got2 aspartate aminotransferase, mitochondrial 5’UTR
Gpatch2 G patch domain-containing protein 2 3’UTR
Gpr133 probable G-protein coupled receptor 133 3’UTR
Gpr179 probable G-protein coupled receptor 179 CDS
Gpr25 probable G-protein coupled receptor 25 CDS
Gpr4 G-protein coupled receptor 4 CDS
Gpr83 probable G-protein coupled receptor 83 5’UTR
Gprc5c G-protein coupled receptor family C group 5 CDS
Gprc5c G-protein coupled receptor family C group 5 3’UTR
Gramd1b GRAM domain-containing protein 1B 5’UTR
Grem1 gremlin-1 precursor CDS
Grid2ip delphilin isoform 1 3’UTR
Grik1 glutamate receptor, ionotropic kainate 1 isoform 5’UTR
Grik4 glutamate receptor, ionotropic kainate 4 CDS
Grin1 glutamate [NMDA] receptor subunit zeta-1 isoform 3’UTR
Grin1 glutamate [NMDA] receptor subunit zeta-1 isoform 5’UTR
Grin2d glutamate [NMDA] receptor subunit epsilon-4 CDS
Grin2d glutamate [NMDA] receptor subunit epsilon-4 3’UTR
Grk6 G protein-coupled receptor kinase 6 isoform b 3’UTR
Grm2 metabotropic glutamate receptor 2 precursor CDS
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Gse1 genetic suppressor element 1 isoform 2 CDS
Gse1 genetic suppressor element 1 isoform 2 5’UTR
Gstm1 glutathione S-transferase Mu 1 3’UTR
Gstt3 glutathione S-transferase, theta 3 3’UTR
Gtf2h2 general transcription factor IIH subunit 2 5’UTR
Gtf3c1 general transcription factor 3C polypeptide 1 CDS
Gtf3c1 general transcription factor 3C polypeptide 1 3’UTR
Gtf3c4 general transcription factor 3C polypeptide 4 5’UTR
Gucy1a2 guanylate cyclase 1, soluble, alpha 2 5’UTR
Gucy2e guanylyl cyclase GC-E precursor CDS
Gys1 glycogen [starch] synthase, muscle CDS
H13 minor histocompatibility antigen H13 isoform 4 CDS
H2afy core histone macro-H2A.1 isoform 1 3’UTR
H47 selenoprotein S 5’UTR
Hapln3 hyaluronan and proteoglycan link protein 3 CDS
Hcn3 potassium/sodium hyperpolarization-activated CDS
Hcn3 potassium/sodium hyperpolarization-activated 5’UTR
Hcn4 potassium/sodium hyperpolarization-activated CDS
Hdac7 histone deacetylase 7 3’UTR
Heatr5a HEAT repeat-containing protein 5A 3’UTR
Hepacam hepatocyte cell adhesion molecule precursor 3’UTR
Hes5 transcription factor HES-5 5’UTR
Hes6 transcription cofactor HES-6 CDS
Hexdc hexosaminidase D isoform 1 CDS
Heyl hairy/enhancer-of-split related with YRPW 3’UTR
Hgs hepatocyte growth factor-regulated tyrosine 3’UTR
Hic1 hypermethylated in cancer 1 protein isoform 1 3’UTR
Hivep3 transcription factor HIVEP3 CDS
Hk1 hexokinase-1 isoform HK1 5’UTR
Hk2 hexokinase-2 3’UTR
Hnrnpd heterogeneous nuclear ribonucleoprotein D0 5’UTR
Hnrnpu heterogeneous nuclear ribonucleoprotein U CDS
Hnrpdl heterogeneous nuclear ribonucleoprotein D-like 5’UTR
Hnrpll heterogeneous nuclear ribonucleoprotein L-like 5’UTR
Hook3 protein Hook homolog 3 5’UTR
Hpca neuron-specific calcium-binding protein 5’UTR
Hpcal1 hippocalcin-like protein 1 CDS
Hps4 Hermansky-Pudlak syndrome 4 protein homolog 3’UTR
Hr protein hairless CDS
Hs2st1 heparan sulfate 2-O-sulfotransferase 1 5’UTR
Hs3st3a1 heparan sulfate glucosamine 3-O-sulfotransferase 5’UTR
Hsf1 heat shock factor protein 1 3’UTR
Hspa4 heat shock 70 kDa protein 4 5’UTR
Htr6 5-hydroxytryptamine receptor 6 CDS
Htt huntingtin CDS
Htt huntingtin 3’UTR
Icam2 intercellular adhesion molecule 2 precursor 3’UTR
Icam4 intercellular adhesion molecule 4 precursor CDS
Ick serine/threonine-protein kinase ICK CDS
Id4 DNA-binding protein inhibitor ID-4 5’UTR
Idh2 isocitrate dehydrogenase [NADP], mitochondrial CDS
Idh3b isocitrate dehydrogenase 3, beta subunit 5’UTR
Iffo2 intermediate filament family orphan 2 CDS
Iffo2 intermediate filament family orphan 2 3’UTR
Ifrd2 interferon-related developmental regulator 2 CDS
Igdcc4 immunoglobulin superfamily DCC subclass member 4 CDS
Igf1r insulin-like growth factor 1 receptor 5’UTR
Igf2r cation-independent mannose-6-phosphate receptor CDS
Igfbp4 insulin-like growth factor-binding protein 4 CDS
Igsf9b immunoglobulin superfamily, member 9B isoform 1 5’UTR
Ikbkb inhibitor of nuclear factor kappa-B kinase CDS
Ikbkb inhibitor of nuclear factor kappa-B kinase 3’UTR
Il12rb1 interleukin-12 receptor subunit beta-1 CDS
Il17rc interleukin-17 receptor C precursor CDS
Il6ra interleukin-6 receptor subunit alpha precursor 3’UTR
Il6st interleukin-6 receptor subunit beta precursor 5’UTR
Ildr1 immunoglobulin-like domain-containing receptor CDS
Ildr2 Lisch-like CDS
Impad1 inositol monophosphatase 3 5’UTR
Ina alpha-internexin 3’UTR
Inha inhibin alpha chain precursor CDS
Inhbb inhibin beta B chain precursor 5’UTR
Ino80d INO80 complex subunit D isoform 1 3’UTR
Inpp1 inositol polyphosphate 1-phosphatase 5’UTR
Inpp4a type I inositol-3,4-bisphosphate 4-phosphatase 5’UTR
Inpp5e 72 kDa inositol polyphosphate 5-phosphatase 3’UTR
Inpp5j phosphatidylinositol 4,5-bisphosphate CDS
Iqcd IQ domain-containing protein D CDS
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Iqsec1 IQ motif and SEC7 domain-containing protein 1 5’UTR
Irf8 interferon regulatory factor 8 3’UTR
Irs4 insulin receptor substrate 4 CDS
Irx1 iroquois-class homeodomain protein IRX-1 CDS
Irx5 iroquois-class homeodomain protein IRX-5 CDS
Ism1 isthmin-1 precursor 5’UTR
Isoc2b isochorismatase domain-containing protein 2B, CDS
Isoc2b isochorismatase domain-containing protein 2B, 3’UTR
Isy1 pre-mRNA-splicing factor ISY1 homolog 3’UTR
Itfg1 T-cell immunomodulatory protein precursor 5’UTR
Itfg3 protein ITFG3 3’UTR
Itga3 integrin alpha-3 5’UTR
Itga4 integrin alpha-4 3’UTR
Itgav integrin alpha-V precursor 5’UTR
Itsn1 intersectin-1 isoform 2 3’UTR
Jam2 junctional adhesion molecule B precursor 5’UTR
Jmjd6 bifunctional arginine demethylase and 5’UTR
Jph4 junctophilin-4 isoform a 5’UTR
Kat2a histone acetyltransferase KAT2A isoform b CDS
Kcna6 potassium voltage-gated channel subfamily A 5’UTR
Kcnab1 voltage-gated potassium channel subunit beta-1 5’UTR
Kcnc1 potassium voltage-gated channel subfamily C 5’UTR
Kcnf1 potassium voltage-gated channel subfamily F 5’UTR
Kcng1 potassium voltage-gated channel subfamily G CDS
Kcng4 potassium voltage-gated channel subfamily G CDS
Kcnh4 potassium voltage-gated channel, subfamily H 3’UTR
Kcnj6 G protein-activated inward rectifier potassium 5’UTR
Kcnk5 potassium channel subfamily K member 5 CDS
Kcnk9 potassium channel subfamily K member 9 CDS
Kcnma1 calcium-activated potassium channel subunit CDS
Kcnt1 potassium channel subfamily T member 1 isoform CDS
Kctd13 BTB/POZ domain-containing adapter for CDS
Kdelc1 KDEL motif-containing protein 1 precursor CDS
Kdelr2 ER lumen protein retaining receptor 2 3’UTR
Kdm5c lysine-specific demethylase 5C 3’UTR
Khsrp far upstream element-binding protein 2 5’UTR
Kif1a kinesin-like protein KIF1A isoform a CDS
Kif26b kinesin-like protein KIF26B CDS
Kif7 kinesin family member 7 CDS
Kifap3 kinesin-associated protein 3 5’UTR
Klf12 Krueppel-like factor 12 3’UTR
Klf7 Krueppel-like factor 7 5’UTR
Klhdc2 kelch domain-containing protein 2 5’UTR
Klhdc8a kelch domain-containing protein 8A 5’UTR
Klhl6 kelch-like protein 6 CDS
Kndc1 protein very KIND 5’UTR
Kpnb1 importin subunit beta-1 5’UTR
Kri1 protein KRI1 homolog CDS
Krt12 keratin, type I cytoskeletal 12 5’UTR
Krt20 keratin, type I cytoskeletal 20 CDS
Krt80 keratin, type II cytoskeletal 80 3’UTR
Ksr1 kinase suppressor of Ras 1 3’UTR
Ksr2 kinase suppressor of Ras 2 isoform 1 5’UTR
Ky kyphoscoliosis peptidase CDS
L1cam neural cell adhesion molecule L1 CDS
Lancl3 lanC-like protein 3 5’UTR
Lasp1 LIM and SH3 domain protein 1 3’UTR
Lasp1 LIM and SH3 domain protein 1 5’UTR
Lass1 LAG1 longevity assurance homolog 1 CDS
Lass6 LAG1 longevity assurance homolog 6 5’UTR
Lbh protein LBH 5’UTR
Ldhd probable D-lactate dehydrogenase, mitochondrial CDS
Ldoc1l protein LDOC1L 5’UTR
Leng8 leukocyte receptor cluster member 8 homolog CDS
Lgals3bp galectin-3-binding protein precursor CDS
Lgmn legumain precursor CDS
Lhfpl4 lipoma HMGIC fusion partner-like 4 protein 5’UTR
Lhfpl5 tetraspan membrane protein of hair cell 5’UTR
Lhx1 LIM/homeobox protein Lhx1 5’UTR
Lhx5 LIM/homeobox protein Lhx5 3’UTR
Lipe hormone-sensitive lipase isoform 2 CDS
Lipg endothelial lipase precursor 3’UTR
Lmln leishmanolysin-like peptidase 3’UTR
Lmna prelamin-A/C isoform C2 5’UTR
Lmo4 LIM domain transcription factor LMO4 5’UTR
Lmtk2 serine/threonine-protein kinase LMTK2 precursor 3’UTR
Lpcat4 lysophospholipid acyltransferase LPCAT4 3’UTR
Lpin2 phosphatidate phosphatase LPIN2 isoform 1 CDS
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Lrfn1 leucine-rich repeat and fibronectin type III 3’UTR
Lrfn5 leucine-rich repeat and fibronectin type-III 5’UTR
Lrp3 low density lipoprotein receptor-related protein 3’UTR
Lrp4 low-density lipoprotein receptor-related protein CDS
Lrp5 low-density lipoprotein receptor-related protein CDS
Lrrc14 leucine-rich repeat-containing protein 14 5’UTR
Lrrc25 leucine-rich repeat-containing protein 25 CDS
Lrrc26 leucine-rich repeat-containing protein 26 CDS
Lrrc32 leucine rich repeat containing 32 CDS
Lrrc38 leucine-rich repeat-containing protein 38 CDS
Lrrc68 leucine-rich repeat-containing protein 68 5’UTR
Lrrc8b leucine-rich repeat-containing protein 8B 3’UTR
Lrrfip1 leucine-rich repeat flightless-interacting CDS
Lrsam1 E3 ubiquitin-protein ligase LRSAM1 CDS
Lxn latexin 5’UTR
Ly6g6f lymphocyte antigen 6 complex, locus G6F 3’UTR
Ly6h lymphocyte antigen 6H isoform b 5’UTR
Lyst lysosomal-trafficking regulator 3’UTR
Mab21l2 protein mab-21-like 2 CDS
Madd MAP kinase-activating death domain protein CDS
Madd MAP kinase-activating death domain protein 3’UTR
Maf transcription factor Maf 5’UTR
Maged1 melanoma-associated antigen D1 CDS
Mageh1 melanoma-associated antigen H1 5’UTR
Man1b1 mannosidase, alpha, class 1B, member 1 CDS
Man1c1 mannosidase, alpha, class 1C, member 1 CDS
Man1c1 mannosidase, alpha, class 1C, member 1 3’UTR
Map3k6 mitogen-activated protein kinase kinase kinase 5’UTR
Map3k9 mitogen-activated protein kinase kinase kinase 9 3’UTR
Map6d1 MAP6 domain-containing protein 1 CDS
Mapk8ip2 C-Jun-amino-terminal kinase-interacting protein 5’UTR
Mapk8ip3 C-Jun-amino-terminal kinase-interacting protein 3’UTR
Mapkbp1 mitogen-activated protein kinase-binding protein CDS
Mapre2 microtubule-associated protein RP/EB family 5’UTR
March4 E3 ubiquitin-protein ligase MARCH4 precursor CDS
Marcksl1 MARCKS-related protein 3’UTR
Mark2 serine/threonine-protein kinase MARK2 isoform 4 5’UTR
Mavs mitochondrial antiviral-signaling protein CDS
Mboat7 lysophospholipid acyltransferase 7 CDS
Mboat7 lysophospholipid acyltransferase 7 5’UTR
Mc3r melanocortin receptor 3 3’UTR
Mcc mutated in colorectal cancers isoform 1 3’UTR
Mchr1 melanin-concentrating hormone receptor 1 5’UTR
Mcm6 DNA replication licensing factor MCM6 CDS
Mdga1 MAM domain-containing 5’UTR
Med23 mediator of RNA polymerase II transcription 3’UTR
Med26 mediator of RNA polymerase II transcription 3’UTR
Mef2d myocyte-specific enhancer factor 2D CDS
Megf9 multiple epidermal growth factor-like domains 5’UTR
Mepce 7SK snRNA methylphosphate capping enzyme 5’UTR
Mettl14 methyltransferase-like protein 14 3’UTR
Mettl3 N6-adenosine-methyltransferase 70 kDa subunit CDS
Mfap3l microfibrillar-associated protein 3-like 5’UTR
Mfge8 lactadherin isoform 2 3’UTR
Mfsd6 major facilitator superfamily domain-containing 5’UTR
Mgat4b alpha-1,3-mannosyl-glycoprotein 3’UTR
Mgat5b alpha-1,6-mannosylglycoprotein CDS
Mgrn1 E3 ubiquitin-protein ligase MGRN1 3’UTR
Mib2 E3 ubiquitin-protein ligase MIB2 3’UTR
Mib2 E3 ubiquitin-protein ligase MIB2 5’UTR
Mical2 protein MICAL-2 isoform B CDS
Mid1 midline-1 CDS
Mid1 midline-1 3’UTR
Midn midnolin CDS
Midn midnolin 5’UTR
Mif4gd MIF4G domain-containing protein 5’UTR
Minpp1 multiple inositol polyphosphate phosphatase 1 5’UTR
Mlf2 myeloid leukemia factor 2 3’UTR
Mlf2 myeloid leukemia factor 2 5’UTR
Mlxip MLX-interacting protein isoform 1 CDS
Mmp14 matrix metalloproteinase-14 3’UTR
Mmp15 matrix metalloproteinase-15 precursor CDS
Mmp28 matrix metalloproteinase-28 isoform 2 3’UTR
Mmrn2 multimerin-2 precursor 3’UTR
Mn1 probable tumor suppressor protein MN1 3’UTR
Mnt max-binding protein MNT CDS
Mobkl2b mps one binder kinase activator-like 2B 3’UTR
Mospd4 motile sperm domain containing 4 CDS
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Mprip myosin phosphatase Rho-interacting protein 3’UTR
Mrgprf mas-related G-protein coupled receptor member F 3’UTR
Mrpl4 39S ribosomal protein L4, mitochondrial 3’UTR
Mrpl46 39S ribosomal protein L46, mitochondrial 3’UTR
Mrps11 28S ribosomal protein S11, mitochondrial 3’UTR
Mrvi1 protein MRVI1 isoform a CDS
Msl1 male-specific lethal 1 homolog 5’UTR
Mtap1a microtubule-associated protein 1A isoform 2 5’UTR
Mtap1b microtubule-associated protein 1B 5’UTR
Mtap2 microtubule-associated protein 2 isoform 2 CDS
Mtap7d1 MAP7 domain-containing protein 1 isoform 2 CDS
Mtdh protein LYRIC 5’UTR
Mtfp1 5’UTR
Mtmr11 myotubularin-related protein 11 3’UTR
Mto1 protein MTO1 homolog, mitochondrial precursor 5’UTR
Mtus2 microtubule-associated tumor suppressor 3’UTR
Mycl1 protein L-Myc-1 5’UTR
Myh14 myosin-14 CDS
Myh7b myosin-7B CDS
Myh9 myosin-9 isoform 1 3’UTR
Myo16 myosin-XVI CDS
Myo1d myosin-Id 3’UTR
Myo1d myosin-Id 5’UTR
Myo5b myosin-Vb CDS
Myst2 histone acetyltransferase MYST2 isoform 3 5’UTR
N28178 hypothetical protein LOC230085 CDS
Naf1 H/ACA ribonucleoprotein complex non-core subunit 5’UTR
Nagpa CDS
Nat6 N-acetyltransferase 6 5’UTR
Nav2 neuron navigator 2 isoform 1 5’UTR
Ncam1 neural cell adhesion molecule 1 isoform 3 CDS
Ncdn neurochondrin 3’UTR
Ncdn neurochondrin 5’UTR
Nckap5 Nck-associated protein 5 isoform 2 CDS
Nckap5 Nck-associated protein 5 isoform 2 3’UTR
Nckap5l nck-associated protein 5-like CDS
Nckap5l nck-associated protein 5-like 3’UTR
Ncor2 nuclear receptor corepressor 2 CDS
Ndel1 nuclear distribution protein nudE-like 1 3’UTR
Ndfip2 NEDD4 family-interacting protein 2 CDS
Ndrg1 protein NDRG1 5’UTR
Ndrg3 protein NDRG3 isoform 1 3’UTR
Ndufb10 NADH dehydrogenase [ubiquinone] 1 beta 5’UTR
Ndufv1 NADH dehydrogenase [ubiquinone] flavoprotein 1, CDS
Nebl nebulette 5’UTR
Nefl neurofilament light polypeptide 5’UTR
Nefm neurofilament medium polypeptide 5’UTR
Nek11 serine/threonine-protein kinase Nek11 3’UTR
Neo1 neogenin isoform 2 5’UTR
Nf1 neurofibromin CDS
Nfam1 NFAT activation molecule 1 3’UTR
Nfat5 nuclear factor of activated T-cells 5 isoform a CDS
Nfat5 nuclear factor of activated T-cells 5 isoform a 5’UTR
Nfatc2 nuclear factor of activated T-cells, cytoplasmic 3’UTR
Nfkbib NF-kappa-B inhibitor beta 3’UTR
Ngef ephexin-1 isoform 1 3’UTR
Nhlrc1 E3 ubiquitin-protein ligase NHLRC1 5’UTR
Nhsl2 NHS-like protein 2 CDS
Nid2 nidogen-2 precursor CDS
Nipal3 NIPA-like protein 3 CDS
Nkain2 sodium/potassium-transporting ATPase subunit 5’UTR
Nkd1 protein naked cuticle homolog 1 isoform 2 CDS
Nkpd1 NTPase KAP family P-loop domain-containing CDS
Nktr NK-tumor recognition protein 3’UTR
Nkx2-1 homeobox protein Nkx-2.1 CDS
Nkx2-1 homeobox protein Nkx-2.1 3’UTR
Nkx2-2 homeobox protein Nkx-2.2 isoform 1 CDS
Nkx2-9 homeobox protein Nkx-2.8 CDS
Nkx2-9 homeobox protein Nkx-2.8 3’UTR
Nlrx1 NLR family member X1 precursor 3’UTR
Nnat neuronatin isoform beta 5’UTR
Nod1 nucleotide-binding oligomerization 3’UTR
Nog noggin precursor 5’UTR
Nosip nitric oxide synthase-interacting protein 3’UTR
Notch1 neurogenic locus notch homolog protein 1 CDS
Notch2 neurogenic locus notch homolog protein 2 CDS
Npas1 neuronal PAS domain-containing protein 1 CDS
Npas4 neuronal PAS domain-containing protein 4 5’UTR
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Npc1 Niemann-Pick C1 protein CDS
Npc2 epididymal secretory protein E1 precursor CDS
Nploc4 nuclear protein localization protein 4 homolog CDS
Npr1 atrial natriuretic peptide receptor 1 precursor CDS
Npr3 atrial natriuretic peptide receptor 3 isoform b CDS
Nptx1 neuronal pentraxin-1 precursor CDS
Nptx1 neuronal pentraxin-1 precursor 3’UTR
Nptx1 neuronal pentraxin-1 precursor 5’UTR
Nptx2 neuronal pentraxin-2 precursor 3’UTR
Nptxr neuronal pentraxin receptor CDS
Npy2r neuropeptide Y receptor type 2 5’UTR
Nr1d1 nuclear receptor subfamily 1 group D member 1 CDS
Nr1h2 oxysterols receptor LXR-beta CDS
Nr4a1 nuclear receptor subfamily 4 group A member 1 5’UTR
Nrgn neurogranin CDS
Nrip1 nuclear receptor-interacting protein 1 5’UTR
Nsun4 putative methyltransferase NSUN4 CDS
Nsun7 putative methyltransferase NSUN7 CDS
Ntn3 netrin-3 precursor 3’UTR
Ntn3 netrin-3 precursor 5’UTR
Ntsr1 neurotensin receptor type 1 CDS
Ntsr1 neurotensin receptor type 1 3’UTR
Nuak2 NUAK family SNF1-like kinase 2 isoform B CDS
Nudcd2 nudC domain-containing protein 2 CDS
Nudt10 diphosphoinositol polyphosphate phosphohydrolase 5’UTR
Nup210 nuclear pore membrane glycoprotein 210 3’UTR
Nup214 nuclear pore complex protein Nup214 CDS
Nup62-il4i1 Nup62-Il4i1 protein 5’UTR
Nyx nyctalopin precursor CDS
Oaf out at first protein homolog precursor 5’UTR
Omp olfactory marker protein CDS
ORF19 WAS protein family homolog 1 CDS
ORF61 membralin CDS
Oscar osteoclast-associated immunoglobulin-like CDS
Oscar osteoclast-associated immunoglobulin-like 3’UTR
Ostm1 osteopetrosis-associated transmembrane protein 1 CDS
Otud5 OTU domain-containing protein 5 CDS
Otud5 OTU domain-containing protein 5 5’UTR
Ovgp1 oviduct-specific glycoprotein precursor CDS
Oxa1l mitochondrial inner membrane protein OXA1L CDS
Pacsin1 protein kinase C and casein kinase substrate in 5’UTR
Pafah1b2 platelet-activating factor acetylhydrolase IB 5’UTR
Palb2 partner and localizer of BRCA2 CDS
Papd7 DNA polymerase sigma isoform 2 5’UTR
Paqr9 progestin and adipoQ receptor family member 9 CDS
Parm1 prostate androgen-regulated mucin-like protein 1 CDS
Parp10 poly (ADP-ribose) polymerase family, member 10 CDS
Parp10 poly (ADP-ribose) polymerase family, member 10 3’UTR
Pbx3 pre-B-cell leukemia transcription factor 3 CDS
Pcbp1 poly(rC)-binding protein 1 5’UTR
Pcdh19 protocadherin-19 isoform a 5’UTR
Pcdh8 protocadherin 8 isoform 2 precursor 5’UTR
Pcdha2 protocadherin alpha 2 3’UTR
Pcdhga8 protocadherin gamma subfamily A, 8 5’UTR
Pcdhgb5 protocadherin gamma-B5 CDS
Pcgf2 polycomb group RING finger protein 2 CDS
Pcgf6 polycomb group RING finger protein 6 CDS
Pcid2 PCI domain-containing protein 2 3’UTR
Pcif1 phosphorylated CTD-interacting factor 1 CDS
Pclo protein piccolo isoform 2 5’UTR
Pcsk1n proSAAS CDS
Pcsk1n proSAAS 3’UTR
Pcsk7 proprotein convertase subtilisin/kexin type 7 5’UTR
Pdcd11 protein RRP5 homolog 3’UTR
Pdcd2 programmed cell death protein 2 5’UTR
Pde1b calcium/calmodulin-dependent 3’,5’-cyclic 5’UTR
Pde4a cAMP-specific 3’,5’-cyclic phosphodiesterase 4A 3’UTR
Pde4c cAMP-specific 3’,5’-cyclic phosphodiesterase 4C 3’UTR
Pdgfb platelet-derived growth factor subunit B 5’UTR
Pdpk1 3-phosphoinositide-dependent protein kinase 1 5’UTR
Pdxk pyridoxal kinase 5’UTR
Peg3 paternally expressed 3 5’UTR
Per2 period circadian protein homolog 2 CDS
Per3 period circadian protein homolog 3 CDS
Pex14 peroxisomal membrane protein PEX14 3’UTR
Pfkl 6-phosphofructokinase, liver type 3’UTR
Pgm2 phosphoglucomutase-1 5’UTR
Pgm2l1 glucose 1,6-bisphosphate synthase 5’UTR
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Pgrmc1 membrane-associated progesterone receptor 5’UTR
Phb2 prohibitin-2 5’UTR
Phf12 PHD finger protein 12 5’UTR
Phf2 PHD finger protein 2 CDS
Phf2 PHD finger protein 2 3’UTR
Phkb phosphorylase b kinase regulatory subunit beta 5’UTR
Phlpp1 PH domain leucine-rich repeat-containing protein 5’UTR
Pi4kb phosphatidylinositol 4-kinase beta 5’UTR
Pias3 E3 SUMO-protein ligase PIAS3 isoform 3 CDS
Picalm phosphatidylinositol-binding clathrin assembly 5’UTR
Pigb GPI mannosyltransferase 3 CDS
Pigo GPI ethanolamine phosphate transferase 3 CDS
Pigv GPI mannosyltransferase 2 isoform 3 5’UTR
Pigz GPI mannosyltransferase 4 CDS
Pih1d1 PIH1 domain-containing protein 1 5’UTR
Pik3c2b phosphoinositide-3-kinase, class 2 beta 3’UTR
Pik3cg phosphatidylinositol-4,5-bisphosphate 3-kinase CDS
Pik3r5 phosphoinositide 3-kinase regulatory subunit 5 CDS
Pip4k2c phosphatidylinositol-5-phosphate 4-kinase type-2 CDS
Pkmyt1 membrane-associated tyrosine- and CDS
Plagl2 zinc finger protein PLAGL2 CDS
Plagl2 zinc finger protein PLAGL2 3’UTR
Plbd2 putative phospholipase B-like 2 3’UTR
Plcb1 1-phosphatidylinositol-4,5-bisphosphate 5’UTR
Plcb3 1-phosphatidylinositol-4,5-bisphosphate CDS
Pld3 phospholipase D3 3’UTR
Pld4 phospholipase D4 CDS
Plekha7 pleckstrin homology domain-containing family A 3’UTR
Plekhj1 pleckstrin homology domain-containing family J 5’UTR
Plekhm1 pleckstrin homology domain-containing family M 3’UTR
Plekhm2 pleckstrin homology domain-containing family M 3’UTR
Plod3 procollagen-lysine,2-oxoglutarate 5-dioxygenase 5’UTR
Plxdc1 plexin domain-containing protein 1 isoform 1 CDS
Plxna4 plexin-A4 precursor 5’UTR
Plxnb2 plexin B2 CDS
Plxnb3 plexin-B3 CDS
Plxnc1 plexin-C1 precursor CDS
Plxnd1 plexin D1 CDS
Plxnd1 plexin D1 3’UTR
Pm20d2 5’UTR
Pnkd probable hydrolase PNKD isoform 1 3’UTR
Pnma1 paraneoplastic antigen Ma1 homolog 5’UTR
Podxl2 podocalyxin-like protein 2 3’UTR
Pogk pogo transposable element with KRAB domain 5’UTR
Polr1a DNA-directed RNA polymerase I subunit RPA1 3’UTR
Polr2f DNA-directed RNA polymerases I, II, and III CDS
Polr3d DNA-directed RNA polymerase III subunit RPC4 CDS
Pom121 nuclear envelope pore membrane protein POM 121 CDS
Pom121 nuclear envelope pore membrane protein POM 121 3’UTR
Pou2f1 POU domain, class 2, transcription factor 1 CDS
Pou2f2 POU domain, class 2, transcription factor 2 3’UTR
Pou6f1 POU domain, class 6, transcription factor 1 5’UTR
Ppap2b lipid phosphate phosphohydrolase 3 3’UTR
Ppapdc3 probable lipid phosphate phosphatase PPAPDC3 CDS
Ppard peroxisome proliferator-activated receptor CDS
Ppard peroxisome proliferator-activated receptor 3’UTR
Ppfia4 liprin-alpha-4 5’UTR
Ppil2 peptidyl-prolyl cis-trans isomerase-like 2 CDS
Ppm1l protein phosphatase 1L CDS
Ppm1l protein phosphatase 1L 5’UTR
Ppp1r10 serine/threonine-protein phosphatase 1 CDS
Ppp1r15b protein phosphatase 1 regulatory subunit 15B 5’UTR
Ppp1r1a protein phosphatase 1 regulatory subunit 1A 5’UTR
Ppp5c serine/threonine-protein phosphatase 5 CDS
Prdm8 PR domain zinc finger protein 8 CDS
Prelp prolargin precursor CDS
Prelp prolargin precursor 3’UTR
Prickle2 prickle-like protein 2 isoform b 5’UTR
Prkar2b cAMP-dependent protein kinase type II-beta 3’UTR
Prkca protein kinase C alpha type 5’UTR
Prmt5 protein arginine N-methyltransferase 5 CDS
Prox1 prospero homeobox protein 1 3’UTR
Prpf8 pre-mRNA-processing-splicing factor 8 5’UTR
Prps2 ribose-phosphate pyrophosphokinase 2 5’UTR
Prr12 proline rich 12 3’UTR
Prr22 CDS
Prr3 proline-rich protein 3 isoform b 3’UTR
Prrt2 proline-rich transmembrane protein 2 5’UTR
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Prrt4 proline-rich transmembrane protein 4 CDS
Prrx1 paired mesoderm homeobox protein 1 isoform b CDS
Psap sulfated glycoprotein 1 isoform D preproprotein 5’UTR
Psd PH and SEC7 domain-containing protein 1 CDS
Psd2 PH and SEC7 domain-containing protein 2 5’UTR
Psen1 presenilin-1 CDS
Pskh1 serine/threonine-protein kinase H1 3’UTR
Psmf1 proteasome inhibitor PI31 subunit 3’UTR
Pth2r parathyroid hormone 2 receptor precursor CDS
Ptk7 tyrosine-protein kinase-like 7 precursor 3’UTR
Ptms parathymosin 5’UTR
Ptp4a3 protein tyrosine phosphatase type IVA 3 isoform CDS
Ptplb 3-hydroxyacyl-CoA dehydratase 2 CDS
Ptpmt1 protein-tyrosine phosphatase mitochondrial 1 5’UTR
Ptpn21 tyrosine-protein phosphatase non-receptor type 3’UTR
Ptpn23 tyrosine-protein phosphatase non-receptor type CDS
Ptpn5 tyrosine-protein phosphatase non-receptor type CDS
Ptprm receptor-type tyrosine-protein phosphatase mu 5’UTR
Ptpro protein tyrosine phosphatase, receptor type, O CDS
Ptpro protein tyrosine phosphatase, receptor type, O 5’UTR
Ptprs receptor-type tyrosine-protein phosphatase S 3’UTR
Ptprz1 receptor-type tyrosine-protein phosphatase zeta 5’UTR
Ptrf polymerase I and transcript release factor 3’UTR
Pum1 pumilio homolog 1 isoform 2 3’UTR
Pvrl2 poliovirus receptor-related protein 2 isoform 2 CDS
Pvrl2 poliovirus receptor-related protein 2 isoform 2 5’UTR
Pxdn peroxidasin homolog precursor CDS
Pxn paxillin isoform alpha 3’UTR
Pycard apoptosis-associated speck-like protein CDS
Pygb glycogen phosphorylase, brain form 5’UTR
Pygo1 pygopus homolog 1 5’UTR
Pygo2 pygopus homolog 2 CDS
Qprt nicotinate-nucleotide pyrophosphorylase CDS
R3hdm2 R3H domain-containing protein 2 isoform 2 3’UTR
Rab10 ras-related protein Rab-10 CDS
Rab11b ras-related protein Rab-11B 5’UTR
Rab11fip1 rab11 family-interacting protein 1 isoform 1 CDS
Rab11fip1 rab11 family-interacting protein 1 isoform 1 3’UTR
Rab14 ras-related protein Rab-14 5’UTR
Rab3a ras-related protein Rab-3A 5’UTR
Rab3il1 guanine nucleotide exchange factor for Rab-3A 5’UTR
Rad23b UV excision repair protein RAD23 homolog B 5’UTR
Rad50 DNA repair protein RAD50 3’UTR
Rad51l3 DNA repair protein RAD51 homolog 4 CDS
Radil ras-associating and dilute domain-containing CDS
Rai1 retinoic acid-induced protein 1 3’UTR
Ramp3 receptor activity-modifying protein 3 precursor 3’UTR
Rap1gap2 rap1 GTPase-activating protein 2 3’UTR
Rapgefl1 rap guanine nucleotide exchange factor-like 1 3’UTR
Rapgefl1 rap guanine nucleotide exchange factor-like 1 5’UTR
Rara retinoic acid receptor alpha isoform 1 CDS
Rara retinoic acid receptor alpha isoform 1 5’UTR
Rarg retinoic acid receptor gamma isoform 2 3’UTR
Rasa3 ras GTPase-activating protein 3 3’UTR
Rasal1 rasGAP-activating-like protein 1 CDS
Rasgrf1 ras-specific guanine nucleotide-releasing factor 5’UTR
Rasl10b ras-like protein family member 10B precursor CDS
Rasl11b ras-like protein family member 11B 5’UTR
Rasl12 ras-like protein family member 12 isoform 1 3’UTR
Rassf5 ras association domain-containing protein 5 3’UTR
Raver1 ribonucleoprotein PTB-binding 1 3’UTR
Rbfox1 fox-1 homolog A isoform alpha 5’UTR
Rbfox3 CDS
Rbm20 probable RNA-binding protein 20 CDS
Rbm20 probable RNA-binding protein 20 3’UTR
Rbm24 RNA-binding protein 24 5’UTR
Rbm42 RNA-binding protein 42 CDS
Rbm45 RNA-binding protein 45 5’UTR
Rbp1 retinol-binding protein 1 CDS
Rcc1 regulator of chromosome condensation isoform 2 3’UTR
Rcn2 reticulocalbin-2 precursor 5’UTR
Reep6 receptor expression-enhancing protein 6 3’UTR
Rela transcription factor p65 3’UTR
Rere arginine-glutamic acid dipeptide repeats 3’UTR
Rfx7 regulatory factor X domain containing 2 5’UTR
Rgag4 5’UTR
Rgl2 ral guanine nucleotide dissociation 5’UTR
Rgma repulsive guidance molecule A precursor 3’UTR
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Rimklb ribosomal protein S6 modification-like protein 5’UTR
Rims4 regulating synaptic membrane exocytosis protein CDS
Rin1 ras and Rab interactor 1 CDS
Ring1 E3 ubiquitin-protein ligase RING1 5’UTR
Rnaseh1 ribonuclease H1 3’UTR
Rnaseh2a ribonuclease H2 subunit A CDS
Rnasel 2-5A-dependent ribonuclease 3’UTR
Rnf103 E3 ubiquitin-protein ligase RNF103 5’UTR
Rnf152 RING finger protein 152 5’UTR
Rnf165 ring finger protein 165 3’UTR
Rnf214 RING finger protein 214 5’UTR
Rnf220 E3 ubiquitin-protein ligase Rnf220 3’UTR
Rnf39 ring finger protein 39 CDS
Rnf43 RING finger protein 43 precursor CDS
Rnpc3 RNA-binding protein 40 5’UTR
Rnps1 RNA-binding protein with serine-rich domain 1 5’UTR
Romo1 reactive oxygen species modulator 1 CDS
Rpgrip1 X-linked retinitis pigmentosa GTPase 3’UTR
Rpn2 dolichyl-diphosphooligosaccharide–protein 5’UTR
Rprd1a regulation of nuclear pre-mRNA domain-containing 5’UTR
Rps6ka1 ribosomal protein S6 kinase alpha-1 CDS
Rreb1 3’UTR
Rsad2 radical S-adenosyl methionine domain-containing 3’UTR
Rtn4rl2 reticulon-4 receptor-like 2 precursor CDS
Runx2 runt-related transcription factor 2 isoform type 5’UTR
Rxrb retinoic acid receptor RXR-beta 5’UTR
Ryr1 ryanodine receptor 1, skeletal muscle CDS
S1pr2 sphingosine 1-phosphate receptor 2 CDS
S1pr4 sphingosine 1-phosphate receptor 4 CDS
Safb scaffold attachment factor B CDS
Sall3 sal-like protein 3 CDS
Samd14 sterile alpha motif domain-containing protein 14 5’UTR
Samd4b protein Smaug homolog 2 CDS
Samd4b protein Smaug homolog 2 3’UTR
Samhd1 SAM domain and HD domain-containing protein 1 CDS
Samhd1 SAM domain and HD domain-containing protein 1 3’UTR
Sarm1 sterile alpha and TIR motif-containing protein 1 CDS
Sart1 U4/U6.U5 tri-snRNP-associated protein 1 CDS
Sash3 SAM and SH3 domain-containing protein 3 3’UTR
Satb2 DNA-binding protein SATB2 3’UTR
Sbno2 protein strawberry notch homolog 2 CDS
Scarb1 scavenger receptor class B member 1 CDS
Scarf1 scavenger receptor class F, member 1 CDS
Scarf2 scavenger receptor class F member 2 precursor CDS
Scd2 acyl-CoA desaturase 2 CDS
Scg3 secretogranin-3 isoform 2 precursor 5’UTR
Scn3b sodium channel subunit beta-3 precursor 5’UTR
Scn5a sodium channel protein type 5 subunit alpha 3’UTR
Scrt2 transcriptional repressor scratch 2 CDS
Sdc4 syndecan-4 precursor CDS
Sdf2 stromal cell-derived factor 2 5’UTR
Sdha succinate dehydrogenase [ubiquinone] CDS
Sdk2 protein sidekick-2 precursor CDS
Sdr39u1 epimerase family protein SDR39U1 3’UTR
Sec1 galactoside 2-alpha-L-fucosyltransferase 3 CDS
Sec24b protein transport protein Sec24B CDS
Sec31a protein transport protein Sec31A 3’UTR
Sec61a1 protein transport protein Sec61 subunit alpha 5’UTR
Sel1l protein sel-1 homolog 1 isoform b 5’UTR
Sema6a semaphorin-6A precursor 3’UTR
Sema6a semaphorin-6A precursor 5’UTR
Sema6c semaphorin-6C precursor CDS
Sema6c semaphorin-6C precursor 3’UTR
Sema6d semaphorin-6D isoform 4 5’UTR
Sept5 septin-5 CDS
Sept6 septin-6 isoform 3 5’UTR
Sept9 septin-9 isoform a CDS
Serhl serine hydrolase-like protein CDS
Serpinh1 serpin H1 precursor CDS
Serpini1 neuroserpin precursor 5’UTR
Sesn3 sestrin-3 CDS
Sestd1 SEC14 domain and spectrin repeat-containing CDS
Setd1a SET domain containing 1A CDS
Setd4 SET domain-containing protein 4 CDS
Sez6l seizure 6-like protein CDS
Sez6l seizure 6-like protein 5’UTR
Sf1 splicing factor 1 isoform 2 CDS
Sfi1 protein SFI1 homolog CDS
Continued on next page
6 Appendix 163
Table 6.3 – continued from previous page
Transcript Symbol Transcript Name Methylation site
Sfmbt1 scm-like with four MBT domains protein 1 5’UTR
Sfn 14-3-3 protein sigma 5’UTR
Sfpi1 transcription factor PU.1 3’UTR
Sfrp2 secreted frizzled-related protein 2 precursor CDS
Sfswap splicing factor, arginine/serine-rich 8 CDS
Sgpl1 sphingosine-1-phosphate lyase 1 5’UTR
Sgsh N-sulfoglucosamine sulfohydrolase 3’UTR
Sgsm1 small G protein signaling modulator 1 isoform a CDS
Sh3bp1 SH3 domain-binding protein 1 5’UTR
Sh3bp5 SH3 domain-binding protein 5 5’UTR
Sh3rf2 putative E3 ubiquitin-protein ligase SH3RF2 CDS
Sh3rf3 SH3 domain-containing RING finger protein 3 3’UTR
Shank2 SH3 and multiple ankyrin repeat domains protein 3’UTR
Shank3 SH3 and multiple ankyrin repeat domains protein 3’UTR
Shb SH2 domain-containing adapter protein B CDS
Shb SH2 domain-containing adapter protein B 5’UTR
Shh sonic hedgehog protein precursor CDS
Shisa6 protein shisa-6 homolog precursor 3’UTR
Shisa7 protein shisa-7 precursor CDS
Shmt1 serine hydroxymethyltransferase, cytosolic 3’UTR
Shpk sedoheptulokinase CDS
Shroom3 protein Shroom3 isoform 2 CDS
Shroom4 protein Shroom4 CDS
Siah3 seven in absentia homolog 3 CDS
Sidt2 SID1 transmembrane family member 2 precursor 3’UTR
Sipa1l1 signal-induced proliferation-associated 1-like 3’UTR
Sipa1l2 signal-induced proliferation-associated 1-like 3’UTR
Sipa1l3 signal-induced proliferation-associated 1-like 3’UTR
Slain1 SLAIN motif-containing protein 1 CDS
Slamf9 SLAM family member 9 precursor CDS
Slamf9 SLAM family member 9 precursor 3’UTR
Slc10a4 sodium/bile acid cotransporter 4 5’UTR
Slc12a7 solute carrier family 12 member 7 3’UTR
Slc12a8 solute carrier family 12 member 8 isoform 2 CDS
Slc13a5 solute carrier family 13 member 5 3’UTR
Slc15a3 solute carrier family 15 member 3 CDS
Slc16a1 monocarboxylate transporter 1 5’UTR
Slc16a13 monocarboxylate transporter 13 CDS
Slc16a6 monocarboxylate transporter 7 isoform b 3’UTR
Slc17a7 vesicular glutamate transporter 1 3’UTR
Slc18a3 vesicular acetylcholine transporter CDS
Slc1a1 excitatory amino acid transporter 3 5’UTR
Slc1a2 excitatory amino acid transporter 2 isoform 3 CDS
Slc1a2 excitatory amino acid transporter 2 isoform 3 5’UTR
Slc1a4 neutral amino acid transporter A CDS
Slc22a15 solute carrier family 22 member 15 5’UTR
Slc22a17 solute carrier family 22 member 17 5’UTR
Slc22a23 solute carrier family 22 member 23 5’UTR
Slc22a4 solute carrier family 22 member 4 CDS
Slc24a4 sodium/potassium/calcium exchanger 4 precursor 5’UTR
Slc25a30 kidney mitochondrial carrier protein 1 3’UTR
Slc25a42 solute carrier family 25 member 42 3’UTR
Slc26a4 pendrin 5’UTR
Slc27a1 long-chain fatty acid transport protein 1 5’UTR
Slc27a4 long-chain fatty acid transport protein 4 CDS
Slc29a2 equilibrative nucleoside transporter 2 3’UTR
Slc29a3 equilibrative nucleoside transporter 3 CDS
Slc2a5 solute carrier family 2, facilitated glucose 5’UTR
Slc30a3 zinc transporter 3 3’UTR
Slc35c1 GDP-fucose transporter 1 isoform 1 CDS
Slc35c1 GDP-fucose transporter 1 isoform 1 5’UTR
Slc36a1 proton-coupled amino acid transporter 1 5’UTR
Slc39a6 zinc transporter ZIP6 precursor 5’UTR
Slc43a2 large neutral amino acids transporter small CDS
Slc43a2 large neutral amino acids transporter small 5’UTR
Slc6a1 sodium- and chloride-dependent GABA transporter CDS
Slc6a1 sodium- and chloride-dependent GABA transporter 3’UTR
Slc6a11 sodium- and chloride-dependent GABA transporter CDS
Slc6a11 sodium- and chloride-dependent GABA transporter 3’UTR
Slc6a12 sodium- and chloride-dependent betaine 3’UTR
Slc6a17 orphan sodium- and chloride-dependent 5’UTR
Slc6a20a sodium- and chloride-dependent transporter 3’UTR
Slc6a5 sodium- and chloride-dependent glycine CDS
Slc7a1 high affinity cationic amino acid transporter 1 CDS
Slc7a10 asc-type amino acid transporter 1 5’UTR
Slc8a3 solute carrier family 8 (sodium/calcium 5’UTR
Slc9a1 sodium/hydrogen exchanger 1 CDS
Slc9a1 sodium/hydrogen exchanger 1 3’UTR
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Slc9a1 sodium/hydrogen exchanger 1 5’UTR
Slc9a5 sodium/hydrogen exchanger 5 CDS
Slc9a5 sodium/hydrogen exchanger 5 3’UTR
Slc9a7 sodium/hydrogen exchanger 7 5’UTR
Slc9a8 sodium/hydrogen exchanger 8 isoform b 3’UTR
Slco5a1 solute carrier organic anion transporter family, 5’UTR
Slit3 slit homolog 3 protein precursor 3’UTR
Slitrk3 SLIT and NTRK-like protein 3 precursor 5’UTR
Smad6 mothers against decapentaplegic homolog 6 CDS
Smarcb1 SWI/SNF-related matrix-associated 3’UTR
Smarcc1 SWI/SNF complex subunit SMARCC1 3’UTR
Smc5 structural maintenance of chromosomes protein 5 CDS
Smek1 serine/threonine-protein phosphatase 4 5’UTR
Smo smoothened homolog precursor CDS
Smurf2 E3 ubiquitin-protein ligase SMURF2 5’UTR
Smyd3 SET and MYND domain-containing protein 3 5’UTR
Sncb beta-synuclein 5’UTR
Snrnp70 U1 small nuclear ribonucleoprotein 70 kDa 5’UTR
Sntb1 beta-1-syntrophin CDS
Snx19 sorting nexin-19 5’UTR
Snx29 sorting nexin-29 CDS
Snx3 sorting nexin-3 CDS
Sod3 extracellular superoxide dismutase [Cu-Zn] CDS
Sorbs1 sorbin and SH3 domain-containing protein 1 5’UTR
Sos1 son of sevenless homolog 1 5’UTR
Sostdc1 sclerostin domain-containing protein 1 3’UTR
Sox10 transcription factor SOX-10 5’UTR
Sox13 transcription factor SOX-13 CDS
Sox18 transcription factor SOX-18 CDS
Sox21 transcription factor SOX-21 CDS
Sox3 transcription factor SOX-3 CDS
Sox7 transcription factor SOX-7 CDS
Sp2 transcription factor Sp2 isoform 2 CDS
Sp8 transcription factor Sp8 CDS
Spcs3 signal peptidase complex subunit 3 5’UTR
Specc1 3’UTR
Spice1 CDS
Spint1 kunitz-type protease inhibitor 1 precursor CDS
Spock2 testican-2 precursor 5’UTR
Spon1 spondin-1 precursor 3’UTR
Spon1 spondin-1 precursor 5’UTR
Spred2 sprouty-related, EVH1 domain-containing protein 3’UTR
Spred3 sprouty-related, EVH1 domain-containing protein CDS
Spty2d1 protein SPT2 homolog 3’UTR
Srcin1 SRC kinase signaling inhibitor 1 CDS
Srebf2 sterol regulatory element-binding protein 2 CDS
Srgap1 SLIT-ROBO Rho GTPase-activating protein 1 CDS
Srgap2 SLIT-ROBO Rho GTPase-activating protein 2 CDS
Srrm3 serine/arginine repetitive matrix protein 3 3’UTR
Sst somatostatin precursor 5’UTR
St13 hsc70-interacting protein 5’UTR
St8sia2 alpha-2,8-sialyltransferase 8B CDS
St8sia2 alpha-2,8-sialyltransferase 8B 3’UTR
St8sia3 sia-alpha-2,3-Gal-beta-1,4-GlcNAc-R:alpha 5’UTR
St8sia5 alpha-2,8-sialyltransferase 8E isoform middle CDS
St8sia5 alpha-2,8-sialyltransferase 8E isoform middle 5’UTR
Stat5b signal transducer and activator of transcription 3’UTR
Stat6 signal transducer and transcription activator 6 3’UTR
Stk40 serine/threonine-protein kinase 40 isoform a 3’UTR
Strn striatin CDS
Stt3b dolichyl-diphosphooligosaccharide–protein 5’UTR
Stub1 STIP1 homology and U box-containing protein 1 5’UTR
Stx1a syntaxin-1A 3’UTR
Stx1b syntaxin-1B 3’UTR
Stx3 syntaxin-3 isoform A 5’UTR
Stxbp1 syntaxin-binding protein 1 isoform b 3’UTR
Stxbp1 syntaxin-binding protein 1 isoform b 5’UTR
Sufu suppressor of fused homolog isoform 2 3’UTR
Supt6h transcription elongation factor SPT6 CDS
Surf4 surfeit locus protein 4 5’UTR
Susd2 sushi domain-containing protein 2 isoform 2 3’UTR
Susd3 sushi domain-containing protein 3 CDS
Susd3 sushi domain-containing protein 3 3’UTR
Sv2a synaptic vesicle glycoprotein 2A 5’UTR
Sv2c synaptic vesicle glycoprotein 2C 3’UTR
Sv2c synaptic vesicle glycoprotein 2C 5’UTR
Swap70 switch-associated protein 70 CDS
Sympk symplekin CDS
Continued on next page
6 Appendix 165
Table 6.3 – continued from previous page
Transcript Symbol Transcript Name Methylation site
Syn1 synapsin-1 isoform b CDS
Syn1 synapsin-1 isoform b 3’UTR
Syn1 synapsin-1 isoform b 5’UTR
Syn2 synapsin-2 isoform IIa CDS
Syn2 synapsin-2 isoform IIa 5’UTR
Syngr3 synaptogyrin-3 5’UTR
Synm synemin isoform H 3’UTR
Syp synaptophysin CDS
Syt12 synaptotagmin-12 5’UTR
Syt3 synaptotagmin-3 CDS
Syvn1 E3 ubiquitin-protein ligase synoviolin 3’UTR
Tacr1 substance-P receptor 5’UTR
Taok1 serine/threonine-protein kinase TAO1 5’UTR
Tap1 antigen peptide transporter 1 isoform 2 CDS
Tapbp tapasin isoform 1 CDS
Tapbp tapasin isoform 1 5’UTR
Tarbp1 TAR (HIV-1) RNA binding protein 1 CDS
Tas1r3 taste receptor type 1 member 3 precursor CDS
Tatdn2 TatD DNase domain containing 2 5’UTR
Tbc1d10c carabin CDS
Tbc1d2 TBC1 domain family, member 2 3’UTR
Tbc1d22b TBC1 domain family member 22B CDS
Tbc1d22b TBC1 domain family member 22B 3’UTR
Tbc1d30 TBC1 domain family member 30 5’UTR
Tbc1d5 TBC1 domain family member 5 3’UTR
Tbc1d8 TBC1 domain family member 8 3’UTR
Tbc1d9 TBC1 domain family member 9 isoform 1 5’UTR
Tbrg4 protein TBRG4 CDS
Tbx2 T-box transcription factor TBX2 CDS
Tbx3 T-box transcription factor TBX3 isoform 1 CDS
Tbx3 T-box transcription factor TBX3 isoform 1 3’UTR
Tbxa2r thromboxane A2 receptor 3’UTR
Tcap telethonin 3’UTR
Tcea1 transcription elongation factor A protein 1 5’UTR
Tcf12 transcription factor 12 5’UTR
Tcf25 transcription factor 25 isoform c 5’UTR
Tcf3 transcription factor E2-alpha isoform 7 CDS
Tcf7l2 transcription factor 7-like 2 isoform 7 CDS
Tcfe3 transcription factor E3 isoform a CDS
Tcfe3 transcription factor E3 isoform a 5’UTR
Tchh trichohyalin CDS
Tcte1 T-complex-associated testis-expressed protein 1 CDS
Tead1 transcriptional enhancer factor TEF-1 isoform 2 3’UTR
Tecpr1 tectonin beta-propeller repeat-containing CDS
Tekt4 tektin-4 CDS
Tekt5 tektin-5 CDS
Tesk1 dual specificity testis-specific protein kinase 5’UTR
Tgfb1 transforming growth factor beta-1 precursor 5’UTR
Tgfbr3 transforming growth factor beta receptor type 3 CDS
Tgfbr3 transforming growth factor beta receptor type 3 3’UTR
Thpo thrombopoietin precursor CDS
Thra thyroid hormone receptor alpha 3’UTR
Thrsp thyroid hormone-inducible hepatic protein CDS
Thrsp thyroid hormone-inducible hepatic protein 3’UTR
Thsd4 thrombospondin type-1 domain-containing protein CDS
Thsd4 thrombospondin type-1 domain-containing protein 3’UTR
Timm17a mitochondrial import inner membrane translocase CDS
Timm50 mitochondrial import inner membrane translocase CDS
Timp2 metalloproteinase inhibitor 2 precursor 5’UTR
Timp3 metalloproteinase inhibitor 3 precursor 3’UTR
Tinagl1 tubulointerstitial nephritis antigen-like CDS
Tle3 transducin-like enhancer protein 3 isoform 2 5’UTR
Tln1 talin-1 5’UTR
Tmem102 transmembrane protein 102 CDS
Tmem104 transmembrane protein 104 CDS
Tmem104 transmembrane protein 104 3’UTR
Tmem108 transmembrane protein 108 precursor CDS
Tmem126b transmembrane protein 126B 3’UTR
Tmem127 transmembrane protein 127 5’UTR
Tmem128 transmembrane protein 128 CDS
Tmem130 transmembrane protein 130 precursor CDS
Tmem131 transmembrane protein 131 CDS
Tmem132d transmembrane protein 132D precursor 5’UTR
Tmem132e transmembrane protein 132E precursor 5’UTR
Tmem145 transmembrane protein 145 3’UTR
Tmem194 transmembrane protein 194A isoform 1 3’UTR
Tmem200c 5’UTR
Tmem201 transmembrane protein 201 isoform b CDS
Continued on next page
166 6 Appendix
Table 6.3 – continued from previous page
Transcript Symbol Transcript Name Methylation site
Tmem25 transmembrane protein 25 precursor 3’UTR
Tmem38b trimeric intracellular cation channel type B CDS
Tmem59l transmembrane protein 59-like precursor CDS
Tmem63b transmembrane protein 63B CDS
Tmem63b transmembrane protein 63B 3’UTR
Tmem80 5’UTR
Tmtc2 transmembrane and TPR repeat-containing protein 5’UTR
Tnc tenascin CDS
Tnfrsf1a tumor necrosis factor receptor superfamily 3’UTR
Tnik traf2 and NCK-interacting protein kinase isoform 5’UTR
Tnip1 TNFAIP3-interacting protein 1 3’UTR
Tnpo2 transportin-2 3’UTR
Tnrc6c trinucleotide repeat-containing gene 6C protein 5’UTR
Tnxb tenascin-X CDS
Tom1l2 TOM1-like protein 2 isoform b CDS
Tomm6 mitochondrial import receptor subunit TOM6 CDS
Tor1aip1 torsin-1A-interacting protein 1 isoform 2 5’UTR
Tox2 TOX high mobility group box family member 2 3’UTR
Tpcn2 two pore calcium channel protein 2 3’UTR
Tpra1 transmembrane protein adipocyte-associated 1 5’UTR
Traf3ip2 adapter protein CIKS CDS
Trappc5 trafficking protein particle complex subunit 5 5’UTR
Trappc9 trafficking protein particle complex subunit 9 3’UTR
Trerf1 transcriptional-regulating factor 1 isoform 1 5’UTR
Trib1 tribbles homolog 1 5’UTR
Tril 5’UTR
Trim17 E3 ubiquitin-protein ligase TRIM17 CDS
Trim25 E3 ubiquitin/ISG15 ligase TRIM25 CDS
Trim26 tripartite motif-containing protein 26 isoform 5’UTR
Trim41 E3 ubiquitin-protein ligase TRIM41 5’UTR
Trim62 tripartite motif-containing protein 62 CDS
Trim66 tripartite motif-containing protein 66 isoform 3’UTR
Trim67 tripartite motif-containing protein 67 CDS
Trim68 E3 ubiquitin-protein ligase TRIM68 CDS
Trim7 tripartite motif-containing protein 7 3’UTR
Trim9 E3 ubiquitin-protein ligase TRIM9 isoform c CDS
Trim9 E3 ubiquitin-protein ligase TRIM9 isoform c 3’UTR
Trnp1 TMF-regulated nuclear protein 1 CDS
Trp53bp2 apoptosis-stimulating of p53 protein 2 5’UTR
Trp53i11 tumor protein p53-inducible protein 11 3’UTR
Trp73 tumor protein p73 isoform c CDS
Trp73 tumor protein p73 isoform c 3’UTR
Trrap transformation/transcription domain-associated 3’UTR
Tsc22d4 TSC22 domain family protein 4 CDS
Tsku tsukushin precursor CDS
Tsn translin CDS
Tspan17 tetraspanin-17 3’UTR
Ttc28 tetratricopeptide repeat protein 28 3’UTR
Ttc7b tetratricopeptide repeat domain 7B CDS
Ttll1 probable tubulin polyglutamylase TTLL1 CDS
Ttll4 tubulin polyglutamylase TTLL4 3’UTR
Ttyh1 protein tweety homolog 1 isoform 2 CDS
Ttyh2 protein tweety homolog 2 CDS
Tubb4 tubulin beta-4 chain 3’UTR
Tubb4 tubulin beta-4 chain 5’UTR
Tubg2 tubulin gamma-2 chain CDS
Tubgcp4 gamma-tubulin complex component 4 5’UTR
Tulp4 tubby-related protein 4 isoform b 3’UTR
Txndc5 thioredoxin domain-containing protein 5 CDS
Txnrd1 thioredoxin reductase 1, cytoplasmic isoform 2 5’UTR
Tysnd1 peroxisomal leader peptide-processing protease CDS
U2af2 splicing factor U2AF 65 kDa subunit 3’UTR
Uap1l1 UDP-N-acetylhexosamine pyrophosphorylase-like CDS
Ubc polyubiquitin-C CDS
Ube2m NEDD8-conjugating enzyme Ubc12 isoform 2 5’UTR
Ube2q2 ubiquitin-conjugating enzyme E2 Q2 CDS
Ube2ql1 ubiquitin-conjugating enzyme E2Q-like protein 1 5’UTR
Ubqln4 ubiquilin-4 CDS
Ubr2 E3 ubiquitin-protein ligase UBR2 isoform 1 5’UTR
Ubxn4 UBX domain-containing protein 4 5’UTR
Unc5a netrin receptor UNC5A precursor CDS
Unc5a netrin receptor UNC5A precursor 3’UTR
Unc5b netrin receptor UNC5B precursor 3’UTR
Unc5b netrin receptor UNC5B precursor 5’UTR
Unc5c netrin receptor UNC5C precursor 5’UTR
Unc5d netrin receptor UNC5D precursor 5’UTR
Uncx homeobox protein unc-4 homolog CDS
Uncx homeobox protein unc-4 homolog 3’UTR
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Ung uracil-DNA glycosylase isoform a 3’UTR
Upf1 regulator of nonsense transcripts 1 isoform a CDS
Upf1 regulator of nonsense transcripts 1 isoform a 5’UTR
Urod uroporphyrinogen decarboxylase CDS
Usf2 upstream stimulatory factor 2 3’UTR
Usp19 ubiquitin carboxyl-terminal hydrolase 19 isoform 5’UTR
Usp2 ubiquitin carboxyl-terminal hydrolase 2 isoform 5’UTR
Usp22 ubiquitin carboxyl-terminal hydrolase 22 3’UTR
Usp30 ubiquitin carboxyl-terminal hydrolase 30 CDS
Usp33 ubiquitin carboxyl-terminal hydrolase 33 isoform 5’UTR
Usp43 ubiquitin carboxyl-terminal hydrolase 43 CDS
Ust uronyl 2-sulfotransferase CDS
Vac14 protein VAC14 homolog CDS
Vat1 synaptic vesicle membrane protein VAT-1 homolog CDS
Vgf VGF nerve growth factor inducible 5’UTR
Vim vimentin CDS
Vps26b vacuolar protein sorting-associated protein 26B 3’UTR
Vps37a vacuolar protein sorting-associated protein 37A 5’UTR
Vps37d vacuolar protein sorting-associated protein 37D CDS
Vps37d vacuolar protein sorting-associated protein 37D 3’UTR
Vps53 vacuolar protein sorting-associated protein 53 3’UTR
Vps8 vacuolar protein sorting-associated protein 8 3’UTR
Vsx2 visual system homeobox 2 CDS
Vtn vitronectin precursor CDS
Vwf von Willebrand factor precursor CDS
Wasf2 wiskott-Aldrich syndrome protein family member 3’UTR
Wasf3 wiskott-Aldrich syndrome protein family member 3’UTR
Wbscr27 Williams-Beuren syndrome chromosomal region 27 5’UTR
Wdfy4 WD repeat and FYVE domain containing 4 CDS
Wdr33 WD repeat domain 33 isoform 2 5’UTR
Wdr45l WD repeat domain phosphoinositide-interacting CDS
Wdr6 WD repeat-containing protein 6 3’UTR
Wdr82 WD repeat-containing protein 82 5’UTR
Wdtc1 WD and tetratricopeptide repeats protein 1 3’UTR
Wfikkn2 WAP, kazal, immunoglobulin, kunitz and NTR CDS
Wfs1 wolframin CDS
Whrn whirlin isoform 5 3’UTR
Whrn whirlin isoform 5 5’UTR
Wipf2 WAS/WASL-interacting protein family member 2 3’UTR
Wnk1 serine/threonine-protein kinase WNK1 5’UTR
Wnt1 proto-oncogene Wnt-1 precursor 5’UTR
Wnt7b protein Wnt-7b isoform 1 CDS
X99384 paladin CDS
Xpnpep1 xaa-Pro aminopeptidase 1 CDS
Xpo6 exportin-6 5’UTR
Xpot exportin-T CDS
Xylb xylulose kinase 3’UTR
Ybey CDS
Yipf2 protein YIPF2 3’UTR
Yipf2 protein YIPF2 5’UTR
Yipf3 protein YIPF3 5’UTR
Ywhag 14-3-3 protein gamma 5’UTR
Yy1 transcriptional repressor protein YY1 CDS
Zbtb26 zinc finger and BTB domain-containing protein 5’UTR
Zbtb33 transcriptional regulator Kaiso 5’UTR
Zbtb39 zinc finger and BTB domain-containing protein CDS
Zbtb39 zinc finger and BTB domain-containing protein 3’UTR
Zbtb40 zinc finger and BTB domain-containing protein CDS
Zbtb40 zinc finger and BTB domain-containing protein 3’UTR
Zbtb7a zinc finger and BTB domain-containing protein 5’UTR
Zbtb7c zinc finger and BTB domain-containing protein 3’UTR
Zc3h15 zinc finger CCCH domain-containing protein 15 CDS
Zc3h7b zinc finger CCCH domain-containing protein 7B CDS
Zdhhc14 probable palmitoyltransferase ZDHHC14 CDS
Zdhhc14 probable palmitoyltransferase ZDHHC14 5’UTR
Zdhhc5 probable palmitoyltransferase ZDHHC5 CDS
Zdhhc8 probable palmitoyltransferase ZDHHC8 3’UTR
Zdhhc9 palmitoyltransferase ZDHHC9 CDS
Zdhhc9 palmitoyltransferase ZDHHC9 3’UTR
Zeb2 zinc finger E-box-binding homeobox 2 isoform 2 5’UTR
Zer1 protein zer-1 homolog 3’UTR
Zfand3 AN1-type zinc finger protein 3 CDS
Zfhx2 zinc finger homeobox protein 2 CDS
Zfhx2 zinc finger homeobox protein 2 3’UTR
Zfp142 zinc finger protein 142 CDS
Zfp148 zinc finger protein 148 5’UTR
Zfp213 zin finger protein 213 5’UTR
Zfp335 zinc finger protein 335 3’UTR
Continued on next page
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Transcript Symbol Transcript Name Methylation site
Zfp358 zinc finger protein 358 CDS
Zfp366 zinc finger protein 366 CDS
Zfp36l1 zinc finger protein 36, C3H1 type-like 1 CDS
Zfp36l2 zinc finger protein 36, C3H1 type-like 2 CDS
Zfp385a zinc finger protein 385A CDS
Zfp385a zinc finger protein 385A 5’UTR
Zfp395 zinc finger protein 395 CDS
Zfp395 zinc finger protein 395 3’UTR
Zfp414 zinc finger protein 414 CDS
Zfp414 zinc finger protein 414 5’UTR
Zfp423 zinc finger protein 423 CDS
Zfp428 zinc finger protein 428 5’UTR
Zfp592 zinc finger protein 592 3’UTR
Zfp598 zinc finger protein 598 3’UTR
Zfp628 zinc finger protein 628 CDS
Zfp652 zinc finger protein 652 5’UTR
Zfp655 zinc finger protein 655 isoform a 5’UTR
Zfp689 zinc finger protein 689 5’UTR
Zfp747 zinc finger protein 747 5’UTR
Zfp831 zinc finger protein 831 3’UTR
Zic2 zinc finger protein ZIC 2 CDS
Zic4 zinc finger protein ZIC 4 CDS
Zmiz1 zinc finger MIZ domain-containing protein 1 3’UTR
Znhit1 zinc finger HIT domain-containing protein 1 5’UTR
Znrf1 E3 ubiquitin-protein ligase ZNRF1 isoform c CDS
Zscan2 zinc finger and SCAN domain-containing protein 3’UTR
Zswim1 zinc finger SWIM domain-containing protein 1 CDS
Zswim1 zinc finger SWIM domain-containing protein 1 3’UTR
Zswim5 zinc finger SWIM domain-containing protein 5 5’UTR
Zzef1 zinc finger ZZ-type and EF-hand CDS
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